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DISSERTATION ABSTRACT
MYELIN, CPLA2, AND AZITHROMYCIN: MODULATION OF MACROPHAGE
ACTIVATION IN SPINAL CORD INJURY INFLAMMATION
Spinal cord injury (SCI) produces a chronic inflammatory state primarily
mediated by macrophages consisting of resident microglia and infiltrating
monocytes. These chronically activated SCI macrophages adopt a proinflammatory, pathological state that continues to cause additional damage after
the initial injury and inhibits recovery. While the roles of macrophages in SCI
pathophysiology are well documented, the factors contributing to this
maladaptive response are poorly understood. Here, we identify the detrimental
effects of myelin debris on macrophage physiology and demonstrate a novel,
activation state-dependent role for cytosolic phospholipase-A2 (cPLA2) in myelinmediated potentiation of pro-inflammatory macrophage activation. Macrophagemediated inflammatory responses are promising therapeutic targets; however,
there are very few therapeutic options to treat SCI and none that target
macrophages. Here, we provide evidence that treatment with the
immunomodulatory antibiotic azithromycin (AZM), initiated after SCI, improves
recovery by targeting macrophage activation. There is an urgent need for the
development of new therapies for the treatment of SCI. Macrophage-targeted
therapies hold great promise; however, these treatment candidates require
additional development before they can advance towards clinical use. Here we
discuss the continued development of cPLA2 as a therapeutic target, the steps
necessary to advance AZM towards clinical use, and lastly, we review additional
macrophage-targeted therapies currently in development. Collectively this body
of work identifies key mechanisms driving macrophage pathophysiology after SCI
and identifies macrophage-targeted therapies that reduce this neuroinflammation
to improve recovery after SCI.
KEYWORDS: Spinal Cord Injury, Neuroinflammation, Macrophage, Microglia,
Neurotrauma
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Chapter 1: Introduction

1- i. Spinal Cord Injury
A spinal cord injury (SCI) is a severe condition in which damage to the
spinal cord produces impairments to spinal functions. The initial damage that
occurs is largely irreversible, with current medical interventions primarily seeking
to stabilize the individual and prevent further damage. Unfortunately, in the initial
days following SCI, the damage to the spinal cord spreads, causing additional
impairments by a process called secondary injury. While the causes of
secondary injury are multifaceted, a primary mechanism is the robust
neuroinflammatory response mediated by infiltrating macrophages and resident
microglia. Given the immense medical challenge of mending the spinal cord
damage, the current body of work aims to understand the underlying
mechanisms driving this detrimental cellular activity and examines therapeutics
that could intervene and improve recovery after SCI.
SCI induces a robust cellular inflammatory response in which resident
cells such as microglia and astrocytes become activated. In the hours and days
after injury, neutrophils, monocytes, lymphocytes, and other cells infiltrate into
the damaged tissue creating a unique neuroinflammatory environment not seen
in typical bodily injuries (Donnelly and Popovich, 2008). There are protective or
reparative events occurring in these cellular populations; however, collectively,
this inflammation causes further damage. Macrophages and microglia, in
particular, are capable of producing reparative or adverse responses depending
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on their activation state. Indeed, macrophages can facilitate repair by increasing
axon growth, stem cell differentiation, and revascularization (Gensel and Zhang,
2015; Kigerl et al., 2009); however, in SCI these, cells predominantly adopt a
pro-inflammatory activation state. Pro-inflammatory macrophages and microglia
contribute to pathology through secondary injury processes involving reactive
oxygen species (ROS), neurotoxin, and pro-inflammatory cytokines release, as
well as by causing axon retraction and dieback (Gensel and Zhang, 2015; Horn
et al., 2008). Further, pro-inflammatory macrophages and microglia remain in the
SCI lesion indefinitely and are thus thought to impair other repair mechanisms.
Here, we seek to examine some of the underlying mechanisms causing this
maladaptive macrophage response and develop therapeutics that may reduce
pro-inflammatory macrophage activation.
To examine the underlying mechanisms underlying the pro-inflammatory
macrophage response, we utilize an in vitro model using bone marrow-derived
macrophages (BMDMs). As described previously (Kopper et al., 2021), BMDMs
are predictive of monocyte-derived macrophage responses in vivo in the injured
spinal cord. This has been observed at transcription (Longbrake et al., 2007) and
functional levels (Gensel et al., 2009), as well as in response to therapeutic
interventions (Gensel et al., 2017). In vitro, we reproduce the pro-inflammatory
macrophage activation state with an “M1” stimulus (LPS and IFN-γ) and the antiinflammatory reparative macrophage activation state with an “M2” stimulus (IL-4).
We also utilize naïve “CTL” or “M0” macrophages that are grown to maturity but
are not given an activation state stimulus. Using this system, we can add
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additional stimulants, chemical inhibitors, or therapeutics to investigate cellular
mechanisms and screen potential therapeutics.

1- ii. Myelin as an Inflammatory Mediator
This section is adapted from (Kopper and Gensel, 2017)
Myelin as an Inflammatory Mediator Summary:
Spinal cord injury (SCI) triggers chronic intraspinal inflammation consisting
of activated resident and infiltrating immune cells (especially
microglia/macrophages). The environmental factors contributing to this protracted
inflammation are not well understood; however, myelin lipid debris is a hallmark
of SCI. Myelin is also a potent macrophage stimuli and target of complementmediated clearance and inflammation. The downstream effects of these neuroimmune interactions have the potential to contribute to ongoing pathology or
facilitate repair. This depends in large part on whether myelin drives pathological
or reparative macrophage activation states, commonly referred to as M1 (proinflammatory) or M2 (alternatively) macrophages, respectively. Here we review
the processes by which myelin debris may be cleared through macrophage
surface receptors and the complement system, how this differentially influences
macrophage and microglial activation states, and how the cellular functions of
these myelin macrophages and complement proteins contribute to chronic
inflammation and secondary injury after SCI.
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Myelin as an Inflammatory Mediator
Spinal cord injury (SCI) triggers a complex cross-talk between resident
cells of the central nervous system (CNS) and infiltrating immune cells. These
neuro-immune interactions can mediate recovery but also inhibit regeneration.
Activated macrophages, consisting of resident microglia and recruited
monocytes, contribute to this dichotomous response. Indeed, macrophages
facilitate repair by increasing axon growth, stem cell differentiation, and
revascularization. However, macrophages can also contribute to pathology
through reactive oxygen species (ROS), neurotoxin, and pro-inflammatory
cytokines release, as well as, by causing axon retraction and dieback. The extent
to which macrophages are polarized toward reparative (also called M2 or
alternative) or pathological (also called M1 or pro-inflammatory) phenotypes
depends in large part on the stimuli present in the injured spinal cord.
While numerous studies examine how macrophage activation states affect
recovery after SCI (for a review see (Gensel and Zhang, 2015)), less is
understood about how the lesion environment contributes to macrophage
polarization. It is well-established that myelin debris generated after SCI inhibits
axonal regeneration and remyelination (McKerracher et al., 1994); however,
myelin can also act as an inflammatory stimulus (Kroner et al., 2014; Wang et al.,
2014; Williams et al., 1994). Lipid-laden myelin debris is taken up and processed
by inflammatory cells, including neutrophils and macrophages. Myelin then
becomes highly concentrated in these phagocytes, persisting in macrophages for
weeks after SCI (Greenhalgh and David, 2014; Vargas and Barres, 2007; Wang
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et al., 2014). In addition, myelin initiates complement-mediated inflammatory
pathways with downstream effects on macrophage activation. Here we examine
the myelin-macrophage and complement neuro-immune interactions after SCI.
Since myelin is ubiquitously present in the acute and chronically injured spinal
cord, we will explore the mechanisms of myelin debris clearance and its
downstream inflammatory effects.

Spinal Cord Injury Causes Myelin Breakdown and Immune Cell Activation.
Acute spinal cord trauma ruptures vasculature leading to tissue ischemia
and blood brain barrier breakdown and generates neuron and myelin debris.
Myelin damage specifically occurs at the time of injury, and cellular debris is
present in areas of white matter damage within 24hrs (Buss et al.; Ek et al.,
2012; Imai et al., 2008). Debris increases within the first week of SCI and persists
in the chronically injured spinal cord (Ek et al., 2012; Kozlowski et al., 2014).
While damaged myelin is cleared within weeks of peripheral nerve injury, myelin
fragments are present for the first year after SCI (Becerra et al., 1995; Vargas
and Barres, 2007). Indeed, myelin debris is not cleared from the chronically
injured spinal cord until years after injury (Becerra et al., 1995). This time course
of acute myelin debris with protracted but eventual removal after SCI occurs
across a range of mammalian models and in humans (Wang et al., 2014). The
sustained presence of myelin debris inhibits axon regeneration, oligodendrocyte
differentiation, and remyelination.
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Immune cell activation follows a similar time course (Gensel and Zhang,
2015). Neutrophils and complement proteins (discussed below) enter the injury
site within the first days after SCI. Microglia are activated at the time of injury,
with peak activation within the first week of injury. Monocyte-derived
macrophages infiltrate the injured spinal cord within days and peak 1–2 weeks
after injury. Over time, neutrophils and complement proteins subside, but
microglia and macrophages persist. Phagocytosis markers are present on these
chronically activated cells (Fleming et al., 2006). It is therefore likely that myelin
lipids are actively processed by macrophages and are environmental stimuli
influencing chronic spinal cord inflammation. Indeed, in areas of Wallerian
degeneration, macrophages disappear from the chronically injured spinal cord
concomitant with myelin debris clearance (Becerra et al., 1995).

Macrophage Receptor-Mediated Myelin Removal
Receptor-mediated phagocytic myelin removal requires binding of
damaged myelin to surface receptors and subsequent phagocytosis. These
receptors have the potential to bind to myelin directly or to opsonized myelin
particles. Both opsonized and non-opsonized myelin removal by
macrophages/microglia has been reviewed extensively and will only be
mentioned here briefly (Hirata and Kawabuchi, 2002; Neumann et al., 2009;
Reichert and Rotshenker, 2003). Complement-mediated receptor binding,
primarily through the pattern recognition receptor (PRR), complement receptor 3
(CR3/CD11b/MAC-1), is a commonly studied mechanism of opsonized myelin
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clearance. Complement proteins (e.g., complement protein 3) and/or antibodies
bind degenerated myelin facilitating CR3 binding and phagocytosis. This
process, and the process of non-opsonized myelin clearance, is regulated in part
through carbohydrate-lectin receptors, including the MAC-2/Galectin-3 receptor
among others. The receptor-mediated internalization of myelin, and myelinreceptor binding itself, potentially alters the functional phenotype of the
phagocyte. The downstream effects of complement and receptor-mediated
myelin removal on macrophage/microglia phenotypes will be discussed below.
It is also well-documented that scavenger receptor AI/II (SRAI/II)
participates in macrophage-mediated myelin clearance, for a review, see
(Rotshenker, 2009). This PRR is capable of binding a variety of lipids and
polyanionic ligands. SRAI/II, in combination with CR3, facilitates myelin
phagocytosis by microglia and macrophages (da Costa et al., 1997; Reichert and
Rotshenker, 2003). Additionally, SRAI/II is implicated as a primary mediator of
oxidized lipoprotein uptake in atherosclerosis and leads to the development of
foam cells (Greaves and Gordon, 2008). Emerging transcriptional evidence
indicates that SCI macrophages increase lipid catabolism after injury and adopt
transcription profiles closely resembling foam cells (Zhu et al., 2017). Lipoprotein
receptors have been implicated in the foam cell transition, but whether SRAI/II
facilities this transition in SCI has yet to be determined. This may be challenging
considering that SCI results in significant free radical generation and lipid
peroxidation (Hall, 2011). It is possible that these oxidative alterations to myelin
lipids may alter the receptor pathways through which they are cleared, and this
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caveat is important to consider when modeling myelin clearance in-vitro and
interpreting experimental results.
Another potential mechanism of receptor-mediated myelin clearance is
through the macrophage receptor with a collagenous structure (MARCO).
MARCO is a scavenger receptor related to SRAI/II. Both contain collagenous and
scavenger receptor cysteine-rich domains in their extracellular portions giving
them similar ligand binding repertoires (Elomaa et al., 1995; Jozefowski et al.,
2005). Thus, it is likely that MARCO can bind myelin lipids effectively. Although it
has not been identified as a myelin receptor in SCI, we recently observed that
macrophages upregulate MARCO in response to pro-inflammatory stimuli and
express MARCO in the injured spinal cord (Gensel et al., 2017; Orr et al., 2017).
MARCO activation, therefore, may be a potential mechanism for proinflammatory macrophage-mediated myelin removal in SCI.
Triggering receptor expressed on myeloid cells 2 (TREM2) facilitates microglial
phagocytic activity (Takahashi et al., 2005). TREM2 is a sensor for lipid
components of damaged myelin and is required for debris clearance in the
cuprizone model of demyelination (Daws et al., 2003; Poliani et al., 2015).
TREM2 binds polyanionic ligands, such as dextran sulphate, bacterial
lipooligosaccharides, and various phospholipids (Cannon et al., 2011). In the
case of myelin, the likely ligands include phosphatidylethanolamine,
phosphatidylserine, and cardiolipin found in myelin membranes (Cannon et al.,
2011). Individuals with TREM2 mutations or deficiencies are at higher risk for
developing amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s
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disease (Lill et al., 2015). Notably, individuals with mutations in TREM2 or
DAP12, a key-signaling component of TREM2, develop lethal and progressive
Nasu-Hakola disease characterized by early onset dementia and demyelinating
brain lesions (Paloneva et al., 2002; Verloes et al., 1997). Therefore, TREM2
may be involved in removing damaged myelin following SCI, MS and other
conditions. Indeed, microglial TREM2 senses lipid components of myelin debris
and is important in regulating transcriptional programs essential for myelin debris
clearance (Cantoni et al., 2015; Poliani et al., 2015; Siddiqui et al., 2016).
Additional work is needed to examine TREM2 within the context of the myelinmacrophage interactions in SCI. Likewise, TREM2 is part of a large family of
TREM and TREM-like receptors with similar ligand binding repertoires that are
also unstudied in the context of myelin uptake after SCI (Cannon et al., 2011).

Myelin-Macrophage Interactions
Some of the first studies to examine macrophage-mediated myelin debris
clearance in the CNS emerged from the multiple sclerosis (MS) field. Electron
microscopy studies revealed myelin debris phagocytosis in active lesions and
identified macrophages as facilitators of continued demyelination (Prineas, 1975;
Prineas and Connell, 1978). These catalyzed further studies largely concerned
with the roles of anti-myelin antibodies, complement, and other pathways in
relation to the chronic demyelination observed in MS. A 1994 publication by
Williams et al. in the Journal of Neuroscience Research identified an
inflammatory role for myelin debris (Williams et al., 1994). Specifically, they
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reported microglial activation with increased pro-inflammatory cytokine and ROS
production with myelin phagocytosis (Williams et al., 1994). These observations
indicate that myelin debris may be an inflammatory stimulus for pro-inflammatory
microglia/macrophage activation.
An 1990’s, work by Brück and Friede and van der Laan et al. demonstrated the
importance of macrophage CR3 in mediating myelin uptake. They observed that
myelin induced production of tumor necrosis factor-alpha (TNF-α) and nitric oxide
(van der Laan et al., 1996a). These effects were enhanced through complement
opsonization of myelin and blocked through antibody-mediated inhibition of CR3
(Brück and Friede, 1990; 1991; van der Laan et al., 1996b). This work is
supported by a more recent study in an SCI model which reported myelin
invoked pro-inflammatory macrophage responses in vivo (Sun et al., 2010). In
that paper, CR3-mediated uptake of myelin and downstream activation of
FAK/PI3K/Akt/NF-κβ signaling pathways increased pro-inflammatory, M1-like
cytokine release and decreased M2 cytokine release (Sun et al., 2010).
Collectively, these data highlight that receptor-mediated myelin removal can alter
macrophage phenotypes and that removal through CR3 drives pro-inflammatory
macrophage activation in SCI.
While these studies implicate myelin as a pro-inflammatory macrophage
stimulus in SCI, the role of myelin and lipid processing on M1/M2 macrophage
polarization in vivo is controversial. Specifically, myelin-laden “foamy” cells
express a wide variety of anti-inflammatory molecules with some intermediate
M1–M2 phenotypes in MS (Boven, 2005; Vogel et al., 2013). In atherosclerosis,
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foam cell formation is associated with a downregulation of pro-inflammatory gene
expression (Spann et al., 2012). In contrast, in SCI, foam cell formation and
macrophage lipid accumulation is associated with decreased M2 activation
(Wang et al., 2014). Further, M1 macrophage polarization predominates in SCI
despite the large presence of myelin debris (Kroner et al., 2014). Interestingly,
the relative expression of pro- and anti-inflammatory markers appears to depend
on the lesion or tissue microenvironment. For example, in active MS lesions, antiinflammatory marker expression predominates on foam cell macrophages in the
lesion center and inner rim while pro-inflammatory marker expression is more
widespread (Boven, 2005; Vogel et al., 2013). Similarly, a more recent evaluation
of foam cells within the context of the M1/M2 macrophage paradigm observed a
full range of M1–M2 foam cell activation states depending upon the
microenvironments from which the cells were isolated (Thomas et al., 2015a;
2015b). In the case of SCI, two environmental cues that may promote M1
polarization in the presence of myelin are TNF and intracellular iron, perhaps
reflective of the increased hemorrhage in SCI lesions relative to those in MS
(Kroner et al., 2014).
To better elucidate the role myelin plays in macrophage polarization,
researchers often stimulate macrophages with myelin in vitro. However, despite
using fairly similar stimulation paradigms, there are contrasting reports that
implicate myelin as both a pro-inflammatory and anti-inflammatory stimulus. To
better understand how to reconcile these conflicting reports, we examined the
myelin stimulations in detail. A few common themes emerged that may account

11

for the conflicting results. First, in several of these in-vitro paradigms,
researchers load macrophages with myelin prior to applying inflammatory stimuli.
In response to pro-inflammatory stimuli, these myelin-laden macrophages almost
invariably express anti-inflammatory mediators and/or stop responding to the proinflammatory stimuli (Bogie et al., 2013; 2012; Boven, 2005). Second, myelin
stimulation in isolation invokes either no phenotypic activation or causes the
release of reactive oxygen species and pro-inflammatory cytokines with a few
reports of subtle M2-like activation in a cell-type specific manner (Sun et al.,
2010; van der Laan et al., 1996b; van Rossum et al., 1999; Wang et al., 2014;
Williams et al., 1994). Third, when myelin is delivered to macrophages already
stimulated to be either M1 or M2, or when myelin and other stimuli are presented
at the same time, a range of responses has been reported. For example, prestimulation with M1 or M2 stimuli results in a myelin-induced potentiation of M1
activation (Siddiqui et al., 2016; Wang et al., 2014). Myelin co-administration with
pro-inflammatory stimuli can invoke further M1 activation, albeit in a timedependent manner with increased M2 activation over time (Liu et al., 2006). A
subtlety distinct protocol added myelin to M1 polarized macrophages following
the removal of the inflammatory stimuli and observed anti-inflammatory effects
(Kroner et al., 2014). Notably, in that study, if pro-inflammatory stimuli are
present during myelin activation, M1 polarization was observed (Kroner et al.,
2014). It is also important to note that researchers utilize various cell types,
including bone marrow-derived macrophages, primary microglia, cell lines,
peritoneal macrophages, and blood monocytes, among others for in vitro models.
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All of these cell types have subtle differences in their basal activation state and
their ability to take up and respond to myelin (Durafourt et al., 2012; van Rossum
et al., 2008). Collectively, these myelin-macrophage studies in vitro indicate that:
1) myelin dampens the macrophage response to subsequent stimuli; 2) in
isolation, myelin may act as a pro-inflammatory stimulus that drives M1 typeactivation; and 3) when combined with other stimuli, initially myelin facilitates M1
polarization but this response varies over time.
The results of these in vitro studies indicate that myelin is capable of
producing downstream effects on macrophages that vary under different cellular
and environmental conditions. This highlights the impact that stimulation type and
timing, relative to myelin application, has on myelin-induced shifts in macrophage
phenotype. Microglia and macrophages in the injured spinal cord would likely be
exposed to inflammatory stimuli before or concurrent with the clearance of myelin
debris. Macrophages also encounter distinct stimuli in the SCI vs. MS lesion
environment. It is therefore possible that different macrophage activation states
during myelin processing lead to varied inflammatory responses in SCI and MS.
Until the molecular mechanisms through which myelin exerts its effects are better
understood, it remains unclear how myelin and inflammatory stimuli synergize to
produce different cellular responses.
In addition, the macrophage response to myelin uptake varies depending
upon the receptors mediating phagocytosis (Figure 1.1). In traditional responses
to infection and damage, macrophage PRRs often share redundancies in the
molecular structures they target. It has been proposed that collective
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engagement of different PRRs can influence the cellular response to an
inflammatory insult (Jozefowski et al., 2005; Mukhopadhyay et al., 2004). Indeed,
in SCI, the collaborative engagement of PRRs vs. activation in isolation yields
distinct reparative or pathological functions (Gensel et al., 2015). Notably, the
PRRs capable of recognizing and clearing myelin, as discussed above, appear to
mediate contrasting cellular responses along the spectrum of macrophage
activation states. This suggests that the specific combination of myelin clearance
receptors utilized after injury may influence the inflammatory effects of myelin
debris. For example, in-vitro, MARCO is important in mediating pro-inflammatory
IL-12 production in response to inflammatory stimuli (Jozefowski et al., 2005).
Similarly, it is well documented that macrophages increase IL-12 release with
myelin stimulation (Sun et al., 2010; Wang et al., 2014). Given that MARCO is
present on macrophages after SCI (Gensel et al., 2017), it is possible that
MARCO-mediated myelin clearance may influence the M1-like polarization
observed in SCI. Conversely, SRAI/II has been implicated in the inhibition of IL12 production (Jozefowski, 2004; Jozefowski et al., 2005). Whether the
differential function and regulation of these macrophage receptors are of similar
importance in the context of myelin debris clearance after SCI is unknown
(Figure 1.1).
Following SCI or other neurological conditions, myelin clearance is likely
influenced simultaneously by multiple receptors. This receptor cross-talk could be
additive, synergistic, or antagonistic in terms of intracellular signaling depending
on which receptors are present and activated during clearance (Lee and Kim,
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2007; Natarajan et al., 2006). Interestingly, certain bacterial strains have evolved
to manipulate this PRR crosstalk by CR3, MARCO, TLRs, and C5aR (discussed
below) to block the production of IL-12 and IFN-γ thereby impairing macrophage
bacterial clearance (Hajishengallis and Lambris, 2011). Although, whether a
similar approach could be harnessed to manipulate myelin-mediated
inflammatory responses after SCI has yet to be studied. Additionally, TREM2
plays a role in myelin clearance and integrity. As discussed above, it is important
in regulating the transcriptional programs essential for myelin phagocytosis
(Cantoni et al., 2015; Poliani et al., 2015; Siddiqui et al., 2016). Further, TREM2
signaling facilitates the production of tropic factors important in oligodendrocyte
differentiation, survival, and remyelination (Poliani et al., 2015). Interestingly,
overexpression of TREM2 increases the efficiency of non-inflammatory
phagocytosis (Takahashi et al., 2005; 2007). TREM2 overexpression in
macrophages also induces an M2 phenotype and M2 activation is inhibited in
TREM2 KO macrophages (Seno et al., 2009; Takahashi et al., 2005). In an
experimental model of MS, TREM2 facilitated myelin removal while increasing
anti-inflammatory cytokine production (Takahashi et al., 2007). Whether TREM2
drives M2 macrophage activation is the context of SCI is unknown but these
studies suggest that it may be a pro-reparative pathway for myelin debris
clearance.
CD36 (a class B scavenger receptor) is also implicated in macrophagemediated myelin clearance after SCI. Recently, (Zhu et al., 2017), examined
shifts in macrophage transcriptional profiles from 3 to 7 days post injury (dpi).
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They observed a significant shift from genes controlling cytokine signaling and
cellular migration at 3dpi to a profile dominated by lipid catabolism at 7dpi
through the liver X and retinoid X receptor (LXR/RXR) and peroxisome
proliferator-activated receptors (PPAR)/RXR canonical pathways (Zhu et al.,
2017). Further, they targeted the most enriched lipid receptor identified, CD36,
and found that its genetic deletion reduced lipid accumulation in macrophages
and improved functional outcomes after SCI (Zhu et al., 2017). Interestingly, the
RXR signaling pathways are similar to those activated by foam cells within
atherosclerotic lesions.
Independent of the receptor mediating myelin clearance, a previous study
of foamy macrophages in SCI showed that myelin stimulation shifted the balance
of macrophage activation towards M1 activation. Specifically, myelin stimulation
increased pro-inflammatory NF-κβ/STAT1 signaling and decreased M2associated STAT3/STAT6 signaling (Wang et al., 2014). Further, while myelin
increased lipid efflux and activated ATP-binding cassette transporter A1 (ABCA1)
in macrophages, in foamy cells, myelin decreased the phagocytic capacity for
necrotic neutrophils (Wang et al., 2014). Since foamy macrophages are present
in SCI, they proposed that these spent, but non-phagocytosed, neutrophils
released toxins and contribute to secondary injury after SCI. This is a novel
potential mechanism through which foam-like, myelin-laden macrophages may
contribute to secondary injury processes (Wang et al., 2014). Given the
extensive lipid debris accumulating within SCI macrophages, additional
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comparisons to foam cells and atherosclerosis may lead to new therapeutic
targets.
Another important factor that likely regulates the myelin-macrophage
neuro-immune interaction in SCI is the phagocytic cell origin. Microglia have the
phagocytic capacity to remove damaged myelin and are the predominant
phagocyte to clear debris in the acutely injured spinal cord (Greenhalgh and
David, 2014). However, by three days post injury, this role is largely taken over
by infiltrating macrophages (Greenhalgh and David, 2014). Specifically, in the
first weeks after SCI, MAC-2 positive bone marrow-derived macrophages enter
the lesion site and are positive for myelin debris (Wang et al., 2014). These
infiltrating macrophages accumulate in the lesion over time and contain lipid
debris for at least 42dpi (Greenhalgh and David, 2014). In contrast,
CX3CR1high resident microglia are primarily found along the periphery of the
lesion/lipid plaque in areas of less concentrated myelin debris (Wang et al.,
2014). The downstream effects of this differential distribution of macrophages
and microglia relative to lipid debris has been discussed previously (Zhou et al.,
2014) but it is interesting to consider how cell-specific receptor expression may
mediate myelin polarization in SCI. For example, MARCO is primarily expressed
by infiltrating and not resident myeloid cells (Getts et al., 2014). Similarly, MAC-2
expression is specific to monocyte derived macrophages after SCI (Wang et al.,
2014). TREM2, however, is predominantly expressed by microglia (Schmid et al.,
2002). As discussed above, these receptors have different propensities for proinflammatory or anti-inflammatory cytokine release in response to myelin
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stimulation (Figure 1.1). It is therefore possible that varied receptor expression
on microglia and monocyte-derived macrophages predisposes these cells for
different inflammatory responses to SCI myelin debris. Determining the relative
contribution of microglia vs. macrophages on myelin-mediated SCI inflammation
will be challenging, however, based upon the observation that macrophage
myelin phagocytosis varies depending upon the inflammatory cues driving
recruitment to the site of injury (Slobodov et al., 2001).
Relative to the injured spinal cord, myelin may induce deleterious proinflammatory macrophage activation (Kroner et al., 2014; Wang et al., 2014).
Myelin and myelin phagocytosis likely potentiate signaling pathways and
polarization states in macrophage and function as direct inflammatory stimuli
(Figure 1.1). Determining the mechanisms and environmental conditions through
which myelin can induce these effects in immune cells could lead to novel
therapies for SCI and other neuroinflammatory disorders.

Complement Mediated Myelin Clearance
In addition to macrophages, the complement system is a key inflammatory
mediator of myelin debris removal. The detailed pathways and diverse roles of
complement have been reviewed in the context of SCI (Peterson and Anderson,
2014). Here we discuss the contributions of complement to myelin clearance and
how this may influence inflammatory pathways after SCI. Within the complement
system, there are numerous proteins in the plasma that enzymatically mark
pathogens for destruction. Specifically, proteins of the complement cascade
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selectively recognize pathogen associated molecular patterns (PAMPs) or
damaged associated molecular patterns (DAMPs) and opsonize, or tag these
PAMPs or DAMPs for removal. Complement component 3 proteins, most notably
C3b, act as opsonizing agents. Opsonized pathogens are targets for removal
through complement receptors on phagocytes (such as CR3 discussed above) or
through secondary complement pathways. Regardless of which complement
pathway is initiated (classical, alternative, or lectin), a secondary complement
membrane attack complex is formed, creating large holes in the target
membrane and ultimately causing pathogen lysis (Parham, 2009). Complement
proteins opsonize myelin debris in the CNS and thus, the complement system is
a critical initiator of myelin invoked inflammatory responses to SCI in addition to
its other direct functions (Peterson and Anderson, 2014; Sun et al., 2010; van der
Laan et al., 1996b). Further, the activation of this immune pathway through
myelin interactions, DAMPs, or other means can directly damage intact myelin,
oligodendrocytes, and neurons, thereby driving inflammation by increasing
myelin and cellular debris or other inflammatory mediators.
The primary source of complement is the liver. It produces substantial
quantities of inactive complement. This complement is stored in the plasma until
it is activated in response to infection or damage. After SCI, disruption of the
blood brain barrier allows complement proteins to enter the lesion site. Indeed,
complement increases in the injured spinal cord within 1 day of SCI in both rats
and humans (Nguyen et al., 2008). SCI-induced inflammatory cytokines may also
increase complement serum levels at these acute time points (Rebhun and
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Botvin, 1980). While plasma-derived complement is likely the main initiator of
early myelin clearance after SCI, complement is present in the chronically injured
spinal cord (Anderson et al., 2004). Many cells of the immune and nervous
systems are capable of producing complement proteins, including
macrophages/monocytes, lymphocytes, and neutrophils, all of which enter the
lesion after SCI, and resident astrocytes, neurons, and microglia within the CNS
(Barnum, 2016; Beck et al., 2010; Peterson and Anderson, 2014). These
endogenous sources of complement in the SCI microenvironment are largely
unstudied but could be critical in complement-mediated reactions and myelin
clearance after injury.
Many factors within the SCI lesion environment potentially activate the
complement cascade with downstream effects on myelin clearance (Figure 1.2).
For example, binding of complement protein C1q to oligodendrocyte myelin
glycoprotein (OMgp) drives myelin opsonization and clearance (Johns and
Bernard, 1997). OMgp contains an amino acid motif that shares homology with
C1q binding sites on PAMPs/DAMPs (Johns and Bernard, 1997). OMgp and C1q
levels increase after SCI (Anderson et al., 2004; Dou et al., 2009). Since C1q
binding to OMgp initiates complement activation, it is likely that C1q mediates
myelin debris clearance and inflammation after SCI (Figure 1.2). Indeed, C1q
knockout mice have improved SCI recovery and tissue sparing and altered
macrophage activation compared to wild-type SCI controls (Galvan et al., 2008).
Another potentially important complement protein in myelin-immune
interactions after SCI is C5. Studies conducted primarily in models of MS and
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Alzheimer’s disease demonstrate that formation of the C5b-9 membrane attack
complex on oligodendrocytes leads to extensive demyelination and
oligodendrocyte cell death (Bradt et al., 1998; Liu et al., 1983; Rus et al., 2009).
This lytic attack requires the proteolytic cleavage of complement into bioactive
proteins including C5a among others (Figure 1.2). While not well understood
within the CNS, in the periphery C5a binds to receptors on mast cells and
basophils ultimately inducing degranulation and release of vasoactive
substances. These substances, such as histamine, increase blood vessel
permeability (Parham, 2009). Further, C5a is a potent chemoattractant for
monocytes and neutrophils (Marder et al., 1985). C5a can therefore drive
inflammation by increasing recruitment and efflux of immune cells from the blood
to sites of cellular debris (Miller and Stella, 2009). In the context of myelin debris
induced complement activation after SCI, increased C5a could act as an ongoing
recruitment signal and mediator of macrophages entry into the injury site. A
recent study demonstrated that loss of C5aR, the receptor for C5a, reduces
macrophage recruitment and inflammatory cytokine production early after SCI
(Brennan et al., 2015). Further, C5a has direct apoptotic effects on neurons that
may contribute to secondary injury, thereby increasing cellular debris (Farkas et
al., 1998; Humayun et al., 2009). It is therefore feasible that complementmediated myelin debris clearance results in pro-inflammatory macrophage
activation, increased demyelination, and further complement activation (Figure
1.2). Collectively, complement, myelin, and macrophage interactions may form a
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positive feedback cycle maintaining a chronic inflammatory state in the injured
spinal cord.

Targeting Myelin as an Inflammatory Mediator in SCI
Spinal cord injuries and other neuroinflammatory conditions inevitably
result in tissue destruction and the generation of cellular and myelin debris. While
debris must be cleared to begin recovery, it has direct effects on the cells that
clear it, namely macrophages and microglia. The mechanisms contributing to the
failed debris clearance in SCI by phagocytes remain unclear, as do the myelinmediated pathways invoking inflammatory responses, including myelin-driven
complement-mediated inflammation. Myelin is not inherently pro-inflammatory in
all scenarios but is capable of producing detrimental outcomes when cleared and
processed under specific cellular and environmental conditions. This indicates
that the pathological effects of myelin may be receptor or activation state
dependent. Targeting these pathways and receptors opens the possibility for
therapeutic interventions to improve recovery after SCI. Further, given myelin’s
ubiquitous presence in the CNS, the development of new therapies will likely
impact a variety of disorders in which complement, myelin, and macrophage
interactions contribute to persistent inflammation.
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1- iii. Cytosolic Phospholipase A2 as an Inflammatory Mediator

Cytosolic Phospholipase A2 as an Inflammatory Mediator Summary
cPLA2 enzymatically releases arachidonic acid (AA) from cellular
membranes in response to inflammatory stimuli. AA is then converted into
dozens of lipid signaling molecules in the eicosanoid signaling family with
diverse, albeit largely pro-inflammatory, roles in inflammation. cPLA2 is implicated
in the vast majority of conditions involving significant inflammatory responses,
including SCI. While cPLA2 is generally pro-inflammatory, it also capable of
inducing protective anti-inflammatory lipids under certain cellular conditions. As a
result, we seek to specifically target pro-inflammatory cPLA2 activity in myelinladen macrophages. To this aim, in this body of work, we detail the pathological
roles of cPLA2 in chronically pro-inflammatory myelin-laden macrophages in
chapter 2 and propose alternative approaches to specifically target cPLA2 in
macrophages after SCI in chapters 4 and 5.

Cytosolic Phospholipase A2 as an Inflammatory Mediator
Cytosolic phospholipase A2 (cPLA2) is a major mechanism initiating and
regulating inflammatory responses in various cell types, including macrophages
(Dennis and Norris, 2015; Gijón and Leslie, 1999). Arachidonic acid is stored at
the sn-2 position of membrane phospholipids, where it is largely inactive.
Enzymes from the lipid-cleaving phospholipase A2 family can release AA from
the membrane, of which cPLA2 is the most ubiquitous and widely studied due to
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its role in the targeted release of AA in response to a variety of agonists (Gijón
and Leslie, 1999). Basal cPLA2 expression is increased in response to growth
factors and inflammation in various cell types, notably macrophages. Enzymatic
activity of cPLA2 is activated by phosphorylation of its serine 505 site by mitogenactivated protein kinase (MAPK) in response to increased intracellular calcium,
inflammatory stimuli, or reactive oxygen species, many of which are substantially
elevated after SCI (van Rossum et al., 1999). The amount of AA released by
activated cPLA2 is then largely dependent on substrate availability, that is, the
amount of AA present in the membranes of the endoplasmic reticulum.
Additionally, the oxidation of lipids in the membrane by ROS alters its viscosity,
further increasing AA availability to cPLA2 (van Rossum et al., 1999).
Upon its release, AA serves as the primary precursor to the eicosanoid
family of inflammatory mediators produced through three synthesis pathways.
The cyclooxygenase (COX) pathways produce prostaglandins, thromboxanes,
and prostacyclins, the lipoxygenase (LOX) pathways produce leukotrienes,
hydroxy fatty acids, lipoxins, and hepoxilins, and finally, the cytochrome P-450
pathway produces fatty acid epoxides and hydroxy fatty acids. These
eicosanoids have diverse, albeit largely pro-inflammatory functions, including the
activation of the inflammatory NF-kB signaling cascade, increasing edema
through vasodilation, and the chemoattraction of immune cells (Brash, 2001;
Cubero and Nieto, 2012; Morcos and Ouf, 1986; Sung et al., 2007). The
synthesis of eicosanoids is regulated predominately by the amount of free AA
available and the activation state of the oxygenases. Together these lipid
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mediators are primary drivers of the initiation and resolution of inflammation
(Farooqui, 2012; Farooqui et al., 2007; 2010). In macrophages, eicosanoids have
influential roles in regulating phagocytic activity and their microbial defenses
(Bailie et al., 1996; Coffey et al., 1998; Knapp and Melly, 1986; Wirth and
Kierszenbaum, 1985; Yong et al., 1994). The specific role of each eicosanoid on
macrophage physiology is poorly understood in the context of SCI inflammation.
General extrapolation from the cPLA2 literature would suggest a predominantly
pro-inflammatory, detrimental role for eicosanoids in macrophage activation
during SCI inflammation (Dennis and Norris, 2015).
cPLA2 has long been investigated as a mediator of inflammation. Early
studies recognized PLA2 enzymes as key mediators of inflammation, notably in
venoms from reptiles and wasps (Fairbairn, 1948). Later work identified the role
of calcium in regulating PLA2 activity, preempting the recognition of calciumdependent phospholipase A2 (cPLA2) (Hülsmann, 1983). In the coming decades,
the role of cPLA2 in inflammatory responses was widely implicated in numerous
disease models, including brain injury, Alzheimer’s disease, ultraviolet skin
damage, kidney diseases, periodontitis, arthritis, programmed cell death in
response to chemotherapy in melanomas, and cervical dilation in pregnancy
(Cybulsky et al., 1995; Gresham et al., 1996; Kramer et al., 1996; Liu et al., 2019;
Shinohara et al., 1992; Stephenson et al., 1996; Voelkel-Johnson et al., 1996).
cPLA2 is a key mediator of inflammation throughout the body. As a result, cPLA2
is nearly ubiquitously involved in nearly every disorder in which inflammation is a
major contributor, including SCI (Liu et al., 2006).
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When cPLA2 is widely activated from a large stimulus, such as a major
injury, the eicosanoid storm is initiated (Dennis and Norris, 2015). Within minutes
of an SCI, there are rapid spikes in the production of specific eicosanoids
downstream of AA. Some like 5-HETE are elevated within 5 minutes of injury and
remain elevated for days; others like LTC4 peak within 10 minutes and dissipate
with the hour (Jacobs et al., 1987; Mitsuhashi et al., 1994). Similarly, other
eicosanoids like TXB2 and 6-keto-PGF1 rise after injury and remain elevated
long after injury (Jacobs et al., 1987). There are dozens of these AA-derived
eicosanoids produced after injury; however, the cellular specific production,
activity, and duration of these mediators are poorly understood in the context of
SCI. While most eicosanoids are generally pro-inflammatory, some can mediate
regeneration and the resolution of inflammation (Dennis and Norris, 2015).
Studies that target cPLA2 in SCI are thereby nonspecifically blocking all
eicosanoid activities downstream of AA.
Interestingly, myelin membranes contain high concentrations of AA, stored
in its inactive esterified state; however, whether cPLA2 can act on these lipids
remains unknown. In theory, myelin could contribute substantial quantities of AA
to cellular stores in the membranes of the endoplasmic reticulum, nuclear
envelope, and other potential sites (Gijón and Leslie, 1999; Schievella et al.,
1995). In this body of work, we examine the activity of cPLA2 across macrophage
activation states and Identify cPLA2 as a key mediator of myelin's effects on the
macrophage inflammatory response.
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cPLA2 has been targeted in SCI with differential results. In a transgenic mouse
study, cPLA2-/- mice were found to have improved recovery after SCI highlighting
cPLA2 as a novel therapeutic target for SCI therapeutics and found pathological
roles for related phospholipases (Lopez-Vales et al., 2008). We hypothesize that
this dichotomy is a byproduct of blocking both beneficial and detrimental
eicosanoids downstream of AA. Lopez et al. did not observe detrimental effects
of cPLA2 ablation until two weeks after injury. It is possible that blocking some of
the anti-inflammatory eicosanoids typically produced later in the inflammatory
response could have contributed. To this aim, in this body of work, we detail the
pathological roles of cPLA2 in chronically pro-inflammatory macrophages in
chapter 2 and propose alternative approaches to specifically target cPLA2 in
macrophages after SCI in chapters 4 and 5.

1- iv. Azithromycin as an Immunomodulatory Antibiotic

Azithromycin as an Immunomodulatory Antibiotic Summary
Azithromycin is a promising therapeutic for the treatment of SCI. First, it is
already FDA-approved, thereby bypassing many of the regulatory challenges of
new therapeutics. Next, the concept that azithromycin drives beneficial
macrophage activation states has been well established in other disease models.
In SCI, our previous pre-clinical studies demonstrated AZM’s ability to shift
macrophage phenotype, thereby improving recovery. In this body of work, we
build upon our prior AZM studies in chapter 3 by delaying the initiation of AZM
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administration until minutes and hours after the injury. This subtle alteration in
experimental design is a critical step in AZM's development as a therapeutic for
SCI as it better reflects the clinical reality of therapeutic administration. Lastly, we
discuss the remaining challenges in advancing AZM towards clinical use.

Azithromycin as an Immunomodulatory Antibiotic
While the role of the macrophage inflammatory response in SCI
pathophysiology has been well characterized through basic research, there is no
therapeutic available to target this pathway in humans. Further, the use of the
only therapeutic available for SCI, methylprednisolone, has diminished due to
potential side effects (Evaniew et al., 2015). This has created an urgent need for
the development of additional therapeutics to improve SCI recovery in humans.
To this aim, our prior works have investigated the FDA-approved
immunomodulatory antibiotic, Azithromycin (AZM), as a therapeutic in a preclinical mouse model of SCI (Gensel et al., 2017; Zhang et al., 2015b).
In these proof of concept studies, we found that “AZM drives alternative
macrophage activation and improves recovery and tissue sparing in contusion
spinal cord injury” (Zhang et al., 2015b). These results were consistent with
studies from other disease models such as stroke and lung infections with
Pseudomonas aeruginosa, where AZM exerted therapeutic effects through its
ability to modulate macrophage phenotype (Amantea et al., 2016b; Feola et al.,
2010a). Specifically, AZM inhibits the STAT1 and NF-κB signaling pathways in
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macrophages, thereby promoting the anti-inflammatory activation state (Haydar
et al., 2019).
In our first proof of concept study (Zhang et al., 2015b), we administered
AZM via oral gavage to three-month-old female mice daily starting three days
prior to injury and then daily for up to seven days. In FACS-sorted macrophages
isolated from the SCI lesion, we observed a significant increase in antiinflammatory (M2) markers (Arginase-1 and CD206) and a significant decrease
in CD86, which is associated with pro-inflammatory (M1) macrophages. Similarly,
at 3dpi, AZM induced a significant increase in CD206 in microglia. Histologically
at 28dpi, AZM significantly increased tissue sparing relative to vehicle. When
examined in an open field during the course of 28dpi we observed significantly
improved locomotion in AZM treated animals as measured by the Basso Mouse
Scale (BMS). Similarly, AZM significantly improved proprioceptive locomotor
function determined by the relative number of hindlimb footfalls with a Gridwalk
apparatus at 28dpi. Lastly, in vitro, supernatant from pro-inflammatory “M1”
macrophages was applied to a Neuro2A neuron culture. Supernatants from
macrophages treated with AZM were significantly less toxic to neurons.
Collectively, this work established the proof of concept that AZM improved SCI
recovery by driving alternative macrophage activation.
In our next study developing AZM as an SCI therapeutic, we sought to
better understand exactly how AZM was altering macrophage activation after
SCI. To this aim, we first utilized our BMDM in vitro system to thoroughly
examine the gene expression profiles of pro-inflammatory “M1” and anti-
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inflammatory “M2” macrophages (Gensel et al., 2017). This identified a series of
gene targets that are differentially expressed in M1 and M2 macrophages. Next,
we administered AZM doses of 10, 40, or 160mg/kg to four-month-old female
mice at the time of injury and then daily for the rest of the survival period (3 or 7
days). We then isolated macrophages from the injury site at the time of
euthanasia and subjected them to the same gene panel utilized on our BMDM
samples. Using this data, we were then able to detect which M1/M2 gene targets
were suppressed or elevated by AZM in each dosing paradigm. Lastly, in a
separate cohort of animals processed for histological analyses (160 mg/kg
dosage), we examined protein expression of a series of M1 and M2 markers at 3
and 7dpi. At 3dpi, AZM significantly increased M2-associated markers CD206
and Arg-1 and decreased M1-associated markers MARCO and CD86. Similarly,
at 7dpi, AZM significantly decreased M1-associated markers MARCO and CD86;
however, at this timepoint CD206 and Arg-1 were unaffected. Collectively, this
work demonstrated a dose-dependent immunomodulatory shift in macrophage
activation following SCI (Gensel et al., 2017).
In this body of work, we build upon our prior AZM studies in chapter 3 by
delaying the initiation of AZM administration until minutes and hours after the
injury. This subtle alteration in experimental design is a critical step in AZM's
development as a therapeutic for SCI as it better reflects the clinical reality of
therapeutic administration. Lastly, we discuss the challenges in advancing AZM
towards clinical use and address the required steps to continue its development.

30

Azithromycin Dosing Strategies
A major limitation of our early study is that we used a pre-injury and postinjury dosing paradigm because it was shown to be effective in another disease
model (Feola et al., 2010b). Indeed, this approach resulted in clear therapeutic
benefits by successfully shifting macrophage activation states (Zhang et al.,
2015b); however, this dosing paradigm is not clinically relevant. In our second
study, we administered AZM beginning 30 minutes after injury; however, we did
not examine long-term functional recovery. This dosing paradigm, while
improved, would still present great challenges for clinical translation. In the
second and third National Acute Spinal Cord Injury Randomized Controlled Trials
(NASCIS) of methylprednisolone for the treatment of SCI, many patients were
unable to begin treatment until several hours after their injury (Bracken et al.,
1991; 1997). Given that AZM is widely regarded as safe even when taken for
extended periods (Uzun et al., 2014) and is already widely prescribed (Durkin et
al., 2018), it is possible that AZM may be administered much faster than
methylprednisolone; however, 30 minutes from injury to administration would
remain a clinical challenge for many patients. In this body of work, we address
this by examining the therapeutic effectiveness of AZM when administered
starting 30-minutes, 3-hours, and 24 hours after SCI throughout a
comprehensive 28 day recovery period.
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1- v. Macrophage-Targeted Therapies for the Treatment of SCI and Other
Neurological Conditions.
Macrophages dominate the SCI lesion environment mediating both
destructive and reparative responses after injury (Kigerl et al., 2009). Generally,
however, SCI macrophages predominately adopt a pro-inflammatory activation
state thought to impair recovery (Gensel et al., 2017; Kigerl et al., 2009). These
macrophages have thus become critical therapeutic targets to improve recovery
after SCI. Specifically, macrophage-targeted therapies generally seek to reduce
pro-inflammatory activation. This could reduce macrophage production of toxic
mediators, including reactive oxygen species (ROS), nitric oxide, and proinflammatory cytokines and eicosanoids, thereby reducing excessive cellular
damage and death. Conversely, macrophage-targeted therapies often aim to
increase anti-inflammatory, pro-reparative macrophage activation states. This
could promote the resolution of inflammation and induce an environment more
supportive of healing and repair. Macrophages exist along a spectrum of
activation states; macrophage-targeted therapies seek to shift the general
activation characteristics of these cells to minimize damage and promote repair.
As discussed previously, AZM is a promising immunomodulatory antibiotic
capable of shifting macrophage activation states to improve recovery after SCI
(Gensel et al., 2017; Zhang et al., 2015b). Similarly, cPLA2 is a key mediator of
pro-inflammatory macrophage activation and detrimental cellular activities. As
such, AZM and cPLA2 inhibitors are promising macrophage-targeted therapies to
improve recovery after SCI. In this body of work, we continue to build pre-clinical
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data developing these macrophage-targeted therapies into therapeutics for SCI.
Additionally, in chapter 4 we continue to develop additional strategies to target
macrophages after SCI, including transgenic manipulation of cPLA2, AZM
derivative pharmaceuticals with altered immunomodulatory profiles, and the
immunomodulatory cytokine leukemia inhibitory factor (LIF). Lastly, we cover the
remaining macrophage-targeted therapies currently and previously in
development in the SCI research field.
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Figure 1.1. Macrophage receptors potentially mediating myelin clearance
and inflammatory activity after spinal cord injury
In addition to activating a number of different receptors, in the context of SCI,
myelin also drives downstream pathways (Stat1) associated with proinflammatory (M1) macrophage activation. References can be found in the main
text.
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Figure 1.2. Complement system in myelin clearance and macrophage
recruitment after spinal cord injury.
Numerous complement pathways are initiated by myelin debris after SCI. (A)
C1q binds directly to myelin oligodendrocyte myelin glycoprotein (OMgp) or to an
antibody intermediate as depicted. (B) C1q binding initiates the formation of a C3
convertase capable of cleaving C3. (C) The C3b cleavage fragment opsonizes
myelin debris and binds to macrophage complement receptor 3 (CR3) initiating
the phagocytosis of myelin debris. (D) C3b can also induce the formation of a C5
convertase. (E) The C5 convertase initiates the cleavage of C5 and the
subsequent recruitment of C6-9 creating the C5b-9 membrane attack complex
capable of rupturing myelin membrane debris or intact oligodendrocytes. (F) The
C5a fragment released during this process acts as both a potent recruitment
signal for macrophages to the site of complement opsonization, through the C5
receptor (C5aR) and as a pro-inflammatory, vasoactive stimulus on a variety of
other cell types. References can be found in the main text.
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Chapter 2: The Effects of Myelin on Macrophage Activation are Phenotypic
Specific via cPLA2 in the Context of Spinal Cord Injury Inflammation
This chapter is adapted from Kopper et al. 2021
2- i. Chapter Summary
Spinal cord injury (SCI) produces chronic, pro-inflammatory macrophage
activation that impairs recovery. The mechanisms driving this chronic
inflammation are not well understood. Here, we detail the effects of myelin debris
on macrophage physiology and demonstrate a novel, activation state-dependent
role for cytosolic phospholipase-A2 (cPLA2) in myelin-mediated potentiation of
pro-inflammatory macrophage activation. We hypothesized that cPLA2 and
myelin debris are key mediators of persistent pro-inflammatory macrophage
responses after SCI. To test this, we examined spinal cord tissue 28-days after
thoracic contusion SCI in 3-month-old female mice and observed both cPLA2
activation and intracellular accumulation of lipid-rich myelin debris in
macrophages. In vitro, we utilized bone marrow-derived macrophages to
determine myelin’s effects across a spectrum of activation states. We observed
phenotype-specific responses with myelin potentiating only pro-inflammatory
(LPS+INF-γ; M1) macrophage activation, whereas myelin did not induce proinflammatory responses in unstimulated or anti-inflammatory (IL-4; M2)
macrophages. Specifically, myelin increased levels of pro-inflammatory
cytokines, reactive oxygen species, and nitric oxide production in M1
macrophages as well as M1-mediated neurotoxicity. PACOCF3 (cPLA2 inhibitor)
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blocked myelin’s detrimental effects. Collectively, we provide novel
spatiotemporal evidence that myelin and cPLA2 play an important role in the
pathophysiology of SCI inflammation and the phenotype-specific response to
myelin implicate diverse roles of myelin in neuroinflammatory conditions.

Keywords: Neuroinflammation, Foamy, Neurotrauma, Secondary Injury,
Eicosanoid, Brain, IL-10, Foam cell, Arachidonic acid, M1/M2.

2- ii. Background:
Spinal cord injury (SCI) triggers a complex neuroinflammatory response
that mediates tissue repair but also potentiates secondary injury processes.
Activated macrophages, consisting of resident microglia and infiltrating
monocytes, contribute to this dichotomous response. Macrophages facilitate
repair by increasing axon growth, stem cell differentiation, and revascularization
(Gensel and Zhang, 2015; Kigerl et al., 2009), however, macrophages can also
contribute to pathology through secondary injury processes involving reactive
oxygen species (ROS), neurotoxins, and pro-inflammatory cytokine release as
well as by causing axon retraction and dieback (Gensel and Zhang, 2015; Horn
et al., 2008). The extent to which macrophages are polarized toward reparative
(also called M2 or anti-inflammatory) or pathological (also called M1 or proinflammatory) phenotypes largely depends on the stimuli present in the injured
spinal cord.
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One notable distinction between SCI and self-resolving peripheral nerve
injuries is the sustained presence of myelin debris. Lipid-laden myelin debris is
taken up and processed predominantly by infiltrating macrophages, rather than
endogenous microglia, after SCI (Wang et al., 2014). Phagocytic markers are
present on these chronically activated macrophages, which become visibly laden
with debris (Fleming et al., 2006; Greenhalgh and David, 2014; Kroner et al.,
2014; Vargas and Barres, 2007; Wang et al., 2014). It is therefore likely that
myelin lipids are actively processed by macrophages and are environmental
stimuli that drive chronic spinal cord inflammation. Indeed, in areas of Wallerian
degeneration, macrophages disappear from the chronically injured spinal cord
concomitant with myelin debris clearance (Becerra et al., 1995; Greenhalgh and
David, 2014; Vargas and Barres, 2007; Wang et al., 2014). The accumulation of
lipid debris in the days and weeks after injury also closely aligns with the
temporal shift in macrophage phenotype, ending with persistent pro-inflammatory
activation by 28 dpi (Kigerl et al., 2009; Wang et al., 2014). Evidence also
suggests that myelin acts as an inflammatory stimulus on macrophages in vitro,
implicating a key link between myelin debris accumulation and the grievous shift
in macrophage phenotype which impairs regeneration after SCI (Kopper and
Gensel, 2017; Kroner et al., 2014; Wang et al., 2014; Williams et al., 1994).
While myelin debris is implicated in macrophage activation state and
recovery after SCI (Kroner et al., 2014; Wang et al., 2014; Zhu et al., 2017), the
intracellular mechanisms mediating myelin’s effects remain unclear. Cytosolic
phospholipase A2 (cPLA2) facilitates arachidonic acid (AA) release from cellular
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membranes following inflammatory stimuli and is largely unstudied in SCI
macrophage responses. Interestingly, myelin membranes contain high
concentrations of AA, stored in its inactive esterified state; however, whether
cPLA2 can act on these lipids remains unknown. cPLA2-mediated breakdown of
AA initiates an eicosanoid storm in which a wide variety of bioactive lipids are
released including prostaglandins, leukotrienes, and thromboxanes. Eicosanoids
have diverse albeit largely pro-inflammatory functions including activating the
inflammatory NF-kB signaling cascade and increasing edema as well as
potentiating immune cell chemoattraction, fibrosis, and inflammatory responses.
The role of cPLA2 in macrophage physiology has been detailed in other systems;
however, it is unknown if cPLA2 has any differential effects in macrophages
polarized along the spectrum of activation states in the presence of myelin, or if it
is a contributor to prolonged pro-inflammatory activation of macrophages after
SCI. cPLA2 activation is induced by inflammatory stimuli such as LPS/IFN-γ, also
known as the M1, pro-inflammatory paradigm in vitro, and is likely induced by the
complex inflammatory environment observed after SCI (Dennis and Norris, 2015;
Liu et al., 2006; 2014). This is the basis of our hypothesis that cPLA2 activity in
myelin-laden macrophages after SCI aggravates tissue damage and
contributes to chronic inflammation. Here we establish these mechanisms in
vitro, and provide the proof-of-concept that these pathways may play an
important role in vivo after SCI.
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2- iii. Methods:
Animals
As described previously (Kopper et al., 2019; Zhang et al., 2015b), in vitro
experiments were performed using 2–4-month-old female C57BL/6 mice
(Jackson Laboratory, Bar Harbor, Maine). In vivo experiments were performed
using 4-month-old female C57BL/6 mice, weighing 20.7 g ± 1.3 g (Jackson
Laboratory, Bar Harbor, ME, USA). Animals were housed in IVC cages with ad
libitum access to food and water. All procedures were performed in accordance
with the guidelines and protocols of the Office of Research Integrity and with
approval of the Institutional Animal Care and Use Committee at the University of
Kentucky. All experiments were carried out in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010).

Cell Culture
Bone marrow-derived macrophages (BMDMs) were extracted from the
femur and tibia of female C57BL/6 mice at 2–4 months old as previously reported
(Gensel et al., 2009; 2015) and were plated at 0.8–1 × 106 cells/mL in
differentiation media containing Roswell Park Memorial Institute medium (RPMI,
Thermo Fisher Scientific, #21870-092) supplemented with 1%
penicillin/streptomycin (P/S, Thermo Fisher Scientific, #5140122), 1% HEPES
(Sigma-Aldrich, #83264-100ML-F), 1% GlutaMAX 0.001 (Thermo Fisher
Scientific, #35050061) 0.001% β-mercaptoethanol (Thermo Fisher Scientific,
#21985023), 10% FBS (Life technologies, #10082147), and 20% supernatant
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from sL929 cells (a generous gift from Phillip Popovich, The Ohio State
University). Supernatant collected from sL929 cells contains macrophage colonystimulating factor, which helps to promote bone marrow cells’ differentiation into
macrophages(Burgess et al., 1985). The BMDMs were allowed to differentiate for
7 days in culture, and cells were then replated on day 7 at a density of
1 × 106 cells/mL in 12-well plates in RPMI, containing 1% P/S, 1% GlutaMAX and
10% FBS. On day 8, cells were stimulated for 24 h to be either M1 using LPS
(50 ng/mL, Invivogen, #tlrl-eblps, standard preparation) plus IFN-γ (20 ng/ml,
eBioscience #14-8311-63) diluted in N2A growth medium (described below), M2
using IL-4 (20 ng/ml, R&D systems, #404-ML-010), or Control/Unstimulated
(CTL) using fresh media without any stimulants. At the time of stimulation cells
were immediately treated with myelin debris (50 µL/mL, preparation described
below), 50 µM PACOCF3 (inhibitor of cPLA2, Tocris Bioscience, CAS 141022-993), or PBS/DMSO vehicles to equalize volume and drug solvent concentrations
across groups. 24 h after stimulation the supernatants were removed, centrifuged
at 13,000 RPM (Fisher Scientific accuSpin Micro R centrifuge), and then this
macrophage conditioned media (MCM) was either applied directly to N2A cells to
measure cytotoxicity, or stored at − 80 °C prior to testing for IL-12p40 levels
using standard ELISA kits (Thermo Fisher Scientific, Rockford, IL # EMIL12P40),
Nitric Oxide with the Griess Reagent Kit (Thermo Fisher Scientific # G-7921), and
phenol red-free RPMI, or a mulit-plex ELISA system measuring protein levels of
TNF-alpha, IL-1Beta, IL-6, CX3CL1, and IL-10 (Meso Scale Diagnostics).
BMDMs for coverslip stains were treated as above, except at a lower plating
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density of 3 × 105 cells/mL. Coverslips were fixed in cold 2% PFA for 30 min,
washed in PBS and stored at 4 °C until staining.
Moderate purity myelin (> 95% myelin, with small contributions from
axolemma and other cellular membranes) was prepared as follows (adapted from
Larocca et al. (Larocca and Norton, 2001)): brains were collected from C57BL/6
mice at the time of BMDM isolation and stored at − 80 °C prior to myelin isolation.
The brains were rinsed and suspended in cold PBS with 1% P/S and placed in a
Dounce homogenizer (DWK Life Science, #357544) under sterile conditions and
blended with the loose and tight pestles. The solution was transferred to a 15 mL
tube and pelleted at 2000 RPM (Thermo Scientific Legend XTR centrifuge) prior
to discarding the soluble supernatant fraction. The pellet was resuspended in the
PBS/P/S, and then 5mLs of a 30% Percoll solution (Sigma-Aldrich, #P1644500ML) was gently underlaid below the myelin solution for density gradient
centrifugation. The layers were then centrifuged at 2000 RPM for 15 min at 4 °C
under gentle acceleration/deceleration, generating three distinct layers (soluble
on top, myelin in middle, and Percoll/cell pellet on bottom). After removing the
soluble fraction, the myelin was transferred to a fresh tube and resuspended in
10 mL distilled water with 1% P/S and incubated for 10 min (hypoosmotic shock)
to separate membranes at 4 °C. The myelin was then re-pelleted at 2000 RPM,
suspended in PBS/1% P/S and separated a second time by density gradient
centrifugation as described above. The myelin was then suspended and pelleted
twice in PBS/1% P/S to remove residual Percoll and water-soluble contaminants,
and then aliquoted before storage at − 80 °C. The final protein concentration of
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the myelin stock solutions produced by this protocol were 10.23 mg/mL with a
standard deviation of 0.282 mg/mL as determined by a BCA Protein Assay Kit
(Thermo Fisher Scientific #23225). With the application of myelin debris to
BMDMs at 50 µL/mL, cells had a mean dosage of 0.51 mg/mL. Lastly, to ensure
our results were not due to endotoxin contamination in our myelin preparations,
we tested aliquots from each batch of myelin stimulant (Thermo Fisher Scientific
#88282).
A mouse neuroblastoma cell line (Neuro-2a or N2A, a gift from Chris
Richards, University of Kentucky) was maintained in N2A growth medium
containing 45% DMEM, 45% OPTI-MEM reduced-serum medium, 10% fetal
bovine serum (FBS), and 1% penicillin/streptomycin. N2A were plated at a
density of 1 × 105 cells/mL in 96-well tissue culture plates and allowed to
proliferate for 48 h. The neurotoxicity of MCM was evaluated as reported
previously using a MTT-based cell growth determination kit according to the
manufacturer’s instructions (Sigma-Aldrich CGD1-1KT) (Zhang et al., 2019).
Briefly, 24 h before testing, N2A growth media was replaced with serum-free N2A
media to induce differentiation. The day of testing this media was replaced by
fresh MCM, and the N2A cells were incubated in MCM for 24 h before thiazolyl
blue tetrazolium bromide (MTT (5 mg/ml), 20 μl per well) was added to each well
and the cells further incubated for 2 h. The tetrazolium ring of MTT can be
cleaved by mitochondrial dehydrogenases of viable cells, yielding purple
formazan crystals, which were then dissolved in acidified isopropanol solvent.
The resulting purple solution was spectro-photometrically measured at 570 nm
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Epoch microplate reader (BioTek Instruments, Inc., Winooski, VT) using 690 nm
as a background absorbance. This data is normalized to the non-toxic CTL
values to generate proportional decrease in viability values and presented
inversely as increased toxicity relative to CTL.
Macrophage reactive oxygen species (ROS) production was measured
using CM-H2DCFDA (Invitrogen #C6827). In short, BMDMs were cultured and
stimulated as described above except in a 96 well plate (1 × 106 cells/mL).
Following the 24-h stimulation the supernatants were removed and replaced with
a 5 µM solution of CM-H2DCFDA in phenol red-free RPMI with 1% GlutaMAX
and penicillin/streptomycin and incubated at 37 °C for 25 min. ROS mediates the
conversion of this compound to fluorescent DCF which was then detected by an
Epoch microplate reader (BioTek instruments, Inc., Winooski, VT) at the
compound’s Excitation/Emission spectra of approx. 492–495/517–527 nm.
Macrophage cPLA2 activity was measured using a Cytosolic
Phospholipase A2 Assay Kit (Abcam #ab133090). In short, cells were cultured as
described above except in six well culture dishes (1 × 106 cells/mL). Cells were
lysed and briefly sonicated on ice in TBS-T (0.4% Triton-X) with a protease
inhibitor (Sigma-Aldrich #11836170001) before proceeding directly into the
manufacturer’s protocol.

Spinal Cord Injury
As described previously (Kopper et al., 2019; Zhang et al., 2015b) ,
animals were anesthetized via intraperitoneal (i.p.) injections of ketamine
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(100 mg/kg) and xylazine (10 mg/kg). Following a T9 laminectomy, a moderatesevere thoracic SCI was produced using the Infinite Horizon (IH) injury device
(75-kdyn displacement; Precision Systems and Instrumentation). Any animals
receiving SCI with abnormalities in the force vs. time curve generated by the IH
device were excluded from analysis. These abnormalities are indicative of bone
hits or instability in the spinal cord at the time of injury and occurred < 10% of the
time. After injury, muscle and skin incisions were closed using monofilament
suture. After surgery, animals received one subcutaneous injection of
buprenorphine-SR (1 mg/kg) and antibiotic (5 mg/kg, enroloxacin 2.27%:
Norbrook Inc., Lenexa, KS) in 2 mL of saline and were housed in warming cages
overnight. Animals continued to receive antibiotic subcutaneously in 1 mL saline
for 5 days. Food and water intake and the incision site were monitored
throughout the course of the study. Bladder expression was performed on injured
mice twice daily. Mice were sacrificed at 7 and 28 days post-injury (n = 8 and 10,
respectively) to generate spinal cord sections for histological analyses.

Tissue processing and immunohistochemistry
As described previously (Kopper et al., 2019; Zhang et al., 2015b) , mice
were anesthetized and then transcardially perfused with cold PBS (0.1 M, pH
7.4), followed by perfusion with cold 4% paraformaldehyde (PFA). Dissected
spinal cords (1 cm) were post-fixed for another 2 h in 4% PFA and subsequently
rinsed and stored in cold phosphate buffer (0.2 M, pH 7.4) overnight at 4 °C. On
the following day, tissues were cryoprotected in 30% sucrose for 3 days at 4 °C,
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followed by rapidly freezing and blocking in optimal cutting temperature (OCT)
compound (SakuraFinetek USA, Inc.) on dry ice. Tissue blocks were cut in serial
coronal sections (10 μm) and mounted onto Colorfrost plus slides (Fisher #12550-17).
Spinal cord sections were stained with Eriochrome Cyanine (myelin) and
anti-Neurofilament (1:1000, Aves labs, NFH) to visualize damage and thereby
identify the epicenter of each lesion, as defined as the point where spared tissue
constitutes the smallest proportion of spinal cord volume (Kopper et al., 2019).
Immunohistochemistry on tissue sections and BMDM coverslips was performed
to stain for phosphylated-cPLA2 (p-cPLA2; rabbit, 1:500, Cell Signaling
Technology #2831S), BODIPY (2 µM 30 min, Thermo Fisher Scientific #D3922),
biotinylated tomato lectin (TomL) (Sigma-Aldrich L0651-1MG, and DAPI (SigmaAldrich #D9542-10MG) overnight at 4 °C. Secondary antibodies were applied at
1:1000 for 1 h at RT: Alexa Fluor 546 goat anti-rabbit (Life Technologies
#11010), and Streptavidin Alexa Fluor 647 conjugate (Thermo Fisher Scientific
#S-21374). Antigen retrieval was performed to improve signal: 10 min in sodium
citrate buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 6.0) at 90 °C.
BODIPY is specific to neutral lipids from the breakdown of myelin and cellular
membranes. TomL binds to poly-N-acetyl lactosamine on macrophages and
microglia. TomL also binds to large blood vessels which were excluded from
analysis when possible based on their large tubular morphology (Schmid et al.,
2002; Villacampa et al., 2013). Imaging was performed at or within 100 µm of
lesion epicenter due to tissue loss during antigen retrieval. All images were taken
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using a C2+ laser scanning confocal microscope (Nikon Instruments Inc.,
Melville, NY, USA). Images were quantified using using the MetaMorph analysis
program (Molecular Devices, Sunnyvale, CA, USA).

Statistical Analysis:
As described previously (Kopper et al., 2019; Zhang et al.,
2015b) statistical analyses were completed using GraphPad Prism 6.0
(GraphPad Software). Data were analyzed using one- or two-way ANOVA
followed by Dunnett’s test for multiple comparisons. Results were considered
statistically significant at p ≤ 0.05. All data are presented as mean ± SEM unless
otherwise noted. All in vitro measurements were done in triplicates, and at least
three independent experiments were carried out. Imaging and quantification were
performed by investigators fully blinded to all experimental conditions. In vitro
experiments were not fully blinded during experimental procedures (due to the
obvious presence of myelin in some conditions); however, all analyses were
confirmed by an investigator blinded to experimental conditions. Figures were
prepared using Adobe Photoshop CS6 (Adobe Systems) and Prism 6.0.

2- iv. Results:
Myelin-Laden Macrophages Contain Active cPLA2 After SCI
In order to determine the extent to which cPLA2 may be contributing to
myelin processing by macrophages after SCI, we examined inflammation within
the injured spinal cord 4 weeks after mouse contusion SCI. As reported

47

previously (Wang et al., 2014), we observed that SCI generated extensive
infiltration of monocyte derived macrophages and activation of resident microglia
(Figure 2.1A,F,K). Similarly, we observed presumptive myelin debris, i.e. neutral
lipid droplets detected by BODIPY staining inside TomL+ macrophages
throughout the injury epicenter (Figure 2.1B,G,L). Extracellular lipid droplets not
clearly contained within macrophages were also present (Figure 2.1B,G,L).
Next, we sought to determine whether the cPLA2 system is active
(phosphorylation indicates activation) in these chronically activated macrophages
within the injured spinal cord. As indicated in Figure 2.1C,H,M, cPLA2 is widely
activated (p-cPLA2) throughout the lesion epicenter images of macrophages, and
critically is observed within macrophages containing lipid debris at 28 days after
injury (dpi). Similar observations were also seen at 7 dpi (Supplemental Figure
2.1). Lastly, uninjured tissue from sham surgery animals contained TomL+
macrophage/microglia populations but no appreciable lipid debris, and minimal
cPLA2 activation (Figure 2.1P-T). Collectively this provides spatiotemporal
evidence that macrophages are chronically present in the injured spinal cord,
loaded with substantial myelin-derived lipid debris, and can contain activated
cPLA2. Furthermore, these results provide the proof-of-concept that myelin and
cPLA2 may play a key role in the prolonged pro-inflammatory macrophage
activation thought to impede semi-acute and chronic recovery after SCI.
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Myelin Potentiates Pro-inflammatory Macrophage Activation in an Activation
State Dependent Manner
To determine the role of myelin in the activation of macrophages we
developed an in vitro model of SCI inflammation. BMDMs are predictive of
monocyte-derived macrophage responses in vivo in the injured spinal cord. This
have been observed at transcription (Longbrake et al., 2007) and functional
levels (Gensel et al., 2015), as well as in response to therapeutic interventions
(Gensel et al., 2017). Further, BMDMs are the primary myeloid cells
phagocytizing myelin after SCI (Wang et al., 2014). Specifically, we used an M1
stimuli (LPS + IFN-γ) to model the detrimental pro-inflammatory activation state,
M2 (IL-4) to model the reparative anti-inflammatory activation state, and CTL
(unstimulated control or M0) to model a mature, yet naïve macrophage. Myelin
stimulation was generated from mouse CNS tissue to model the myelin debris
“stimulant” generated after SCI in vivo. Using this system, we observe both
myelin up-take across activation states and increased cPLA2 activation under M1
conditions (p<0.001) (Supplementary Figure 2.2). Interestingly, we observed
that many of myelin’s effects on macrophage physiology were activation state
dependent, with differential effects when applied in the M1, M2, or CTL activation
states. In Figure 2.2A pro-inflammatory (M1) macrophages had increased
production of the pro-inflammatory cytokine IL-12 compared to unstimulated
(CTL) or anti-inflammatory (M2) macrophages, as would be expected (p<0.001).
Upon the concurrent addition of myelin to these groups, however, the M1
production of IL-12 rises substantially (p<0.01), whereas CTL and M2 cells were
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not significantly affected. In Figures 2.2B and 2.2C we performed additional
stimulations and measured the production of reactive oxygen species (ROS) and
nitric oxide, two toxic macrophage byproducts thought to contribute to cell death
and SCI pathogenesis. With this, we observed a similar phenotype-specific effect
in which only pro-inflammatory M1 cells were significantly potentiated by the
addition of myelin, whereas CTL and M2 cells were not significantly affected.
Specifically, M1 stimulation significantly increased levels of ROS (p<0.001), and
nitric oxide relative to unstimulated (CTL) cells, as would be expected. Critically,
each of these M1 mediated increases were significantly increased with the
application of myelin alongside the M1 stimulation, indicating that myelin
potentiates pro-inflammatory responses (p<0.001 and p<0.001 respectively).
Interestingly, this novel phenomenon occurred despite observing similar degrees
of myelin debris uptake across all treatment groups (Supplemental Fig 2.2),
suggesting that differences in phagocytosis is not a contributing factor. The
mechanisms through which the myelin was taken up under each phenotype,
however, was not evaluated. To test the effects of myelin on an anti-inflammatory
associated functional outcome we examined the activity of the arginase-1
enzyme in cell lysates from each of our stimulations (Figure 2.2D). As would be
expected M2 macrophages had higher arginase activity relative to M1 and CTL
(p<0.001 and p<0.0001 respectively). The addition of myelin, however, did not
alter arginase activity in any of the stimulations tested. Lastly, the myelin
stimulants did not contain any endotoxin contamination that would confound our
results (Supplemental Figure 2.3). Collectively, this suggests that the pro-
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inflammatory effects of myelin on macrophage activation states are phenotypespecific.
Next, we sought to determine the cellular implications of these shifts in
macrophage polarization states by applying BMDM conditioned media from these
cells to a neuronal cell line (N2A) to determine the relative neurotoxicity of each
stimulation. In Figure 2.2E, we observed that M1 neurotoxicity was again
significantly potentiated by the addition of myelin, whereas CTL and M2 cell
toxicity was unaffected by the addition of myelin.

cPLA2 Inhibition Blocks Myelin’s Pro-inflammatory Potentiation of M1
Macrophages
The activation of cPLA2 by inflammatory stimuli is thought of as the
primary rate-limiting step in the release of AA and the initiation of the production
of various eicosanoids during the onset of inflammation. Given that we observed
significant effects of myelin in macrophages in the presence of pro-inflammatory
stimuli (LPS and IFN-γ), we hypothesized that cPLA2 activation in M1
macrophages may be a key mediator of myelin’s cellular effects. To test this
hypothesis, we targeted cPLA2 in our in vitro model using the chemical inhibitor
Palmityl trifluoromethylketone (PACOCF3) as used previously (Schaeffer et al.,
2005). As in our initial studies, we found myelin induced significant increases in
ROS, nitric oxide, and neurotoxicity when applied with an M1 stimulus,
potentiating the M1 pro-inflammatory response (Figure 2.3). Critically,
application of the cPLA2 inhibitor, PACOCF3, significantly reduced the myelin-
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mediated increases of ROS, nitric oxide, and neurotoxicity, indicating an
important role for cPLA2 in this system (Figure 2.3). Interestingly, PACOCF3 did
not influence arginase activity in any of the stimulations tested (Figure 2.3D and
Supplemental Figure 2.4D and 2.4H), suggesting that cPLA2 is not linked to
cellular arginase activity. Given that myelin did not previously affect ROS, nitric
oxide, neurotoxicity, or arginase in the context of CTL or M2 stimulation, we
would not expect cPLA2 to influence these outcomes. Indeed, PACOCF3 had no
significant effects on CTL or M2 simulations groups (Supplemental Figure 2.4).
Collectively these data suggest that cPLA2 may play a key role in mediating
myelin’s effects on pro-inflammatory macrophage activation.

Macrophage Cytokine Profiles Indicate a Mixed Neuroinflammatory Phenotype.
Macrophages exist along a spectrum of activation states commonly
simplified to pro- vs. anti-inflammatory states in vivo, or M1/M2 in vitro. While
these terms are used for practical purposes, macrophages are further
characterized by many factors including morphology, surface markers, secreted
cytokines, byproducts and functional outcomes. Our measures of neurotoxicity,
IL-12, nitric oxide and ROS indicate a pathological phenotype; however, these
are not comprehensive phenotypic indicators. To begin to address this complex
phenotypic analysis we sought to measure additional inflammatory cytokines
using a multiplex ELISA in our in vitro myelin/cPLA2 system. In line with our
previous observations, M1 macrophages had significantly increased production
of the pro-inflammatory cytokines TNFα (p>0.001) and CX3CL1 (p>0.001) upon
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the addition of myelin (Figure 2.4A, 2.4C), and for TNFα, cPLA2 inhibition
blunted this effect (p<0.01) (Figure 2.4B). Similarly, myelin significantly reduced
the production of anti-inflammatory IL-10 in M1 cells, exacerbating their proinflammatory phenotype (p<0.001) (Figure 2.4E). Conversely, the proinflammatory cytokine IL-1β was significantly decreased in M1 cells following the
addition of myelin (p<0.001) (Figure 2.4G). For the pro-inflammatory cytokine, IL6, M1 cells were unaffected by the addition of myelin. Interestingly, for CX3CL1,
myelin induced a small but significant increase in cytokine levels in CTL and M2
cells (Figure 2.4C); IL-10 and IL-6 had similar trends in this regard, however,
they were not statistically significant. Lastly, in some instances the cPLA2
inhibitor (PACOCF3) alone induces significant cytokine shifts, decreasing
CX3CL1 (p<0.01) and increasing anti-inflammatory IL-10 (p<0.001) (Figures
2.4D, 2.4F), suggesting that cPLA2 inhibition has anti-inflammatory effects
outside the context of myelin stimulation. Interestingly, when examining the
effects of myelin and cPLA2 inhibition specifically within CTL and M2 stimulation
we observed statistically significant but biologically small, relative to M1,
increases in both pro (TNF-alpha, CX3CL1, IL-6) and anti-inflammatory (IL-10)
cytokines suggesting myelin can induce a limited mixed phenotype in M2 and
CTL groups (Supplemental Figure 2.5). Collectively, these data indicate that
myelin induces a mixed neuroinflammatory cytokine profile.
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Myelin Increases cPLA2 Activity in an Activation State Dependent Manner.
Myelin has long been proposed as an inflammatory stimulus in CNS
models of neuroinflammation (Williams et al., 1994). Similarly, cPLA2’s activation
in response to a wide variety of chemokines and inflammatory signal has been
well documented (Gijón and Leslie, 1999). Despite this, the formal hypothesis of
whether myelin can directly increase macrophage cPLA2 activation has not been
directly tested. To this aim we performed a PLA2 activity assay on cell lysates
from CTL, M1, and M2 treated cells with or without myelin. Myelin increased
PLA2 activity in an activation state dependent manner, with M1 cells containing
active PLA2, which was further increased (* p<0.05) with the addition of myelin
(Figures 2.5A-C). Conversely, PLA2 activity in CTL and M2 cells was below the
detection limit of the assay with or without the addition of myelin. To distinguish
cPLA2 activity from iPLA2, cell lysates were incubated in Bromoenol Lactone to
inhibit iPLAs. iPLA2 inhibition did not significantly reduce total PLA2 activity in any
of the groups tested indicating cPLA2 is likely the primary source of this
enzymatic activity (Figures 2.5A-C).

2- v. Discussion:
The continual inflammatory response observed after spinal cord injury
(SCI) is a primary mechanism impairing recovery, however, the factors
contributing to this maladaptive response are poorly understood. One unique
aspect of the CNS injury environment not present in peripheral injuries is the
accumulation of large volumes of myelin debris within phagocytes at the lesion
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epicenter. Indeed, recent literature suggests that myelin may drive proinflammatory macrophage activation, supporting the notion that myelin
accumulation within macrophages may be a key driver of the persistent proinflammatory macrophage response observed after injury (van der Laan et al.,
1996c; Wang et al., 2014; Williams et al., 1994). However, there are conflicting
reports regarding the role of myelin on macrophage activation (Boven, 2005;
Kroner et al., 2014) and the mechanisms governing these discrepancies are not
well understood. In this study we provided the proof of concept that myelin and
cPLA2 may play a key role in the prolonged pro-inflammatory macrophage
activation thought to impede semi-acute and chronic recovery after SCI.
Specifically, we found that myelin potentiates macrophage polarization in an
activation state-dependent manner. The addition of myelin alongside a proinflammatory M1 macrophage stimulus (LPS and IFN-γ) further polarized proinflammatory activation as indicated by increased IL-12 production. Conversely,
myelin had minimal effects on anti-inflammatory M2 (IL-4 stimulated) or control
(unstimulated) macrophages. Similar patterns emerged when examining ROS,
nitric oxide, arginase activity (indicative of M2 activation), and the neurotoxic
potential of the macrophage supernatants. Inhibition of cPLA2 significantly
blunted these harmful effects while arginase activity was unaffected. In vivo we
observed ubiquitous myelin debris in, and around, macrophages expressing
active cPLA2, providing the key spatiotemporal evidence that cPLA2 may also
mediate the detrimental effects of myelin in macrophages after SCI.
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Myelin and cPLA2’s pro-inflammatory activities appear to be largely
exclusive to the M1 phenotype as M2 and CTL cells were unresponsive to myelin
in most outcome measures. This interesting observation becomes clearer upon
closer examination of cPLA2 biology. AA is stored at the sn-2 position of
membrane phospholipids where it is largely inactive. Enzymes from the lipidcleaving phospholipase A2 family can release AA from the membranes, of which
cPLA2 is the most ubiquitous and widely studied due to its role in the targeted
release of AA in response to a variety of agonists (Brash, 2001; Gijón and Leslie,
1999). Here, we demonstrate that myelin itself can induce increased
cPLA2 activity. Once activated, cPLA2 translocates from the cytosol to the
membranes of the endoplasmic reticulum and nuclear envelope. These are the
primary sites of cPLA2 activity under homeostatic conditions, however, any
alterations in cPLA2 activity within the myelin-laden macrophage is currently
unknown (Schievella et al., 1995). It remains uncertain if myelin’s AA rich lipids
could be a direct substrate for cPLA2 or if these lipids could be trafficked within
the cell to the endoplasmic reticulum and other membranes and be targeted. For
each AA molecule released by cPLA2, lysophosphatidylcholine is also produced,
which is known to cause further demyelination and thus could contribute to the
prolonged myelin debris production observed after SCI (Lopez-Vales et al.,
2008). Basal cPLA2 expression is increased in response to growth factors and
inflammation in a variety of cell types, notably macrophages. cPLA2 is activated
by mitogen-activated protein kinase (MAPK) phosphorylation of its serine 505
sites in response to increased intracellular calcium, inflammatory stimuli, or ROS,
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many of which are substantially elevated after SCI (or in our in vitro model LPS
and IFN-γ) (Liu et al., 2006; van Rossum et al., 1999). The amount of AA
released by activated cPLA2 is then largely dependent on substrate availability,
of which myelin could contribute substantial quantities to cellular stores in the
membranes of the endoplasmic reticulum, nuclear envelope and other potential
sites. Further, the oxidation of lipids in the membrane by ROS alters its viscosity
further increasing AA availability to cPLA2 (van Rossum et al., 1999). Collectively,
this suggests that the detrimental effects of myelin are restricted to the M1
phenotype, as only under these conditions could cPLA2 become robustly
activated and release AA.
Given the influential roles cPLA2 activation and subsequent eicosanoid
storms play in the initiation and resolution of inflammation, it is perhaps
unsurprising that cPLA2 has been previously studied in the context of SCI.
Indeed, following SCI there is a substantial acute and sustained production of AA
derived inflammatory mediators (Hanada et al., 2012; Mitsuhashi et al., 1994;
Murphy et al., 1994). One such study by NK Liu et al. found that
pharmacologically or genetically targeting cPLA2 improved locomotor and
anatomical recovery after SCI. Conversely, López-Vales et al. found cPLA2 to
have protective functions after SCI. Given the immensely diverse factors
controlling cPLA2 activation, AA release, and the downstream production of
inflammatory mediators, it is quite possible that cPLA2 has differential effects
depending on the treatment paradigm or cell type (i.e. toxic mediators produced
by M1 macrophages as in our in vitro model, and anti-inflammatory mediators in
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other cell types with different enzymatic processing of AA released by cPLA2).
Indeed, in the spinal cord after injury, in addition to macrophages, we observed
appreciable cPLA2 activity in many non-macrophage cell types within the lesion
epicenter. Given the great heterogeneity of lipid signaling molecules downstream
of cPLA2, and differential capacities of each cell type to produce these mediators,
it is uncertain whether cPLA2 is mediating detrimental or beneficial effects in
these other non-macrophage cell types. Prior studies targeting cPLA2 have used
a global approach to target cPLA2 either genetically or with chemical inhibitors
with conflicting results (Liu et al., 2006; Lopez-Vales et al., 2011). Our results
suggest that cPLA2 plays a clear detrimental role in macrophage physiological
responses to myelin, and thus future studies specifically targeting macrophage
cPLA2 in vivo may hold more therapeutic potential than the previous systemic
approaches in which both detrimental and beneficial mechanisms are likely being
affected. One important caveat to consider when using therapeutics targeting
cPLA2 is that many chemical inhibitors are cross-reactive with closely related
phospholipases. In this study our cPLA2 inhibitor of choice PACOCF3, for
example, can also inhibit a related enzyme calcium-independent phospholipase
A2 (iPLA2). While our data suggests that iPLA2 is not contributing significantly to
total PLA2 activity at 24-h post-stimulation, it’s activities prior to cell lysis were not
examined. Consequently, the influence of iPLA2 cannot be ruled out in this study.
Similarly, previous work has demonstrated that inhibiting cPLA2 can influence the
breakdown and phagocytosis of myelin during Wallerian degeneration (De et al.,
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2003). Continued work is needed to determine if such a mechanism could be
occurring in the SCI Myelin-macrophage and our in vitro model.
Our results are consistent with a number of previous observations.
Specifically, a 1994 publication by Williams et al. demonstrated that the treatment
of microglia with myelin debris increased microglial activation as indicated by
increased pro-inflammatory cytokine and ROS production (Williams et al., 1994).
Next, Van der laan et al. demonstrated that myelin increases TNF-alpha and
nitric oxide when applied to peritoneal macrophages. Lastly, Wang et al. (2014),
observed similar increases in pro-inflammatory macrophage activation with
myelin application to bone marrow-derived macrophages, and demonstrated the
key role that this infiltrating macrophage population plays in clearing myelin
debris in vivo after SCI (Wang et al., 2014).
While these papers support a mechanism linking myelin phagocytosis to
the pro-inflammatory macrophage response observed after SCI, our results
conflict with other data reporting anti-inflammatory actions of myelin in in vitro
models of various CNS disorders (Boven, 2005; Kroner et al., 2014). This
suggests that the effects myelin has on macrophage activation may depend on
the type of macrophage, stimulation timing, myelin source, dosage, and the CNS
condition being modeled as discussed previously (Kopper and Gensel, 2017).
Similarly, others have observed pro-inflammatory effects of myelin without an M1
co-stimulus (Wang et al., 2014). Our data presented here indicate that the effect
of myelin is phenotype specific, which may further account for these differences.
For example, Kroner et al., utilized a sequential approach: applying an M1
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stimulus to the BMDMs, washed thoroughly, and then applied bovine-derived
myelin (Kroner et al., 2014). While this approach is certainly appropriate for some
studies, it may not capture our phenotype-specific cPLA2 mediated inflammation,
as cPLA2 could need sustained LPS/IFN-γ to remain activated and exert its
effects with myelin. Specifically, cPLA2 activity is regulated by both a rapid
transient calcium influx induced by inflammatory stimuli and its phosphorylation
state allowing for complex regulation of either brief or sustained activation (Lee et
al., 2015; Leslie, 1997). Given this, sequential or simultaneous application of
myelin and LPS/IFN-γ could induce cPLA2 to activate and interact with myelin
under very different regulatory conditions; however, further studies are needed to
better understand how phenotype, cPLA2 regulation, and methodological
variation such as this synergize to produce differential responses to myelin. In
doing so we could better understand the immune dysregulation leading to chronic
inflammation after human SCI.
Our model utilized in this work has its own strengths and limitations in
modeling the complex SCI inflammatory response. First, we chose to use BMDM
as our cell choice as recent literature has implicated this monocyte derived
population as the primary mediator of myelin clearance, and as being more
detrimental to recovery relative to microglia (Bellver-Landete et al., 2019; Wang
et al., 2014). Second, we utilized a high dose of myelin which was not overtly
toxic yet provided excess myelin to overwhelm the cell’s phagocytic capacity over
the 24-h stimulation window similar to what occurs after SCI (Becerra et al.,
1995; Greenhalgh and David, 2014; Vargas and Barres, 2007; Wang et al.,
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2014). Lower doses may be better suited to shorter duration stimulations or
studies investigating the effects of myelin upon binding to extracellular receptors.
Third, our myelin preparations are from the same species and strain as the mice
from which we collected the BMDMs (i.e. mouse myelin on mouse cells, and
when feasible, myelin derived from the same mouse sacrificed for BMDM
isolation). This was done to minimize any unintended cross-species immune
effects. A limitation here, however, is that we used myelin derived from both brain
and spinal cord tissue to yield sufficient myelin for our studies, it is possible that
subtle differences in myelin composition between these sites could have
differential effects. Similarly, the protein and lipid composition of CNS and PNS
myelin differs and was not evaluated in this study (Quarles et al.). Fourth, we
utilized a prolonged 24-h stimulation paradigm to allow for complete lipid loading
of the cells as occurs in vivo. It is certainly possible that the results could be
different at earlier time points. Similarly, studies interested in true chronic effects
could adapt these protocols using cell lines to overcome the short lifespan of
BMDMs. Fifth, we applied the myelin and stimulants at the same time and for the
entire stimulation, as this is what likely occurs after SCI. Lastly, we applied
myelin with multiple types of stimulates to begin to capture how myelin may affect
macrophages across the spectrum of phenotypic states. An important caveat to
this, however, is that we primarily investigated pathological BMDM features
associated with impaired SCI recovery. There are likely other effects of myelin on
CTL and M2 macrophage physiology not captured in this study.
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While in many ways our macrophage model closely replicates the cellular
populations found after SCI (Gensel et al., 2017), there are certainly other factors
not utilized here in our model. Notably, TNF and iron are implicated as key
environmental mediators of detrimental macrophage activation (Kroner et al.,
2014). Similarly, in vivo after SCI there are numerous other factors that can
influence macrophage activation, including cross talk between macrophages and
microglia, T-cell responses, and damage associated molecular patterns released
by necrotic tissue (Greenhalgh et al., 2018; Wynn and Vannella, 2016). While not
investigated here, these are all likely important factors contributing to proinflammatory macrophage activation in myelin-laden macrophages and represent
an important caveat in extrapolating our results to the human SCI condition.
Similarly, while the data presented here implicate cPLA2 as an important
regulator of myelin’s activity, other cellular mechanisms are certainly involved.
Myelin uptake/phagocytosis, for example, is clearly a key step prior to any
intracellular mechanism. Injection of myelin directly into the spinal cord previously
by Sun and colleagues was found to induce leukocyte chemoattraction, however,
this effect was lost in CR3 KO animals with deficient phagocytic capacity. Next,
they implicated the FAK/Akt/NF-κB signaling cascade as a mediator of myelin’s
activity (Sun et al., 2010). These observations are certainly compatible with our
current observations as the NF-κB signaling cascade is activated by similar
stimuli as the cPLA2 signaling cascade including our LPS in-vitro stimulant.
Interestingly, activation of NF-κB by myelin may even drive increased
cPLA2 expression, further demonstrating the intertwined nature of many
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proposed mechanisms (Lee et al., 2011). Collectively, this demonstrates the
need for continued investigation of these pathways to identify a clinically viable
treatment for SCI in the human condition.
Our in vitro data suggest that myelin debris potentiates pro-inflammatory
functions specifically within the M1 macrophage population. Intriguingly, the time
course of peripheral macrophage infiltration and initial clearance of myelin debris
between 3 and 7 days post-SCI correlates with the peak presence of M2
macrophage activation markers, which then progressively drop as the cells shift
to a pronounced and prolonged M1 activation state (Gensel and Zhang, 2015;
Kigerl et al., 2009). By chronic time points only M1 markers can be detected,
indicative of the prolonged pro-inflammatory macrophage activation thought to
impede recovery (Becerra et al., 1995; Vargas and Barres, 2007; Wang et al.,
2014). Here we demonstrate that cPLA2 is present within myelin-laden
macrophages well into chronic time points. Together with our in vitro data, this
provides the proof of concept that myelin and cPLA2 may play a key role in the
prolonged pro-inflammatory macrophage activation thought to impede semiacute and chronic recovery after SCI. Collectively this highlights macrophage
cPLA2activity as a potential key mediator of the neuroinflammatory response
after SCI and thereby warrants continued investigation as a therapeutic target.

Conclusions:
Spinal cord injury (SCI) produces chronic intraspinal inflammation
consisting of resident microglia and infiltrating monocytes. These chronically
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activated SCI macrophages adopt a persistent pro-inflammatory, pathological
state that potentiates secondary damage and impairs SCI recovery (Gensel and
Zhang, 2015; Horn et al., 2008). The mechanisms driving chronic macrophage
activation in SCI are poorly understood. Here we implicate myelin debris and
cPLA2 as key mediators of pathological macrophage activation. In vitro we found
that the effects of myelin on macrophage activation are phenotype-specific, with
myelin potentiating only pro-inflammatory (LPS + INF-γ; M1) macrophage
activation, whereas myelin had no pro-inflammatory effect on unstimulated or
anti-inflammatory (IL-4; M2) macrophages. Inhibition of cPLA2 significantly
reduced the detrimental effects of myelin on M1 macrophages, implicating cPLA2
as a key regulator of maladaptive macrophage activation. In vivo we observed
ubiquitous myelin debris in, and around, macrophages expressing active cPLA2
providing the key spatiotemporal evidence that cPLA2 may also mediate the
detrimental effects of myelin in macrophages after SCI. Collectively, this
establishes a novel mechanism driving detrimental macrophage activation and
provides key evidence identifying macrophage cPLA2 activity as a therapeutic
target to improve recovery after SCI.
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Figure 2.1. Macrophages can contain both myelin-derived lipids and active
cPLA2 28 days after spinal cord injury (SCI).
Ten adult, 4-month-old C57/b female mice received a T9 75kdyn infinite horizons
(IH) contusion SCI. A-E) Representative example of TomL positive macrophages
(blue) in injured white matter containing both lipid debris (green, Bodipy, staining
for neutral lipids) and active p-cPLA2 (red) (imaged area is represented by box
within spinal cord diagram). DAPI (white) was excluded from merged images. FJ) Example of TomL positive macrophages (blue) in injured grey matter
containing both lipid debris (green, Bodipy, staining for neutral lipids) and active
p-cPLA2 (red). K-O) Example of TomL positive macrophages (blue) in injured
grey matter in the core of the injury epicenter containing both lipid debris (green,
Bodipy, staining for neutral lipids) and active p-cPLA2 (red). P-T) Example of
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TomL positive macrophages (blue) in uninjured tissue from sham animals with
minimal lipid debris or active p-cPLA2 (red). Boxes indicate examples of triple
positive cells. Maximum intensity projection confocal images. Scale bar in image
P=50µm.
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Figure 2.2. Myelin potentiates pro-inflammatory macrophage activation in
vitro.
Bone marrow derived macrophages (BMDMs) were utilized to determine the
function outcomes resulting from myelin debris application under three distinct
activation states: M1 (IFN-γ and LPS), M2 (IL-4), or CTL (media, i.e.
unstimulated). A) Myelin stimulation significantly increased pro-inflammatory IL12 cytokine levels relative to M1 alone (*** p<0.001), however myelin did not
increase IL-12 in CTL or M2 treated cells. M1 stimulations had increased IL-12
relative to CTL or M2 (### p<0.001). B) Following the stimulation BMDMs were
washed and treated with 2 µM H2DCFDA for 25 min. Myelin stimulation
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increased ROS relative to M1 alone (*** p<0.001), however myelin did not
increase ROS in CTL or M2 treated cells. M1 stimulations had increased ROS
relative to CTL or M2 (### p<0.001). C) Nitric oxide levels in treated
supernatants were examined using the Griess assay of nitrite accumulation.
Myelin stimulation increased nitric oxide relative to M1 alone (*** p<0.001),
however myelin did not increase nitric oxide in CTL or M2 treated cells. M1
stimulations had increased nitric oxide relative to CTL or M2 (### p<0.001). D)
Cell lysates were tested for arginase enzymatic activity. M2 macrophages had
higher arginase activity relative to M1 and CTL (p<0.001 and p<0.0001
respectively). The addition of myelin however did not significantly alter arginase
activity in any of stimulations tested. E) Supernatants were applied to a neuron
culture (N2A cells) for 24 hours to determine supernatant toxicity. Myelin
stimulation increased neurotoxicity relative to M1 alone (* p<0.05), however
myelin did not increase neurotoxicity in CTL or M2 treated cells. M1 stimulations
had increased ROS relative to CTL or M2 (### p<0.001). Representative of 3
independent biological replications of both BMDMs and myelin source. * p<0.05,
** p<0.01, *** p<0.001, # p<0.05, ## p<0.01, ### p<0.001 mean ± SEM.
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Figure 2.3. Inhibition of cPLA2 with PACOCF3 reduces the pro-inflammatory
effects of myelin on M1 macrophages.
BMDMs were grown and stimulated as in Figure 2, with or without the addition of
cPLA2 inhibitor, PACOCF3 (50 µM). A) cPLA2 inhibition reduced myelin mediated
ROS increases in M1 (IFN-γ and LPS) macrophages. B) cPLA2 inhibition reduced
myelin mediated Nitric oxide production. C) cPLA2 inhibition reduced the
neurotoxic potential of M1 macrophages treated with myelin as determined by an
MTT assay measurement of N2a cell viability. D) cPLA2 inhibition did not
significantly alter arginase activity. Representative of 3 biological replications of
both BMDMs and myelin source. *p<0.05, ** p<0.01, *** p<0.001 mean ± SEM.
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Figure 2.4. Macrophage cytokine profiles indicate a mixed
neuroinflammatory phenotype.
Supernatants from treated BMDMs were collected to measure pro- and antiinflammatory cytokine production in response to phenotype, myelin stimulation,
and cPLA2 inhibition with PACOCF3. A-B) Myelin significanty increases the
production of TNF-alpha in M1 cells, but has no effect on CTL and M2 cells.
cPLA2 inhibition significantly reduced myelin potentiation of M1 TNF-alpha
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production. C-D) Myelin increases CX3CL1 in CTL, M1, and M2 cells. cPLA2
inhibition significantly reduced this effect in M1 cells, but not under M1 and
Myelin co-stimulation. E-F) Myelin significantly decreased IL-10 production in M1
cells, but this effect was not reversed with cPLA2 inhibition. cPLA2 inhibition alone
increased IL-10 production in M1 cells. G-H) Myelin significantly reduced proinflammatory IL-1beta production in M1 cells, whereas CTL and M2 cells were
unaffected. cPLA2 inhibition did not alter this effect. I-J) Pro-inflammatory IL-6
was not significantly altered by myelin or cPLA2 inhibition. Refer to
Supplementary Figure 5 for CTL and M2 cPLA2 inhibition data. Representative of
3 biological replications. *p<0.05 ** p<0.01, *** p<0.001 mean ± SEM.

71

Figure 2.5. Myelin increases cPLA2 activity in an activation state dependent
manner.

Cell lysates were collected from BMDM cultures to measure cPLA2 activity
following stimulation into CTL, M1, and M2 cells with or without myelin. Samples
containing Bromoenol Lactone, an inhibitor of iPLA2 were used to exclude the
possibility of iPLA2 contributing to enzymatic activity. A) CTL treated cells had no
discernable activity with or without myelin and Bromoenol Lactone. B) M1 treated
cells had a mean enzymatic activity of 4.88nmol/min/ml. Addition of myelin
significantly increased cPLA2 enzymatic activity (*p<0.05). Addition of Bromoenol
Lactone did not significantly alter enzyme activity. C) M2 treated cells had no
discernable activity with or without myelin and Bromoenol Lactone.
Representative of 3 biological replications. *p<0.05 ** p<0.01, *** p<0.001 mean
± SEM.
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Supplemental Figure 2.1. Macrophages can contain both myelin-derived
lipids and active cPLA2 7 days after spinal cord injury (SCI).
Eight adult, 4-month-old C57/b female mice received a T9 75kdyn infinite
horizons (IH) contusion SCI. A-E) Representative examples of TomL positive
macrophages (blue) in injured white matter containing both lipid debris (green,
Bodipy, staining for neutral lipids) and active p-cPLA2 (red). DAPI (white) was
excluded from merged images. Imaged area is represented by box within spinal
cord diagram. Boxes on image indicate examples of triple positive cells.
Maximum intensity projection confocal images. Scale bar in image A=25µm
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Supplemental Figure 2.2. In Vitro modeling of cPLA2 activity in myelin
loaded macrophages.
Coverslip plated BMDMs were stained for TomL (macrophage marker, blue),
Bodipy (myelin derived lipids, green) and active p-cPLA2 (red). Myelin uptake
was quantified as the threshold area ratio of Bodipy or p-cPLA2 to TomL positive
stain. A-F) Representative images of CTL, M1, and M2 BMDMs treated with or
without myelin debris. G) CTL, M1, and M2 BMDMs treated with myelin
contained significantly more neutral lipids (Bodipy) than each of their respective
untreated counterpart (### p<0.001); however, there were no significant
differences between groups treated with myelin. H) M1 stimulated BMDMS has
significantly higher p-cPLA2 immunoreactivity than either M1 or M2 (###
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p<0.001); however, myelin was not found to alter p-cPLA2 immunoreactivity in
any of the groups tested.
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Supplemental Figure 2.3. Myelin stimulants did not contain detectable
endotoxin contamination.
Aliquots from each myelin isolation were stored at -80 °C prior to testing. Myelin
stimulants and negative control (1x sterile PBS) had endotoxin levels below the
level of detection (<.055 EU/mL). The positive control (LPS 50 ng/mL) exceeded
the detection limit (>1.045 EU/mL). mean ± SEM.
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Supplemental Figure 2.4. cPLA2 inhibition has no effects on CTL or M2
stimulated cells.
Cells were grown and stimulated as detailed in Figures 2 and 3. A-D) cPLA2
inhibition did not significantly change levels of reactive oxygen species (ROS),
nitric oxide, supernatant neurotoxicity, or arginase activity in CTL (unstimulated)
cells with or without the addition of myelin. E-H) cPLA2 inhibition did not
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significantly change levels of reactive oxygen species (ROS), nitric oxide,
supernatant neurotoxicity, or arginase activity in M2 (IL-4) cells with or without
the addition of myelin. Representative of 3 biological replications of both BMDMs
and myelin source n.s.=non-significant, p>0.05, mean ± SEM.
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Supplemental Figure 2.5. Macrophage cytokine profiles indicate a mixed
neuroinflammatory phenotype in CTL and M2 stimulated cells in response
to myelin and inhibition of cPLA2 with PACOCF3.
Supernatants from treated BMDMs were collected to measure pro and antiinflammatory cytokine production in response to phenotype, myelin stimulation,
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and cPLA2 inhibition with PACOCF3. A-J) Myelin significantly increases the
production of pro and anti-inflammatory cytokines TNF-alpha, CX3CL1, IL-10 and
IL-6. IL-1Beta was unaffected. cPLA2 inhibition induced small but statistically
significant adjustments in cytokine levels in myelin treated CTL and M2 cells.
Representative of 3 biological replications. *p<0.05 ** p<0.01, *** p<0.001 mean
± SEM.
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Chapter 3: Delayed Azithromycin Treatment Improves Recovery After
Mouse Spinal Cord Injury
This chapter is adapted from Kopper et al., 2019

3- i. Chapter Summary
After spinal cord injury (SCI), macrophages infiltrate into the lesion and
can adopt a wide spectrum of activation states. However, the pro-inflammatory,
pathological macrophage activation state predominates and contributes to
progressive neurodegeneration. Azithromycin (AZM), an FDA approved
macrolide antibiotic, has been demonstrated to have immunomodulatory
properties in a variety of inflammatory conditions. Indeed, we previously
observed that post-SCI AZM treatment reduces pro-inflammatory macrophage
activation. Further, a combined pre- and post-injury treatment paradigm improved
functional recovery from SCI. Therefore, for the current study, we hypothesize
that post-injury AZM treatment will improve recovery from SCI. To test this
hypothesis, we examined the therapeutic potential of delayed AZM treatment on
locomotor, sensory, and anatomical recovery. We administered AZM beginning
30-min, 3-h, or 24-h following contusion SCI in female mice, and then daily for 7
days. AZM administration beginning 30-min and 3-h post-injury improved
locomotor recovery with increased stepping function relative to vehicle controls.
Further, delaying treatment for 30-min after SCI significantly reduced lesion
pathology. Initiating AZM treatment 24-h post-injury was not therapeutically
effective. Regardless of the timing of the initial treatment, AZM did not statistically
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reduce the development of neuropathic pain (mechanical allodynia) nor increase
neuron survival. Collectively, these results add to a growing body of evidence
supporting AZM’s translational potential as a therapeutic agent for SCI and other
neuroinflammatory conditions in which patients currently have very few options.
This chapter was adapted from Kopper et. Al 2019

3- ii. Background
Spinal cord injury (SCI) induces a complex heterogeneous inflammatory
response largely mediated by resident microglia and infiltrating monocyte-derived
macrophages. While these cells are capable of adopting a wide spectrum of
beneficial and detrimental functions, the acute SCI microenvironment promotes
pro-inflammatory macrophage activation (Kigerl et al., 2009). Pro-inflammatory
macrophages and microglia are widely believed to be major contributors to the
continued neurodegeneration and tissue loss observed following the initial
mechanical SCI. Targeting macrophage activation acutely is, therefore, a
promising therapeutic approach to improve recovery. However, to date there are
no FDA approved drugs to target these pathways after SCI.
Azithromycin (AZM) is a widely prescribed, FDA-approved, antibiotic with
a well-established safety record. AZM has significant anti-inflammatory and
immunomodulatory actions across a wide array of disease states (Amantea et
al., 2016a; Banjanac et al., 2012; Barks et al., 2019; Feola et al., 2010b; Gensel
et al., 2017; Ivetić Tkalčević et al., 2011; Murphy et al., 2008; 2010; Nujić et al.,
2012a; Osman et al., 2017; Polancec et al., 2012; Varano et al., 2017; Vrancic et
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al., 2012; Zhang et al., 2015b). Specifically, AZM promotes anti-inflammatory
activation by inhibiting macrophage STAT1 and NF-κB signaling pathways
(Haydar et al., 2019). Emerging evidence supports the use of AZM as a
treatment for neurological conditions including stroke, retinal ischemia, spinal
muscular atrophy, and neonatal hypoxic–ischemic brain injury (Amantea et al.,
2016a; 2019; Barks et al., 2019; Osman et al., 2017; Varano et al., 2017).
Previously, we demonstrated that AZM improves tissue sparing and locomotor
recovery in a mouse model of contusion SCI when dosing is initiated 3 days prior
to injury (Zhang et al., 2015b). In our previous work, the neuroprotective effects
of AZM were coincident with increased anti-inflammatory and decreased proinflammatory macrophage activation (Zhang et al., 2015b). More recently, we
established that delaying treatment for 30 min post-injury substantially decreases
markers associated with pro-inflammatory (M1) macrophage activation while
significantly increasing anti-inflammatory (M2) macrophage markers(Gensel et
al., 2017). Further, we recently found that AZM decreases neurotoxic, proinflammatory macrophage activation independent of its antibiotic properties
(Zhang et al., 2019). Collectively, these findings highlight AZM as a promising
SCI immunomodulatory therapeutic; however, the long-term effects of delayed
AZM treatment are unknown. For the current study, we hypothesized that postinjury AZM treatment improves recovery from SCI. Specifically, we evaluated the
therapeutic efficacy of post-SCI AZM treatment on long-term locomotor, sensory,
and anatomical recovery. Initial treatment was delayed 30 min, 3-h, or 24 h postinjury and recovery evaluated for 4 weeks after injury.
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3- iii. Methods
Experimental Design:
The current data includes the combined results of three independent
studies.
Study One
Mice (n = 10/group) were treated with vehicle (initiated at 30 min postinjury) or AZM (160 mg/kg/day) by oral gavage beginning 30 min, 3 h, or 24 h
after a moderate-severe (75 kdyn) T9 contusion SCI. Drug and vehicle
administration was continued daily for 7 days post-injury (dpi). Locomotor
function of all animals, as determined by the Basso Mouse Scale (BMS), was
assessed prior to injury and again at 1, 3, 7, 14, 21 and 28 dpi. At 28 dpi, all the
animals were sacrificed for the generation of spinal cord sections for histological
analyses of tissue sparing, lesion length, and neuron survival. One mouse was
euthanized due to surgical complications. Three mice were excluded based upon
a prior exclusion criteria for abnormal impactor parameters reported by the
Infinite Horizons (IH) SCI device (indicative of a bone hit or spinal cord
movement during injury; n = 2) and abnormally high functioning locomotor
behavior at 1 dpi (BMS >3) indicative of incomplete injury (n = 1).

Studies Two and Three
Mice (n = 10/group/study) were injured and treated as study one except
that the 24 h delayed treatment group was discontinued due to clear therapeutic
ineffectiveness in study one (Figures 3.1A,B; p > 0.98 for all outcomes). In
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addition, horizontal ladder performance and measures of neuropathic pain (Von
Frey, mechanical allodynia) were collected prior to injury and at 26 and 27 dpi,
respectively. Group sizes for studies two and three (n = 10) were calculated
based upon a priori power analysis of the BMS behavior data collected in study
one. Specifically, we estimated that with a significance of α = 0.05, a power of 1β = 0.80, and expected levels of animal attrition, that we would need an
additional 20 animals per group. Two mice in study two and three mice in study
three were excluded based upon a priori impact or behavioral criteria for
incomplete/abnormal injuries. Rostral-caudal neuronal survival was only
assessed in studies two and three because unknown temperature
inconsistencies during study one tissue processing and sectioning caused tissue
folding and tissue loss, making histological analysis impossible. Discrepancies
between n’s in behavioral vs. histological analyses are due to the fact that mice
without an obvious and fully intact injury epicenter (due to tissue processing
complications) were not included for histological analyses. Final animal numbers
are reported in the figure legends and/or results.

Animals
Experiments were performed using 4-month-old female C57BL/6 mice
(Jackson Laboratory, Bar Harbor, ME, USA). Animals were housed in IVC cages
with ad libitum access to food (Teklad Irradiated Global 18% Protein Rodent Diet)
and purified water. Housing is set to maintain a 14 h light/10 h dark cycle, at 70°F
and 50% humidity. All experimental procedures were conducted during the light
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cycle and were performed in accordance with the guidelines and protocols of the
Office of Research Integrity and with approval of the Institutional Animal Care
and Use Committee at the University of Kentucky.

Spinal Cord Injury
Animals were anesthetized via intraperitoneal (i.p.) injections of ketamine
(100 mg/kg) and xylazine (10 mg/kg). Following a T9 laminectomy, a moderatesevere thoracic SCI was produced using the IH injury device (75-kdyn; Precision
Systems and Instrumentation; (Scheff et al., 2004)). Any animals receiving SCI
with abnormalities in the force vs. time curve generated by the IH device were
excluded from analysis. These abnormalities are indicative of bone hits or
instability in the spinal cord at the time of injury and occurred <10% of the time.
After injury, muscle and skin incisions were closed using monofilament suture.
Post-surgery, animals received one subcutaneous injection of buprenorphine-SR
(1 mg/kg) and one injection of antibiotic (5 mg/kg, enrofloxacin 2.27%: Norbrook
Inc., Lenexa, KS, USA) in 2 ml of saline and were housed in warming cages
overnight. Animals continued to receive antibiotic subcutaneously in 1 ml saline
for 5 days. AZM (160 mg/kg) or vehicle (1% methylcellulose) was delivered in
0.1-ml volume via oral gavage daily beginning 30 min, 3 h or 24 h after injury and
again daily for 7 days post-injury. Animal health and the incision site were
monitored throughout the course of the study. Bladder expression was performed
on injured mice twice daily.
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Behavioral Analysis
All experimental animals were assessed using the BMS to score hindlimb
function as previously described (Basso et al., 2006). Mice were tested in an
open field for 4 min before surgery and at 1, 3, 7, 14, 21, and 28 days post-injury
(dpi). Each hindlimb was scored separately based on movement (e.g., ankle
placement and stepping) and whole-body coordination and trunk stability were
also scored; the average of both hindlimb scores was used to generate a single
score for each animal. A score of 0 indicated complete paralysis and a score of 9
indicated normal locomotion. Animals receiving a score of 3 or higher at 1 dpi, or
less than 2 at 28 dpi were excluded from the study based on a priori statistical
assessment of over 450 prior 75 kdyn mouse SCI surgeries. These scores are
rare (greater than 2 standard deviations from mean BMS score) and are
indicative of surgical/injury abnormalities (bone hit, low/high impact force, etc.).

Mechanical Allodynia Testing
Mechanical allodynia was measured using the manual up-down approach
with von Frey monofilaments as described previously (Chaplan et al., 1994).
Animals were first acclimated to the testing apparatus consisting of a wire mesh
floor within an acrylic enclosure. A monofilament was pressed perpendicularly
against the plantar surface of the hindlimb until bent, beginning with the 1.4 g
monofilaments and ranging from the 0.4 g to 6.0 g monofilaments. Fifty
percentage withdrawal threshold was calculated and reported as the average of
both hind paws at each time point (Chaplan et al., 1994). Positive responses
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include rapid paw withdrawal, paw shaking and/or paw licking. Paw movement
due to normal locomotor activity and responses occurring after the removal of the
filament were not considered positive responses and were excluded from
analysis.

Tissue Processing and Immunohistochemistry
At 28 dpi, mice were anesthetized then transcardially perfused with cold
PBS (0.1 M, pH 7.4), followed by perfusion with cold 4% paraformaldehyde
(PFA). Dissected spinal cords (1 cm) were post-fixed for another 2 h in 4% PFA
and subsequently rinsed and stored in cold phosphate buffer (0.2 M, pH 7.4)
overnight at 4°C. On the following day, tissues were cryoprotected in 30%
sucrose for 3 days at 4°C, followed by rapidly freezing and blocking in optimal
cutting temperature (OCT) compound (Sakura Finetek USA Inc., Torrance, CA,
USA) on dry ice. Tissue was systematically randomized into blocks (each block
contained spinal cords from four subjects) with equal group distribution to ensure
uniformity of staining across groups and blocked tissue was stored at −80°C
before sectioning. Tissue blocks were cut in serial coronal sections (10 μm) and
mounted onto Colorfrost plus slides (Fisher #12-550-17).
Spinal cord sections were stained with Eriochrome Cyanine (myelin) and antiNeurofilament (1:1,000, Aves labs: NF-H) to visualize damage and thereby
identify the epicenter and length of each lesion as described previously (Zhang et
al., 2015b). To examine the epicenter in greater detail, slides were stained with
glial fibrillary acidic protein (GFAP; 1:500, Aves: GFAP) and macrophage marker
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F4/80 (1:1,500, AbD serotec, MCA497) primary antibodies overnight at 4°C,
followed by Alexa Fluor 488 goat anti-chicken (1:1,000, Life Technologies
A11039) and goat anti-rat Alexa Fluor 633 (1:1,000, Thermo Fisher Scientific: A21094) secondary antibodies for 1 h at room temperature. To assess neuron
survival, slides were subjected to antigen retrieval for 5 min in hot citrate buffer
pH 6, incubated with rabbit anti-NeuN (1:4,000, Novus Biologicals NBP1-77686)
primary antibody overnight at room temperature, then biotinylated goat anti-rabbit
(1:500, Vector BA-1000) secondary antibody for 2 h at room temperature, then
elite-ABC (prepared according to manufacturer’s instructions, Vector PK-6100)
for 2 h at room temperature, and finally DAB (prepared according to
manufacturer’s instructions, Vector SK-4100) with nickel additives for 5 min at
room temperature. Slides were cover-slipped with Permount mounting medium
(Fisher Scientific, Hampton, NH, USA) or Immu-Mount (Thermo Scientific,
Waltham, MA, USA) for brightfield and fluorescent stains, respectively.
Images were taken using a C2+ laser scanning confocal microscope
(Nikon Instruments Inc., Melville, NY, USA) or a ZEISS Axio Scan.Z1 (Munich,
Germany), then analyzed using the MetaMorph analysis program (Molecular
Devices, Sunnyvale, CA, USA) or HALO Image Analysis Platform (Indica Labs,
Albuquerque, NM, USA). To identify the rostral-caudal lesion length, Eriochrome
Cyanine and Neurofilament (EC/NF) stained tissue sections were examined at
100 μm intervals rostral and caudal from the lesion epicenter until damage
became entirely localized to the dorsal column totaling less than 2% of the total
spinal cord area. To quantify tissue sparing at the lesion epicenter (i.e., the tissue
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section with the least amount of intact EC/NF stained tissue) the regions of
dense GFAP positive staining were outlined and measured using the MetaMorph
analysis program (Molecular Devices, Sunnyvale, CA, USA) or HALO. These
spared areas as defined by the GFAP+ glial scar closely align with areas of
Neurofilament positive axons as determined previously (Freria et al., 2017;
Zhang et al., 2015b). Lesion area, intact tissue area, and overall spinal cord size
were used to calculate the percentage of spared tissue at the lesion epicenter.
While not quantified directly, F4/80 positive macrophages were used as a
secondary tracing guide in any areas of ambiguity as they densely accumulate
within the core of the lesion as described previously (Wang et al., 2014). To
quantify neurons, NeuN-stained cells within the gray matter were quantified using
HALO software. Spinal cross-sections at 100 μm intervals from the epicenter
were analyzed, and average values were calculated from equidistant
rostral/caudal sections. Folded or torn sections were excluded from analysis.

Statistical Analysis
Investigators blinded to experimental conditions performed all data
acquisition and analysis. Statistical analyses were completed using GraphPad
Prism 6.0 (GraphPad Software). Data were analyzed using one- or two-way
ANOVA followed by Dunnett’s or Holms–Sidak post hoc tests for multiple
comparisons to the vehicle groups. Chi square and independent-sample t-tests
were used when appropriate. Results were considered statistically significant
at p ≤ 0.05. All data are presented as mean ± SEM unless otherwise noted.
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Figures were prepared using Adobe Photoshop CC 2014 (Adobe Systems) and
Prism 6.0.

3- iv. Results
Post-injury Administration of Azithromycin Improves Locomotor Recovery After
SCI:
As described previously, initiating AZM treatment 30 min after SCI,
followed by repeated daily doses for 7 days, mediates an immunomodulatory
shift in macrophage phenotype resulting in the downregulation of markers
associated with pro-inflammatory M1 macrophage activation and upregulation of
anti-inflammatory M2 markers (Gensel et al., 2017). Because this type of
macrophage phenotypic transition is often associated with an increase in
reparative functions after SCI, we sought to determine whether post-injury
administration of AZM led to long-lasting locomotor improvement up to 28 days
after injury. AZM was administered beginning 30 min, 3 h, or 24 h post-injury and
then daily for 7 days in three compiled studies. The 24 h delayed treatment group
was discontinued due to clear therapeutic ineffectiveness in study one (Figures
3.1A,B; p > 0.98 for all outcomes). The 30 min and 3 h administration groups,
however, displayed improved locomotor recovery relative to vehicle. Specifically,
overall locomotor recovery out to 28 dpi, as measured by the BMS, varied as a
function of treatment (p = 0.008 main effect of treatment; time × treatment
interaction p = 0.02). Locomotor recovery significantly improved when AZM was
administered at 30-min relative to vehicle (p = 0.004 main effect; Figure 3.2A).
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This treatment effect was significant beginning at 14 dpi (p = 0.005; Figure
3.2A). Delaying the initial dose for 3-h after SCI improved recovery relative to
vehicle (p = 0.058 vs. vehicle, main effect) with significant improvements by 28
dpi (p= 0.0004).
By 28 dpi, delaying AZM treatment by either 30 min or 3 h after SCI
significantly improved locomotor function vs. vehicle with an average BMS score
of ~5 for AZM groups vs. ~4 for the vehicle-treated group (Figure 3.2A). A
transition from a score of 4–5 is largely dependent on the mouse’s ability to fully
support its body weight on its hind legs while stepping. Because we observed
this group-dependent separation along the 4/5 score of the BMS scale, we
further quantified stepping ability. As seen in Figure 3.2B; a significantly greater
proportion of mice treated with AZM beginning at either 30 min or 3 h post-injury
recovered frequent plantar stepping function vs. vehicle controls (Chisquared, p = 0.001 and p = 0.04, respectively). We also evaluated proprioceptive
hindlimb stepping function with the horizontal ladder task. There were no
differences among groups prior to SCI (p = 0.99, one-way ANOVA, data not
shown). However, since few animals in the vehicle group recovered stepping
function and were able to perform the horizontal ladder task, results of this test
were not compared among groups after SCI.

Azithromycin and Neuropathic Pain:
We recently reported that AZM is an analgesic that alleviates chronic SCI
pain when dosed 30 min prior to measuring heat-induced hyperalgesia (Gensel
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et al., 2019). Here, we expanded upon this by testing whether AZM limits the
development of neuropathic pain (mechanical allodynia) after SCI. As seen
in Figure 3.3, SCI induced allodynia (p < 0.0001), however, AZM administration
beginning 30 min and 3 h following injury did not significantly reduce long-term
pain responses (mechanical allodynia) relative to vehicle-treated animals at 27
dpi (p = 0.89).

The Effect of Post-SCI Azithromycin Treatment on Tissue Pathology:
Previously, we observed improved locomotor recovery along with
increased tissue preservation using a combined pre- and post-SCI dosing
paradigm for AZM (Zhang et al., 2015b). As seen in Figures 3.4A–E, the effect
post-SCI AZM treatment on tissue sparing at the lesion epicenter did not reach
statistical significance for either the 30 min or 3 h treatment groups in the current
studies (p = 0.07 and 0.54, respectively). AZM administration significantly
reduced the mean rostral-caudal lesion length when given 30 min after injury (p =
0.03; Figures 3.5A,B); the 3-h delivery timepoint was not statistically significant
(p= 0.55; Figure 3.5). Given that pro-inflammatory macrophages are neurotoxic
and that AZM limits this activation in vitro we sought to quantify whether post-SCI
AZM treatment improved the number of surviving neurons at 28 dpi (Zhang et al.,
2015b; 2019). However, AZM treatment did not affect neuron sparing throughout
the rostral-caudal extent of the lesion (ANOVA main effect of treatment p =
0.26; Figures 3.6A,B) or total neuron sparing according to area under the
neuron by distance curve (ANOVA p = 0.98; Figure 3.6C).
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3- v. Discussion
The clinical use of methylprednisolone, the only FDA-approved drug to
complete phase three clinical trials for SCI to date, has fallen substantially in
recent years with concerns that its side effects may out-weigh its clinical benefits.
As a result of this decline, many individuals with a SCI have been left with no
pharmacological treatments for their injuries. Here, we provide evidence that
azithromycin (AZM) treatment, initiated after SCI, improves recovery. Specifically,
delaying treatment for 30 min or 3 h post-injury significantly increased locomotor
recovery in mice. We observed therapeutic effects even when delayed for 3 h,
although less robust than our 30-min timepoint. When delayed 24 h after injury
AZM administration had no discernable therapeutic effect. Azithromycin is
routinely given to SCI individuals with limited side effects (Evans et al., 2013) and
our results here demonstrate that AZM may have a viable therapeutic window as
a neuroprotective treatment for SCI.
Clinically, AZM is widely used for its antibiotic properties, however,
increasing evidence indicates that the neuroprotective effects are a result of a
distinct cellular mechanism. Specifically, AZM has a remarkable ability to
accumulate within cells, in particular, within phagocytes such as macrophages
(Zimmermann et al., 2018). Subsequently, AZM appears to inhibit the activation
of the NF-κB signaling cascade, a potent regulator of macrophage activation
states (Aghai et al., 2007; Cigana et al., 2007; Feola et al., 2010b; Haydar et al.,
2019). In support of the concept that the immunomodulatory effects of AZM are
independent of its antibacterial actions, we recently developed a library of AZM

94

derivatives with reduced antibiotic properties. Indeed, even compounds with
reduced antibiotic activity retained the ability to blunt pro-inflammatory
macrophage activation and macrophage-mediated toxic effects on neurons
(Zhang et al., 2019). Similarly, investigators in other disease models have utilized
AZM as an immunomodulatory agent and have attributed its efficacy to its antiinflammatory effects on macrophage physiology (Amantea et al., 2016b; Feola et
al., 2010b; Kitsiouli et al., 2015). We have identified a similar mechanism of
action for AZM in SCI previously (Gensel et al., 2017; Zhang et al., 2015b; 2019).
Specifically, we found that AZM administration 30 min post-injury at doses of 10,
40, or 160 mg/kg decreased pro-inflammatory M1 macrophage gene expression
at 3 dpi while the lowest (10 mg/kg) and highest (160 mg/kg) doses increased
anti-inflammatory M2 macrophage gene expression at 7 dpi (Gensel et al., 2017).
One small caveat to this, and the current study, is that all of the mice receive
prophylactic antibiotic (enrofloxacin) during surgical recovery. It is thereby
possible that there is a drug interaction effect, although their intended
antimicrobial mechanisms have distinct cellular targets. Collectively, increasing
evidence demonstrates that AZM accumulates in macrophages and improves
outcomes by driving a shift in macrophages from pro-inflammatory and
pathological M1 phenotypes to more reparative, anti-inflammatory M2
phenotypes. These AZM mediated shifts in macrophage activation states are
thereby likely to be important factors mediating the long-term therapeutic benefits
detailed in the current study, however, we did not specifically evaluate the impact
of treatment timing on macrophage phenotype.
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Our observations are consistent with reports of AZM being neuroprotective
in other neurological conditions through the promotion of anti-inflammatory
macrophage polarization. For example, Amantea et al. demonstrated that
administration of AZM is neuroprotective in a transient middle cerebral artery
occlusion model of stroke. Importantly, they attributed AZM’s protective effects to
its ability to drive macrophages to an anti-inflammatory M2 phenotype (Amantea
et al., 2016b). Similarly, Varano et al. utilized AZM to target CNS inflammation in
a rat model of retinal ischemia/reperfusion injury (Varano et al., 2017) (pathology
associated with glaucoma, diabetic retinopathy, and anterior ischemic
neuropathy; (Zheng et al., 2007). In that study, a single dose of AZM (150 mg/kg,
i.p.) given after 50 min of ischemia, increased retinal ganglion cells survival by
reducing the excitotoxicity and propagation of the macrophage response (Varano
et al., 2017). Together with our prior observation of AZM decreasing M1
activation and increasing M2 macrophage in vivo after SCI (Gensel et al., 2017;
Zhang et al., 2015b) these studies suggest that AZM could have important
therapeutic implications across many neurological conditions. In particular, CNS
disorders such as traumatic brain injury, Alzheimer’s disease, and multiple
sclerosis are known to be heavily influenced by inflammatory pathways.
However, the efficacy AZM in these models remains to be determined. In many
CNS disorders there is the added complexity of having both bone marrow
derived monocytes/macrophages and microglial derived macrophage
populations. While emerging evidence suggests that microglia may be more
neuroprotective than monocyte-derived macrophages, we do not yet know
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through which population AZM exerts its therapeutic effects (Bellver-Landete et
al., 2019; Greenhalgh et al., 2018). Our prior work using a combined pre- and
post-injury AZM administration paradigm demonstrated that both microglia (in
vivo) and macrophages (in vitro) are affected by AZM (Gensel et al., 2017; Zhang
et al., 2015b). The relative contribution of microglia vs. monocyte-derived
macrophages to the therapeutic effects of AZM observed in the current study,
however, remains unclear. To address these uncertainties, we are currently
developing small molecule labeling techniques to track AZM after administration
and methods to separate and analyze microglia and monocyte populations
individually after SCI.
One limitation of the current study is that only one AZM dosing paradigm
(160 mg/kg/day) was tested. Using typical interspecies allometric scaling, this
dose may translate to a high, but still clinically relevant dose in humans (Anroop
B Nair, 2016)However, additional dose-response studies or alternative
formulations may improve the neuroprotective potential or therapeutic window of
AZM. Indeed, we previously observed that AZM retains its ability to modulate
macrophage phenotype even at substantially lower doses (10 and 40 mg/kg)
when administration begins 30 min post-SCI (Gensel et al., 2017). Similarly,
using alternative dosing strategies, Amantea et al. (Amantea et al., 2016a)
demonstrated that both intravenous and intraperitoneal administrations of AZM
were neuroprotective in a rodent model of stroke. In the case of intraperitoneal
administration, AZM remained neuroprotective after stroke at doses from 150
mg/kg down to as low as 1.5 mg/kg, suggesting that alternative administration
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routes may offer greater effectiveness with reduced doses (Amantea et al.,
2016b). We have also begun modifying AZM structure through medicinal
chemistry to produce derivatives that lack antibiotic activity yet maintain their
immunomodulatory effects on macrophages (Zhang et al., 2019). Ongoing work
seeks to identify a derivative with enhanced anti-inflammatory activity, which may
allow for further reductions in dosages prior to clinical translation.
The therapeutic efficacy of AZM in the current study decreased with the
timing of the first oral dose after SCI with the 30-min time point being the most
effective, 3-h being moderately effective, and no efficacy when the first treatment
was delayed 24 h. It may be possible to extend this treatment window. For
example, here we administered AZM by oral gavage, whereas faster and more
direct methods such as intravenous administration may allow for more robust
effects and a more flexible dosing window. In the treatment of stroke,
intraperitoneal administration of AZM was effective when administered out to 4.5
h post-injury suggesting that alternative dosing approaches may be able to
extend AZM’s dosing window post-SCI (Amantea et al., 2016b; 2019).
Collectively, while the data showed here demonstrate that early oral
administration of AZM is therapeutically effective, there are ample opportunities
to both improve its efficacy and minimize any associated risks.
In our current dosing paradigm, we dosed for 7 days after injury, yet our
most robust behavioral improvements are seen from days 14–28 post-injury. This
delayed response is consistent with observations in humans and may be due in
part to AZM’s ability to accumulate within macrophages. Indeed, in human
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patients treated with AZM for 3 days, AZM accumulation in monocytes is still
evident by 14 days with minimal depletion (Wildfeuer et al., 1996). Presumably,
there is a similarly prolonged presence of AZM within macrophages after SCI
contributing to the neuroprotective effects well into chronic time points. We
observed a similar response in using a pre-treatment dosing strategy in that we
only saw significant behavioral differences relative to vehicle starting at 14 dpi
(Zhang et al., 2015b). This suggests that AZM accumulation in macrophages
after SCI is sufficient to facilitate long-term improvements. Therefore, methods to
enhance AZM’s targeted delivery to macrophages, such as with liposome-based
drug delivery systems may facilitate greater therapeutic efficacy.
In the weeks and months following SCI, animals develop neuropathic pain
with both hyperalgesia (increased pain from a stimulus that normally provokes
pain) and allodynia (pain due to a stimulus that does not normally provoke pain;
(Deuis et al., 2017). Previously we demonstrated that AZM has analgesic
properties when given to these chronically injured animals 30 min prior to pain
testing (Gensel et al., 2019). This is in contrast with the current study in which
AZM had no analgesic effects. The two key differences are that in the current
study we dosed with AZM for 7 days, stopping 3 weeks prior to pain testing and
we evaluated pain using a mechanical withdrawal (allodynia) test instead of
thermal-induced pain test (allodynia and hyperalgesia). It is possible that the
analgesic properties of AZM are modality-specific and AZM could block the
development of heat but not mechanically induced pain responses. The results of
the current study, however, suggest that AZM has no effect on the overall
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development of mechanical allodynia after SCI, but maintains promise as a pain
relief alternative to opioid and non-steroidal anti-inflammatory based
therapeutics. Further, it has become increasingly important to include tests for
the affective components of pain in animal models when identifying new drugs to
treat SCI (Kramer et al., 2017). It is possible that future studies evaluating the
effects of AZM treatment on affective pain may reveal additional benefits of
treatment.
In the current study, we administered AZM through oral gavage after SCI
and detected modest, yet significant therapeutic benefits. It is possible that
alternate dosages and routes of delivery could broaden AZM’s treatment window
and increase its therapeutic effects. Despite these challenges, AZM holds great
promise in the treatment of SCI and a broad variety of other inflammatory
disorders. Fortunately, AZM’s excellent safety history, and wide availability at
essentially all healthcare centers would greatly reduce barriers preventing rapid
use after injury (Trifirò et al., 2017; Uzun et al., 2014). The results of the current
study add to a growing body of evidence supporting AZM’s translational potential
as a neuroprotective agent for SCI and other neuroinflammatory conditions in
which patients currently have very few options.
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Figure 3.1. Azithromycin (AZM) administration beginning 24 h after injury is
not therapeutically effective.
Adult (4-month-old) female mice received a moderate-severe thoracic T9
contusion spinal cord injury (SCI; 75-kdyn). AZM was first administered at 24-h
post-injury and then daily for 7 days (160 mg/kg/day). Functional recovery was
assessed before injury and at 1, 3, 7, 14, 21, and 28 dpi. (A,B) Initiating AZM
treatment 24-h after SCI did not improve locomotor recovery relative to vehicle
control (p = 0.99, n = 9–10) or improve tissue sparing [as defined by glial fibrillary
acidic protein (GFAP) reactivity] at the lesion epicenter at 28 dpi relative to
vehicle (n.s. = not significant, p = 0.98, n = 7–8). Mean ± SEM.
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Figure 3.2. Early AZM administration improves locomotor recovery in SCI
mice.
Adult (4-month-old) female mice received a moderate-severe thoracic T9
contusion SCI (75-kdyn). AZM was first administered at 30-min or 3-h post-injury
and then daily for 7 days (160 mg/kg/day). Functional recovery was assessed
before injury and at 1, 3, 7, 14, 21, and 28 dpi. (A) Mice treated with AZM
beginning 30-min post-injury displayed significantly improved locomotor recovery
relative to vehicle (main effect of treatment vehicle vs. 30 min, p = 0.004) with
significant improvement from 14 to 28 dpi (**,***p < 0.05 30 min vs. vehicle,
Holms–Sidak’s post hoc). Mice first treated at 3 h post-injury had increased
recovery relative to vehicle (p = 0.06 main effect of treatment vehicle vs. 3 h) with
significant improvements at 28 dpi (##p < 0.05 vs. vehicle Holms–Sidak’s post
hoc). (B) Mice treated at 30-min recovered significantly improved frequent plantar
stepping frequency than vehicle controls (58% and 17% respectively, Chisquared, p = 0.001). Similarly, mice treated at 3-h recovered significantly more
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frequent plantar stepping relative to vehicle (37% and 17%, respectively, Chisquared, p = 0.04). n = 24–29, mean ± SEM. *p < 0.05.
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Figure 3.3. AZM administration does not alter the development of
mechanical allodynia in mice after SCI.
Gram-force withdrawal threshold to Von Frey filaments stimuli decreased after
SCI, relative to baseline, indicative of the development of allodynia after SCI
(***p > 0.0001). However, AZM did not alter the development of allodynia at 27
dpi relative to vehicle (n.s. = not significant, p = 0.89). There were no baseline
differences in withdrawal threshold prior to injury (p = 0.29). n = 15–20, mean ±
SEM.
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Figure 3.4. AZM does not significantly increase long-term, 28-day tissue
sparing at lesion epicenter.
Tissue sections representative of the mean values for (A) vehicle or AZM
beginning (B) 30 min or (C) 3 h post-SCI. (D)Quantification of tissue sparing at
28 days post-injury based on GFAP reactivity did not demonstrate any
statistically significant differences across groups, however, the mean tissue
sparring was higher in the 30-min group (56%) than the vehicle-treated group
(49%; p = 0.07). (E) The injury displacement values were equal across groups
(p = 0.69) indicative of comparable injury severities prior to treatment
administration. n = 19–25, mean ± SEM. Scale bar: 500 μM. n.s = not significant.
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Figure 3.5. Post-SCI treatment with AZM reduces rostral-caudal lesion
length.
(A) Representative images of EC/NF stained sections 28 days after SCI detailing
the lesion characteristics for vehicle, 30-min AZM, and 3-h AZM administration
paradigms. (B) AZM administration beginning 30 min post-injury reduced overall
rostral-caudal lesion length to an average of 1.9 mm relative to the 2.4 mm
average in vehicle-treated animals (p = 0.03). This is evident in (A) by the
relatively intact spinal cord at 0.8 mm rostral and caudal to the epicenter in the 30
min AZM vs. vehicle. group. Mice with treatment beginning at 3-h post-injury had
a slightly lower average lesion length at 2.2 mm, however this was not
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statistically significant (p = 0.55). n = 23–29, mean ± SEM. Scale bar: 500 μM.
* p< 0.05; n.s = not significant.
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Chapter 4: Advancing macrophage-targeted therapies into successful
treatments
for SCI

4- i. Summary:
Chapter Summary
There is an urgent need for the development of new therapies for the
treatment of SCI. While AZM and cPLA2 inhibitors are promising macrophagetargeted therapy candidates, there are numerous other approaches to target
macrophages being developed. In this Chapter we examine: 1) A transgenic
approach to target cPLA2 in vitro. 2) The immunomodulatory properties of
macrolide derivatives of AZM. 3) The shift in pro-inflammatory macrophage
cytokine profiles in response to leukemia inhibitory factor (LIF). Lastly, we cover
a general discussion of these approaches and of additional macrophage-targeted
therapies currently in development. Respective topics are indicated by section
headings.

Summary: Transgenic Targeting of cPLA2 In Vitro
We previously targeted cPLA2 using a chemical inhibitor, PACOCF3. Here
we build on these prior studies using a transgenic approach. We isolated BMDMs
from cPLA2-/- (KO) and cPLA2+/+ (WT) and examined the impact of cPLA2 ablation
on ROS, nitric oxide, neurotoxicity, and arginase enzymatic activity during myelin
exposure. cPLA2 reduced myelin induced ROS, nitric oxide, and neurotoxicity
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relative to WT BMDMs, although arginase enzymatic activity was not affected.
This is additional evidence indicating a key role of cPLA2 in mediating the myelin
induced potentiation of pro-inflammatory macrophage activation.

Summary: AZM Derivatives
This section is adapted, in part, from Zhang et al. 2019. All excluded content can
be found in the original source material.
Azithromycin (AZM) and other macrolide antibiotics are applied as
immunomodulatory treatments for CNS disorders. The immunomodulatory and
antibiotic properties of AZM are purportedly independent. To improve the efficacy
and reduce antibiotic resistance risk of AZM-based therapies, we evaluated the
immunomodulatory and neuroprotective properties of novel AZM derivatives. We
semisynthetically prepared derivatives by altering sugar moieties established as
important for inhibiting bacterial protein synthesis. Bone marrow-derived
macrophages (BMDMs) were stimulated in vitro with proinflammatory, M1, stimuli
(LPS + INF-gamma) with and without derivative costimulation. Pro- and antiinflammatory cytokine production, IL-12 and IL-10, respectively, was quantified
using ELISA. Neuron culture treatment with BMDM supernatant was used to
assess derivative neuroprotective potential. Azithromycin and some derivatives
increased IL-10 and reduced IL-12 production of M1 macrophages. IL-10/IL-12
cytokine shifts closely correlated with the ability of AZM and derivatives to
mitigate macrophage neurotoxicity. Sugar moieties that bind bacterial ribosomal
complexes can be modified in a manner that retains AZM immunomodulation and
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neuroprotection. Since the effects of BMDMs in vitro are predictive of CNS
macrophage responses, our results open new therapeutic avenues for managing
maladaptive CNS inflammation and support utilization of IL-10/12 cytokine
profiles as indicators of macrophage polarization and neurotoxicity.

Summary: LIF
Leukemia inhibitory factor (LIF) was previously implicated in promoting
oligodendrocyte survival and reducing demyelination following SCI. Here, we
examine the role of LIF in our in vitro model of SCI inflammation previously
shown to be predictive of monocyte-derived macrophage responses in vivo in the
injured spinal cord. Application of LIF to pro-inflammatory “M1” macrophages
resulted in reduced production of the pro-inflammatory cytokine IL-12, and
increased production of the anti-inflammatory cytokine IL-10. This suggests that
LIF exerts its protective effects at least in part by driving a shift in macrophage
activation state towards an anti-inflammatory phenotype.

4- ii. Background:
There is only one therapeutic, methylprednisolone, that is available to
improve neurological recovery after SCI (Hall, 2011). Unfortunately, due to the
risk of side effects and a modest therapeutic benefit, many physicians no longer
give methylprednisolone to their SCI patients (Evaniew et al., 2015). This means
that many individuals who sustain an SCI do not receive any therapeutics to
improve their recovery, highlighting the urgent need to develop new therapeutics
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to treat SCI. Macrophages are key mediators of the complex neuroinflammatory
response observed after SCI contributing to the secondary injury process, and
thus macrophages are promising targets for therapies to treat SCI. While AZM
and cPLA2 inhibitors are promising macrophage-targeted therapy candidates,
there are numerous other macrophage-targets therapies being developed. These
include strategies to reduce macrophage infiltration into the injury site and
additional methods to shift macrophage activation towards a pro-reparative state.
The macrophage inflammatory response is a key component of the
pathophysiology of numerous disorders, including SCI. In addition to AZM, and
cPLA2 inhibition discussed previously, there have been additional approaches to
modulate macrophage activation states. cPLA2 inhibition, for example, is a simple
approach to target cPLA2; however, it comes with the major caveat of off target
effects on related phospholipases. Here, we build upon this work by repeating
our previous observations in transgenic mice. Complete genetic ablation of
cPLA2 allows for clear comparisons without the caveats of cPLA2 inhibitors.
Similarly, AZM is a macrolide antibiotic developed through chemical
modifications to erythromycin to improve efficacy; it was not developed with
immunomodulatory activities intentionally. Because of this, we hypothesized that
additional chemical modifications through medicinal chemistry could allow for
further enhancement of its immunomodulatory activity. Here we examine the
therapeutic efficacy of these AZM derivatives in our in vitro model of SCI
neuroinflammation. Next, we examine the ability of the cytokine leukemia
inhibitory factor (LIF) to improve pro-inflammatory macrophage cytokine
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production profiles. Lastly, we discuss some of the other approaches utilized to
target macrophage inflammatory responses in SCI inflammation.
With continued development, macrophage-targeted therapies hold great
promise in the treatment of SCI and related neuroinflammatory conditions for
which patients currently have very few therapeutic options.

Transgenic Targeting of cPLA2 In Vitro
cPLA2 selectively releases arachidonic acid (AA) from cellular membranes
where it is stored in its inactive state. Once released it is rapidly converted into
numerous eicosanoids by enzymes such as the LOX and COX families of
enzymes. These eicosanoids have diverse, albeit largely pro-inflammatory
functions. Previous work has sought to target cPLA2 in rodent models of SCI with
conflicting results (Liu et al., 2006; Lopez-Vales et al., 2008). We hypothesized
that specifically targeting macrophage cPLA2 activity may be more beneficial as it
would target detrimental cPLA2 activity while leaving other beneficial cPLA2 intact.
To this aim, we previously investigated the role of cPLA2 in myelin induced
potentiation of pro-inflammatory macrophage activation using the chemical
inhibitor of cPLA2 PACOCF3 (Kopper et al., 2021). This approach includes many
known and unknown caveats including off target effects on other phospholipases
and the inclusion of solvents like DMSO to suspend the chemical. Here we
repeat these previous studies using BMDMs derived from cPLA2-/- (KO)
transgenic mice and their cPLA2+/+ (WT) littermates. This approach allows us to
confirm our previous observations without the previous caveats of PACOCF3.
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AZM Derivatives
This section is adapted, in part, from Zhang et al. 2019. All excluded content can
be found in the original source material.
The management of maladaptive inflammation is an emerging therapeutic
target for many neuropathologies. Different macrophage phenotypes have been
identified in the injured central nervous system (CNS) in conditions such as
ischemic brain damage, spinal cord injury, and traumatic brain injury. After spinal
cord injury, for example, there is a heterogeneous neuroinflammatory response
mediated by resident microglia and infiltrating macrophages. Classically activated
macrophages (M1) secrete proinflammatory cytokines and chemokines and
contribute to continued cell death and a persistent inflammatory
microenvironment within the injured spinal cord (Gensel and Zhang, 2015; Kigerl
et al., 2009). In contrast, alternatively activated macrophages (M2) release antiinflammatory cytokines and facilitate tissue repair (Kigerl et al.,
2009). Increasingly, clinicians and researchers are testing the therapeutic
potential of drugs that polarize macrophage activation toward reparative
phenotypes in a variety of CNS disorders.
Macrolide antibiotics are a class of natural products consisting of a highly
substituted macrocyclic 14-, 15-, or 16-membered lactone ring. Azithromycin
(AZM) is a 15-membered, second generation, synthetic derivative of
erythromycin with improved pharmacokinetic properties and a broad antimicrobial
spectrum (Parnham et al., 2014). Azithromycin is well tolerated and commonly
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prescribed. Moreover, AZM becomes highly concentrated in macrophages and
other phagocytes (Miossec-Bartoli et al.; Wilms et al., 2006). Across a variety of
inflammatory conditions, AZM attenuates proinflammatory cytokine production by
macrophages and other immune cells (Murphy et al., 2008).
Azithromycin and other macrolide antibiotics are now being tested as
immunomodulatory agents for CNS disorders. Specifically, we and others
observed immunomodulatory effects and improved recovery with AZM treatment
in spinal cord injury, stroke, and retinal ischemia/reperfusion injury (Amantea et
al., 2016a; 2016b; Gensel et al., 2017; Petrelli et al., 2016; Varano et al., 2017;
Zhang et al., 2015b).
The neuroprotective properties of AZM in these models are associated
with direct effects on macrophages (Amantea et al., 2016b; Gensel and Zhang,
2015; Gensel et al., 2017). We have shown that in vitro application of AZM to
proinflammatory M1 bone marrow-derived macrophages (BMDMs) dampens the
release of proinflammatory cytokines, increases M2-associated anti-inflammatory
cytokines, and reduces the neurotoxicity of M1 macrophage-conditioned medium
(Gensel and Zhang, 2015).
In efforts to improve efficacy and/or reduce the risk of increasing antibiotic
resistance, researchers are evaluating the immunomodulatory potential of AZM
derivatives and other macrolide derivatives with the goal of separating the
antibiotic from immunomodulatory properties. As a result, some macrolide
derivatives have been shown to retain immunomodulatory properties in models of
lung inflammation, inflammatory bowel diseases, arthritis, and skin inflammation
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(Balloy et al., 2014; Bosnar et al., 2012; Hodge et al., 2017; Mencarelli et al.,
2011; Rodriguez-Cerdeira et al., 2012; Sugawara et al., 2012). The ability of
macrolide derivatives to reduce macrophage-mediated neurotoxicity, however, is
unknown. With the increased use of AZM as an immunomodulatory agent for
macrophage-mediated neurotoxicity in CNS pathologies, our goal in the present
study was to determine whether macrolide derivatives retain neuroprotective
properties. Using a semisynthetic approach to target modification of the sugar
moieties of AZM, we generated a small library of derivatives, some of which
lacked the cladinose found in the parent. We then tested the cytokine profiles
and neurotoxicity of M1-stimulated BMDMs treated with derivatives and observed
that unique derivatives reduce M1-macrophage activation and subsequent
neuron death. Previously we determined that the effect of BMDMs in vitro is
predictive of macrophage responses in the injured CNS (Gensel et al., 2009;
2015; 2017); therefore, the results of the current study open new therapeutic
avenues for the management of maladaptive inflammation in CNS disorders.

LIF
Leukemia inhibitory factor (LIF) is an IL-6 class cytokine with numerous
functions depending on cell type. In the nervous system LIF has been shown to
be neuroprotective in models of stroke (Rowe et al., 2014; Suzuki et al., 2005),
multiple sclerosis (Butzkueven et al., 2006; Linker et al., 2008), amyotrophic
lateral sclerosis (Azari et al., 2001), and SCI (Azari et al.; Kerr and Patterson,
2005). In SCI, LIF was found to increase oligodendrocyte survival during the
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secondary injury process (Kerr and Patterson, 2005). Interestingly, this was not
thought to be a direct effect of LIF on oligodendrocytes, but instead through
LIF’s actions on an ancillary cell population (Kerr and Patterson, 2005). While not
specified here, macrophages could be a possible mediator in this process. A
similar work demonstrated LIF’s role in arresting oligodendrocyte death and
demyelination (Azari et al.). Here we examine the effects of BMDM in our proinflammatory in vitro model of neuroinflammation. As described previously
(Kopper et al., 2021), BMDMs are predictive of monocyte-derived macrophage
responses in vivo in the injured spinal cord. This has been observed at
transcription (Longbrake et al., 2007) and functional levels (Gensel et al., 2009),
as well as in response to therapeutic interventions (Gensel et al., 2017) as
described previously (Kopper et al., 2021). These data were collected in
collaboration in a study examining the role of LIF in modulating the peripheral
immune response in a rat stroke model of emergent large vessel occlusion
(Davis et al., 2018).

4- iii. Methods:
Transgenic Targeting of cPLA2 In Vitro:
As described previously (Kopper et al., 2021), bone marrow-derived
macrophages (BMDMs) were extracted from the femur and tibia of female
C57BL/6 mice as, previously reported (Gensel et al., 2009; 2015), from both
cPLA2-/- (KO) and cPLA2+/+ (WT) mic developed previously (Bonventre, 1999).
Mice were generated from breeding pairs kindly provided by Dr. Xiao-Ming Xu at
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the Indiana University School of Medicine. BMDMs were plated at 0.8–
1 × 106 cells/mL in differentiation media containing Roswell Park Memorial
Institute medium (RPMI, Thermo Fisher Scientific, #21870-092) supplemented
with 1% penicillin/streptomycin (P/S, Thermo Fisher Scientific, #5140122), 1%
HEPES (Sigma-Aldrich, #83264-100ML-F), 1% GlutaMAX 0.001 (Thermo Fisher
Scientific, #35050061) 0.001% β-mercaptoethanol (Thermo Fisher Scientific,
#21985023), 10% FBS (Life technologies, #10082147), and 20% supernatant
from sL929 cells (a generous gift from Phillip Popovich, The Ohio State
University). Supernatant collected from sL929 cells contains macrophage colonystimulating factor, which helps to promote bone marrow cells’ differentiation into
macrophages (Burgess et al., 1985). The BMDMs were allowed to differentiate
for 7 days in culture, and KO or WT cells were then replated on day 7 at a
density of 1 × 106 cells/mL in 12-well plates in RPMI, containing 1% P/S, 1%
GlutaMAX and 10% FBS. On day 8, cells were stimulated for 24 h to be “M1”
cells using LPS (50 ng/mL, Invivogen, #tlrl-eblps, standard preparation) plus IFNγ (20 ng/ml, eBioscience #14-8311-63) diluted in N2A growth medium (described
below). At the time of stimulation cells were immediately treated with myelin
debris (50 µL/mL, preparation described below), 24 h after stimulation the
supernatants were removed, centrifuged at 13,000 RPM (Fisher Scientific
accuSpin Micro R centrifuge), and then this macrophage conditioned media
(MCM) was either applied directly to N2A cells to measure cytotoxicity, or stored
at − 80 °C prior to testing for Nitric Oxide with the Griess Reagent Kit (Thermo
Fisher Scientific # G-7921).
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Moderate purity myelin (> 95% myelin, with small contributions from
axolemma and other cellular membranes) was prepared as follows (adapted from
Larocca et al. (Larocca and Norton, 2001)): brains were collected from C57BL/6
mice and stored at − 80 °C prior to myelin isolation. The brains were rinsed and
suspended in cold PBS with 1% P/S and placed in a Dounce homogenizer (DWK
Life Science, #357544) under sterile conditions and blended with the loose and
tight pestles. The solution was transferred to a 15 mL tube and pelleted at 2000
RPM (Thermo Scientific Legend XTR centrifuge) prior to discarding the soluble
supernatant fraction. The pellet was resuspended in the PBS/P/S, and then 5mLs
of a 30% Percoll solution (Sigma-Aldrich, #P1644-500ML) was gently underlaid
below the myelin solution for density gradient centrifugation. The layers were
then centrifuged at 2000 RPM for 15 min at 4 °C under gentle
acceleration/deceleration, generating three distinct layers (soluble on top, myelin
in middle, and Percoll/cell pellet on bottom). After removing the soluble fraction,
the myelin was transferred to a fresh tube and resuspended in 10 mL distilled
water with 1% P/S and incubated for 10 min (hypoosmotic shock) to separate
membranes at 4 °C. The myelin was then re-pelleted at 2000 RPM, suspended in
PBS/1% P/S and separated a second time by density gradient centrifugation as
described above. The myelin was then suspended and pelleted twice in PBS/1%
P/S to remove residual Percoll and water-soluble contaminants, and then
aliquoted before storage at − 80 °C. The final protein concentration of the myelin
stock solutions produced by this protocol were 10.23 mg/mL with a standard
deviation of 0.282 mg/mL as determined by a BCA Protein Assay Kit (Thermo
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Fisher Scientific #23225). With the application of myelin debris to BMDMs at
50 µL/mL, cells had a mean dosage of 0.51 mg/mL. Lastly, to ensure our results
were not due to endotoxin contamination in our myelin preparations, we tested
aliquots from each batch of myelin stimulant (Thermo Fisher Scientific #88282).
A mouse neuroblastoma cell line (Neuro-2a or N2A, a gift from Chris
Richards, University of Kentucky) was maintained in N2A growth medium
containing 45% DMEM, 45% OPTI-MEM reduced-serum medium, 10% fetal
bovine serum (FBS), and 1% penicillin/streptomycin. N2A were plated at a
density of 1 × 105 cells/mL in 96-well tissue culture plates and allowed to
proliferate for 48 h. The neurotoxicity of MCM was evaluated as reported
previously using a MTT-based cell growth determination kit according to the
manufacturer’s instructions (Sigma-Aldrich CGD1-1KT) (Zhang et al., 2019).
Briefly, 24 h before testing, N2A growth media was replaced with serum-free N2A
media to induce differentiation. The day of testing this media was replaced by
fresh MCM, and the N2A cells were incubated in MCM for 24 h before thiazolyl
blue tetrazolium bromide (MTT (5 mg/ml), 20 μl per well) was added to each well
and the cells further incubated for 2 h. The tetrazolium ring of MTT can be
cleaved by mitochondrial dehydrogenases of viable cells, yielding purple
formazan crystals, which were then dissolved in acidified isopropanol solvent.
The resulting purple solution was spectro-photometrically measured at 570 nm
Epoch microplate reader (BioTek Instruments, Inc., Winooski, VT) using 690 nm
as a background absorbance. This data is normalized to the non-toxic CTL
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values to generate proportional decrease in viability values and presented
inversely as increased toxicity relative to CTL.
As described previously (Kopper et al., 2021), Macrophage reactive
oxygen species (ROS) production was measured using CM-H2DCFDA
(Invitrogen #C6827). In short, BMDMs were cultured and stimulated as described
above except in a 96 well plate (1 × 106 cells/mL). Following the 24-h stimulation
the supernatants were removed and replaced with a 5 µM solution of CMH2DCFDA in phenol red-free RPMI with 1% GlutaMAX and
penicillin/streptomycin and incubated at 37 °C for 25 min. ROS mediates the
conversion of this compound to fluorescent DCF which was then detected by an
Epoch microplate reader (BioTek instruments, Inc., Winooski, VT) at the
compound’s Excitation/Emission spectra of approx. 492–495/517–527 nm.
Macrophage cPLA2 activity was measured using a Cytosolic
Phospholipase A2 Assay Kit (Abcam #ab133090). In short, cells were cultured as
described above except in six well culture dishes (1 × 106 cells/mL). Cells were
lysed and briefly sonicated on ice in TBS-T (0.4% Triton-X) with a protease
inhibitor (Sigma-Aldrich #11836170001) before proceeding directly into the
manufacturer’s protocol.

Statistical analyses:
As described previously (Kopper et al., 2021), results are expressed as
mean ± standad error od the mean (SEM) and analyzed using GraphPad Prism
6.0 (GraphPad Software). Data were compared by one-way analysis of variance

120

(ANOVA) among groups followed by Dunnett's multiple comparison tests.
Differences were determined to be statistically significant at P value ≤0.05.

AZM Derivatives:
This section is adapted from Zhang et al. 2019
Semisynthesis of AZM derivatives:
The semisynthesis of AZM derivatives and detection of antibiotic activity
was performed in collaboration with Xiaodong Liu, Zheng Cui, and Steven G.
Van Lanen in the College of Pharmacy, University of Kentucky, Lexington,
Kentucky as detailed in Zhang et al. 2019. Table 4.1 summarizes the
modifications made to each derivative of AZM.

Preparation of bone marrow-derived macrophages (BMDMs) and macrophageconditioned medium (MCM):
BMDMs were isolated from the femurs and tibias of C57BL/6 mice at 1016 weeks of age. In a tissue culture hood, the bones were flushed with a syringe
filled with cold washing media (RPMI 1640 supplemented with 10% FBS and 1%
penicillin/streptomycin) to extrude bone marrow into a sterile falcon tube. The
bone marrow was then triturated three times using syringes fit with 18 gauge
needles and then centrifuged at 1000 rpm for 5 minutes at 4°C. After removing
supernatant, red blood cells were lysed in lysis buffer (0.15 mol/L NH4Cl,
10 mmol/L KHCO3, and 0.1 mmol/L Na2EDTA, pH 7.4) for 3 min. The remaining
cells were washed once in washing media and then centrifuged at 212 g for
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5 minutes at 4°C. The resulting cell pellet was resuspended in BMDM culture
media (RPMI 1640 supplemented with 1% penicillin/streptomycin, 1% HEPES,
0.001% β-mercaptoethanol, 10% FBS, and 20% supernatant from sL929 cells)
and then plated in T75 flasks at a density of 1 × 106 cells/mL. The sL929 cell
supernatant (cells, a generous gift from Phillip Popovich at The Ohio State
University) contains macrophage colony stimulating factor, which is needed to
promote differentiation of bone marrow cells into macrophages (Burgess et al.,
1985). Cell culture media was changed on days 2, 4, and 6, and then, cells were
replated at the density of 1 × 106 cells/mL on day 7 for designated stimulation
and/or azithromycin (AZM) treatment. The following day, BMDMs were
stimulated to be M1 using LPS (50 ng/mL; Invivogen) plus IFN-gamma
(20 ng/mL; eBioscience) diluted in N2A growth medium as previously described
(Zhang et al., 2015b). AZM (Sigma PHR1088) or AZM derivatives were diluted to
the concentrations of 1, 5, 25, and 125 μmol/L and then added to the BMDMs at
the time of stimulation. Unstimulated BMDMs maintained in N2A growth medium
were used as control. Six hours following incubation, the supernatant of the
stimulated macrophages (macrophage-conditioned media (MCM)) was collected
and centrifuged to remove the cell debris. The resulting media was either applied
to Neuro-2a cells for the measurement of neurotoxicity or tested for IL-10 and IL12p40 levels using standard ELISA kits (Thermo Scientific, Rockford, IL).
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Assessment of macrophage viability:
BMDMs seeded in 96-well plates (1 × 106 cells/mL) were treated with a
range of concentrations (1-125 μmol/L) of AZM or AZM derivatives for 24 hours.
Cells were cultured in N2a growth media, which contains 45% DMEM and 45%
Opti-MEM Reduced-Serum Medium (Life Technologies) supplemented with 10%
FBS and 1% penicillin/streptomycin (Wendy M Dlakic and Bessen, 2007).

Assessment of Neuron viability:
Assessment of neuron viability was performed by Bei Zhang. These
methods can be found in full in Zhang et al. 2019 and described above

Statistical analyses:
Results are expressed as mean ± standard deviation (SD) and analyzed
using GraphPad Prism 6.0 (GraphPad Software). Data were compared by oneway analysis of variance (ANOVA) among groups followed by Dunnett's or
Holmes-Sidak multiple comparison tests. Differences were determined to be
statistically significant at P value ≤0.05.

LIF
Adapted from Davis et al. 2018
Cell Culture
Bone marrow-derived macrophages (BMDMs) were isolated from
C57BL/6 mice (3 months of age) as described previously and above (Gensel et
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al., 2009; Zhang et al., 2015b). On the day of BMDM stimulation, a classically
activated phenotype (M1) was induced using N2A medium containing LPS
(50 ng/ml) and IFNγ (20 ng/ml). LIF (20 ng/ml) or PBS was co-administered with
the LPS and IFNγ. Macrophage-conditioned media was collected 24 h after
stimulation and centrifuged at 13,000 rpm at 4 °C for 10 min prior to
measurement of IL-12 p40 and IL-10 via ELISA (Kigerl et al., 2009).

4- iv. Results:
Transgenic Targeting of cPLA2 In Vitro
Previously we targeted cPLA2 in vitro with the inhibitor PACOCF3 (Kopper et al.,
2021), here, we repeated these studies using bone marrow derived
macrophages from cPLA2-/- (KO) or cPLA2+/+ (WT) mice (Figure 4.1). Under M1
conditions KO macrophages produced less reactive oxygen species (ROS), and
nitric oxide in response to myelin compared to WT cells (Figures 4.1a, and
4.1b). Similarly, BMDM supernatants from myelin treated KO M1 macrophages
were less toxic to neurons compared to myelin treated WT M1 macrophages
(Figures 4.1c). Arginase enzymatic activity was unaffected by myelin treatment
or genetic ablation of cPLA2 (Figure 4.1c).

AZM Derivatives
This section is adapted, in part, from Zhang et al. 2019. All excluded content can
be found in the original source material.
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Assessment of Macrophage Viability
We chose to use primary bone marrow-derived macrophages (BMDMs)
for our studies as BMDM responses in vitro are predictive of CNS macrophage
response in vivo. When stimulated with LPS+IFN-gamma), BMDMs model
proinflammatory macrophages found in neuropathologies (Gensel et al., 2009;
2017; Kigerl et al., 2009). No doses of AZM or its derivatives were toxic to
BMDMs when applied directly to the cells for 24 hours (Figure 4.2) Interestingly,
this prolonged stimulation of BMDMs with high doses of AZM and its derivatives
resulted in increased readouts on the MTT assay indicative of increased BMDM
proliferation or increased metabolic activity (Figure 4.2). This effect was not as
robust after 6 hours of stimulation (Supplemental Figure 4.1), and therefore, a
6-hr stimulation time point was used for subsequent assays.

Macrophage IL-12/IL-10 Levels with Derivatives
The relative expression of IL-10 and IL-12 is a defining feature of M1 and
M2 macrophages (Mantovani et al., 2004) with M2 macrophages producing high
levels of IL 10 and low levels of IL-12. Conversely, M1 macrophages produce
substantial amounts of IL-12 and minimal IL-10. These cytokine profiles are also
predictive of the neurotoxic potential of stimulated macrophages with toxic
potential decreasing with increased IL-10 and reduced IL-12 production (Gensel
and Zhang, 2015; Zhang et al., 2015a). Similar to previous observations (Zhang
et al., 2015b), AZM reduced production of the proinflammatory cytokine, IL-12,
and elevated the secretion of the anti-inflammatory cytokine IL-10 in M1
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macrophages in a dose-dependent manner 6 hours after stimulation. Compared
to M1-stimulated macrophages, costimulation of M1 stimulant (LPS +IFNgamma) with either 25 or 125 μmol/L AZM significantly decreased IL-12
(P < 0.01 and <0.001, respectively) and increased IL-10 (P < 0.01 and <0.0001,
respectively; (Figure 4.3).
To determine the immunomodulatory properties of our azithromycin
derivatives, we examined IL-10 and IL-12 production in BMDMs costimulated
with derivatives and M1 stimulants (LPS + INF-gamma). We detected
significantly decreased IL-12 production with 125 μmol/L cotreatment
concentrations for derivatives 4 (P < 0.001) and 7 (P < 0.05) relative to M1
stimulation alone (Figure 4.3). Derivative 5 had significantly reduced IL-12
production with 25 μmol/L (P < 0.01) and 125 μmol/L (P < 0.0001)
concentrations. There was no significant effect on IL-12 with derivative 1. We
observed reciprocal significant increases in IL-10 with all derivatives at the
highest dose of 125 μmol/L (P < 0.05, Figure 4.3). In addition, the 25 μmol/L
stimulation with derivative 5 significantly increased production of IL-10 relative to
M1 (P < 0.001; Figure 4.3). RT-PCR analyses of select genes associated with
M1 or M2 macrophage phenotypes (ie, IL-6, IL-1b, TNF-a, and TGF-b)
demonstrated similar immunomodulatory effects between AZM and derivatives 4
and 7 (Supplementary Figure 4.2).Collectively, these data demonstrate that
altering the bacterial binding residues of AZM does not reduce its
immunomodulatory properties with AZM5 having similar dose-response
properties as the parent compound.
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Macrophage-Mediated Neurotoxicity with Derivatives
Assessment of neuron viability was performed by Bei Zhang. These
results can be found in full in Zhang et al. 2019 and described above.

LIF
Other strategies to target macrophage inflammatory responses typical to
aim to modulate macrophage activation states including AZM and cPLA2 ablation
discussed previously. Another method we’ve utilized to reduce pro-inflammatory
macrophage activation in vitro is with leukemia inhibitory factor (LIF), a cytokine
important in cellular differentiation. When given to pro-inflammatory “M1” BMDMs
(LPS + IFN-γ) LIF significantly decreased the production of pro-inflammatory IL12, and significantly increased the production of anti-inflammatory IL-10 (Figure
4.4, adapted from Davis et al. 2018).

4- v. Discussion:
Transgenic Targeting of cPLA2 In Vitro
The gold standard in defining biological mechanisms in biomedical
research is through the use of transgenic rodent models. In the case of cPLA2,
genetic ablation of this enzyme was found to improve locomotor recovery and
reduce tissue damage after SCI (Liu et al., 2014) suggesting a detrimental role
for cPLA2 in SCI pathogenesis. Conversely, in sciatic nerve injury models,
genetic ablation of cPLA2 resulted in fewer regenerating axons and reduced
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macrophage recruitment (Lopez-Vales et al., 2008). Similarly, chemical inhibition
of cPLA2 with AX059 after SCI was found to impair locomotor recovery
suggesting a protective role for cPLA2 (Lopez-Vales et al., 2011). Here, we
demonstrate a clear pathological role of cPLA2 in macrophage inflammatory
responses. Specifically, we observed that macrophage inflammatory responses
under pro-inflammatory “M1” conditions were significantly potentiated by the
addition of myelin. When cPLA2 is ablated, however, this potentiation in
macrophage inflammation is significantly abated. Given that macrophages after
SCI are largely pro-inflammatory and contain myelin, these results implicate
cPLA2 as a major contributor to detrimental macrophage activities after SCI. This
highlights the need to develop safe therapeutics to target cPLA2 in the human
condition.

AZM Derivatives
This section is adapted, in part, from Zhang et al. 2019. All excluded content can
be found in the original source material.
In this study, we demonstrate the retention of immunomodulatory activity
in AZM derivatives with altered sugar moieties using our in vitro model of
macrophage CNS inflammation. This model accurately predicts the
macrophage/microglial response in the injured CNS (Gensel et al., 2009; 2015;
2017b; Zhang et al., 2015b). Specifically, we demonstrate that these derivatives,
like the AZM parent compound, have no negative toxic effects on macrophage
viability, retain the ability to polarize M1 macrophages toward the M2 phenotype
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as determined by IL-10/12 cytokine profiles, and are equally effective in reducing
the neurotoxic effects of M1 macrophage supernatants on neuronal cultures. In
these studies, the ability of the derivatives to shift IL-10/12 cytokine profiles
closely correlated with their ability to mitigate M1 supernatant toxicity to neurons.
This supports our notion of utilizing IL-10/12 cytokine profiles as an indicator of
M1/M2 macrophage polarization and neurotoxicity. Recent literature
demonstrates that AZM increases reparative macrophage activation in rodent
models of spinal cord injury, stroke, lung infection, skin inflammation, and in
humans with cystic fibrosis (Amantea et al., 2016a; 2016b; Čulić et al., 2001;
Feola et al., 2010b; Gensel et al., 2017; Murphy et al., 2010; Petrelli et al., 2016;
Varano et al., 2017; Zhang et al., 2015b). This anti-inflammatory mechanism,
potentially unrelated to AZM's antibacterial properties, holds great promise in the
treatment of these diverse inflammatory conditions.
Further, this relatively unexplored therapeutic approach could likely be
exploited more effectively with continued optimization of therapeutics such as
AZM and related macrolides. In particular, one major obstacle in the clinical
development of anti-inflammatory macrolide antibiotics, such as AZM, is the
concern that increased use of these drugs for their secondary anti-inflammatory
effects may inadvertently promote bacterial resistance to this antibiotic in the
treatment of a variety of infections. In the spinal cord injury patient population, for
example, AZM is the antibiotic of choice for treating recurrent respiratory
infections and pneumonia (Evans et al., 2013), a leading cause of death following
spinal cord injury; thus, antibiotic resistance is a major concern. Fortunately,
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recent studies have indicated that macrolides modified to remove their
antibacterial activity retain beneficial anti-inflammatory effects in models of
inflammatory skin disorders and chronic lung diseases (Hodge et al., 2017;
Rodriguez-Cerdeira et al., 2012).
Collectively, we demonstrate that AZM derivatives with altered sugar
moieties retain immunomodulatory properties. We did not, however, observe
uniform immunomodulatory and neuroprotective properties with all derivatives
tested. AZM7, which had the most extensive chemical modifications
(diacetylation and the removal of the cladinose moiety), invoked modest
immunomodulatory effects exclusively at the highest concentration tested.
Interestingly, however, AZM7 did not retain any antistaphylococcal activity.
Similarly, AZM4, which also lacks the cladinose that is replaced by a carbonyl,
had modest yet significant immunomodulatory effects with minimal
antistaphylococcal activity. Although AZM1 at the concentration of 125 μmol/L
significantly increases IL-10 level, it has no effect in reducing IL-12 production.
Interestingly, AZM1 also induced significant but small changes, relative to AZM,
in BMDM metabolic activity at this high dose. AZM5, which was the only
derivative tested without the cladinose removed, closely mimicked or slightly
exceeded AZM's activity at all concentrations tested including the BMDM MTT
assay. Unfortunately, the acetylation of both sugars in AZM5 did not abolish the
antistaphylococcal activity as desired. This may suggest, however, that chemical
modifications to substitute the cladinose with functional variants may be an
effective approach in developing subsequent generations of derivatives. Future
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studies that systematically alter each of these components may better clarify
which of these modifications are beneficial or detrimental in retaining/improving
AZM's immunomodulatory activity.
We demonstrated the clear anti-inflammatory activity of these AZM
derivatives in vitro; however, related studies utilizing derivatives of AZM and
other macrolides suggest that these drug candidates likely hold great potential for
treating inflammatory disorders of the CNS in vivo. For example, Sugawara et. al
(2012) developed a series of anti-inflammatory nonantibiotic macrolide
derivatives in vitro and then successfully used these derivatives in an in vivo
model of inflammatory bowel disease (Sugawara et al., 2012). Together with our
prior work demonstrating the predictive nature of our in vitro model (Gensel et al.,
2009; 2015; 2017a; Zhang et al., 2015b), these results suggest that our
compounds hold great promise in treating the detrimental neuroinflammatory
conditions. Given that there are extremely few treatment options for most
neurological disorders, our current findings clearly demonstrate the importance of
these drugs and support their continued development into novel therapeutics to
treat CNS inflammation.
While the current study and related publications show encouraging
therapeutic outcomes following stimulations with derivatives of AZM and other
macrolides, the exact mechanisms of action remain uncertain. Much of the work
in this regard has converged in identifying the NF-κB signaling cascade as the
core regulator of the observed shifts in cytokine profiles following macrolide
treatment (Aghai et al., 2007; Cigana et al., 2007; Feola et al., 2010b; Vrancic et
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al., 2012). While this is clearly important, the molecular target upstream of the
NF-κB cascade on which these drugs act remains unclear (Nujić et al., 2012b). In
vitro studies show that AZM accumulates in macrophage lysosomes, where it
increases the pH, interacts with membrane lipids, induces phospholipidosis, and
alters vesicular trafficking which may affect endocytosis and phagocytosis
(MuniÄ et al., 2011; Nujić et al., 2012a). Other suggested mechanisms indicate
that AZM may alter cellular autophagy, or alter the TLR4 signaling pathways by
changing endosome trafficking (Nujić et al., 2012a). Further, it remains unknown
whether these findings remain valid in vivo or whether derivatives of AZM retain
the same mechanism of action. While complicated, continued work in these
areas is essential as it could lead to new therapeutics, such as the compounds
described here, or provide novel therapeutic targets for future drug development.
One interesting finding in the current study was the fairly pronounced
increase in macrophage viability when treated with the highest dose of AZM or
derivative for 24 hours (widely used time point for measuring drug toxicity in
vitro). This assay measures the conversion of tetrazolium dye MTT 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to formazan by NAD(P)Hdependent cellular oxidoreductase enzymes, and this measure of metabolic
activity is routinely used to quantify changes in cell number or vitality. How AZM
and its derivatives induce this effect at high concentrations, and how this may
alter inflammatory activities remains unclear, however, it is unlikely that this is
directly related to our observed shifts in cytokine profiles and neurotoxicity across
drug concentrations. If the observed increases in IL-10 following AZM
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stimulations were simply a result of cellular proliferation, then IL-12 would also be
expected to rise, instead, however, IL-12 levels fell dramatically. Similarly,
measurements of cellular proliferation/metabolism at the 6-hour time point, when
we measure IL-10/12 levels, displayed more modest increases in
proliferation/metabolism and are thus less likely to influence our cytokine profiles.
In conclusion, we have identified AZM derivatives that retain key
immunomodulatory functions in our in vitro model of CNS inflammation. While the
antiinfective properties of the derivatives were associated with neuroprotection,
we also observed that some derivatives with greatly reduced antiinfective
characteristics retained neuroprotective and anti-inflammatory functions.
Although a limited sample size of derivatives was created and tested, this
indicates that the antibiotic properties of AZM may not be required for
immunomodulatory-mediated neuroprotection. With continued development,
these compounds could become viable clinical neuroprotectants and
immunomodulatory treatments for neuropathologies. Additionally, given the
usage of AZM's anti-inflammatory properties across disciplines, these drugs hold
great potential in treating a wide variety of inflammation-based human disorders.

LIF
LIF’s effects on BMDM cytokine production profiles indicate that it holds
immunomodulatory properties. This and previous evidence indicating therapeutic
effects in rodent models of SCI suggest that LIF is a promising therapy to
improve recovery after SCI. Importantly, LIF has already been investigated in US
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clinical trials to prevent chemotherapy-induced peripheral neuropathy. In the
phase I study recombinant human LIF was observed to have a biological effect in
hemopoietic recovery after chemotherapy without any appreciable safety
concerns (Gunawardana et al., 2003). Unfortunately, in a phase II study LIF was
not successful in reducing chemotherapy-induced peripheral neuropathy (Davis
et al., 2005). Nonetheless, these studies provide promising evidence that LIF can
be safely administers to humans. With continued work LIF thus holds significant
promise in improving recovery after SCI and other neurological conditions.

Conclusions
Many individuals who sustain an SCI do not receive any pharmacological
agent to improve their functional recovery. This highlights the critical need to
develop new therapeutics to treat SCI. Macrophages are significant mediators of
SCI pathophysiology and are thus important therapeutic targets. There are
numerous approaches to target macrophages after SCI; however, there are
important considerations as these therapies continue to develop.
Macrophages are known to contribute to pathological inflammation in
numerous conditions including stroke, SCI, lung infections, myocardial infarction,
and many others (Al-Darraji et al., 2018; Amantea et al., 2016b; Feola et al.,
2010b; Zhang et al., 2015b). As a result, there have been several strategies
developed to target these cellular populations. The two general approaches are
those that seek utilize a therapeutic or therapeutic target to alter macrophage
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activation (such as AZM and cPLA2 ablation), while others target macrophages to
prevent them from reaching sites of inflammation.
One frequent strategy used to target macrophages relies on their innate
propensity to phagocytose debris and foreign material. A rapidly developing use
of this approach is with carefully engineered liposomes. These spherical lipid
structures can be engineered to be preferentially engineered to be phagocytose
by macrophages and monocytes through manipulations of lipid composition, size,
charge, and membrane proteins (Kelly et al., 2010). These liposomes can then
be loaded with clodronate resulting in the selection depletion of macrophages.
This has been used to prevent macrophages from reaching the site of injury after
SCI, thereby improving recovery (Popovich et al., 1999). A similar strategy has
been developed using immune-modifying microparticles, derived from
microdiamonds, poly(lactic-co-glycolic) acid, or polystyrene. Uptake of these
particles by macrophages causes these cells to sequester in the spleen instead
of migrating into sites of inflammation (Getts et al., 2014). These cells are then
cleared through apoptotic pathways (Getts et al., 2014)
Others have utilized the macrophage targeted liposomes strategy
differently, by instead loading them with a therapeutic, allowing for a relatively
specific delivery to macrophages. For example, this strategy has recently been
employed to delivery AZM to macrophages in a rodent model of myocardial
infarction and was shown to improve recovery (Al-Darraji et al., 2020). Similarly,
another group developed vessels engineered from M1 and M2 macrophages
creating nanocarriers capable of modulating macrophage phenotype (Neupane
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et al., 2021). Intriguingly, another group has investigated using macrophages
themselves as drug carriers across the blood brain barrier using “cellular
backpacks” loaded with pharmaceuticals attached to the macrophage cell
surface (Klyachko et al., 2017).
To date, there has been one macrophage-targeted therapy to reach
clinical trials. This therapy was derived from pre-clinical studies in which
macrophages were isolated from blood and stimulated with nerve tissue or skin
tissue to stimulate the cells into a pro-reparative phenotype (Bomstein et al.,
2003; Rapalino et al., 1998). These cells were then injected into transected
spinal cords, resulting in partial recovery of paraplegic rats as determined by
open field examination, electrophysiological recordings from hind limb muscles,
or histological analysis. The phase I clinical trial indicated that the procedure was
safely tolerated by the participants (Knoller et al., 2005); however, phase II trials
failed to show any therapeutic benefits (Lammertse et al., 2012). While
disappointing, there are numerous reasons why this macrophage-target therapy
failed to improve neurological recovery. First, the time to treatment from the time
of injury was a average of 12.93 days, with most patients clustered towards the
maximum 14-day post-injury inclusion criteria limit (Lammertse et al., 2012).
Considering many key events of SCI pathophysiology occur soon after injury, it is
possible the injection delay was too late to impart significant therapeutic effects.
While the procedure itself took at least 36 hours to collect cells, stimulate them,
and surgically inject the cells into the injury site, any future iteration of this study
should consider earlier injection criteria. Second, macrophages are highly plastic
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cells that can shift between activation states depending on their environment.
Given the predominantly pro-inflammatory environment observed after SCI, it is
possible that the macrophages that were “trained” to be reparative with nerve or
skin tissue simply reverted to a pro-inflammatory state. There is a strong
precedent for this in pre-clinical research. When M2 macrophages were injected
into naïve spinal cords or an SCI lesion at 7dpi, the cells in the lesion quickly lost
indicators of M2 activation states (Kigerl et al., 2009). In this regard, future
iterations of this study should consider this strategy for chronic injury where
inflammation has subsided or investigate methods to reduce macrophage
plasticity before injection. Lastly, like many therapies, differential responses to
therapeutics in rodents and humans are common, so this strategy may simply be
ineffective in humans. Collectively, this is an interesting macrophage-targeted
therapy; however, additional work is needed before this can be successfully
implemented.
The most consequential decision impacting the success of novel
therapeutics is likely the route and timing of administration. First, macrophages
can be targeted through a systemic administration or through macrophagespecific approaches. This selection will likely have a significant impact on dosing
and potential side effects. With AZM, for example, we utilized a systemic
administration and successfully improved functional outcomes (Kopper et al.,
2019). Others, however, have enhanced the therapeutic benefits of AZM by
loading AZM into liposomes targeting macrophages (Al-Darraji et al., 2020).
Similarly, others have found that liposomal delivery can increase drug
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concentrations at the site of inflammation while reducing the ED 50 of the drug,
presumably from a reduction in off-target effects (Rose, 2005). While promising,
whether a targeted or systemic approach results in increased efficacy is likely
drug-specific. cPLA2, for example, is expressed in numerous cell types with likely
differential functions. While we hypothesize that a macrophage-targeted delivery
may improve efficacy, others have shown significant improvement from a
systemic approach (Liu et al., 2006). Whether the targeting of additional cell
types improves or decreases therapeutic efficacy will likely differ for each
therapy. Similarly, as discussed previously (Gensel et al., 2017; Kopper and
Gensel, 2021; Kopper et al., 2019), the selection of dosage, dose timing, and
route of administration are critical factors in therapeutic efficacy.
The macrophage population after SCI is predominantly composed of
infiltrating myeloid-derived macrophages and resident microglia. Historically
these cell types were used interchangeably; however, growing evidence has
suggested they may have differential roles in inflammation, myelin clearance,
and recovery (Bellver-Landete et al., 2019; Greenhalgh et al., 2018; Wang et al.,
2014). Specifically, microglia may hold more protective roles than previously
thought, as microglia depletion further impairs locomotor recovery and neuronal
survival (Bellver-Landete et al., 2019). Conversely, infiltrating monocyte populate
the core of the lesion and appear to be the primary cell type taking up myelin
(Wang et al., 2014). Lastly, growing evidence suggests that microglia and
peripherally derived macrophages may communicate within the lesion and
differentially regulate each other’s cellular activities (Greenhalgh and David,
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2014). Continued work is needed to better understand the differential roles of
microglia and monocyte-derived macrophages. Targeting a specific macrophage
population is an important consideration when selecting routes and timing of
administration, as each may have a distinct impact on each population. For
example, intravenously injected liposomes may disproportionately affect
circulating monocytes vs. tissue-resident microglia. Similarly, direct spinal
injections may be required to target both cellular populations, particularly after
the closure of the blood-brain barrier post-SCI.
While there is a critical need for therapeutics to treat acute SCI, there is
also an existing population of over 250,00 individuals in the United States living
with an SCI. This is an important consideration when advancing therapeutics
towards clinical use. Pro-inflammatory macrophages are present in the
chronically injured spinal cord and are likely a continuous barrier to recovery
(Horn et al., 2008). Thus, it is especially important to evaluate macrophagetargeted therapies at chronic timepoints. While locomotor and histological
recovery are common outcomes in animal research, the SCI population generally
prioritize improvements to their bowel, bladder, and sexual health (Anderson,
2004). Because of this, it is essential to include these outcome measures when
examining macrophage-targeted therapies in chronic injuries.
Macrophage-targeted therapies hold great promise in the treatment of
SCI; however, various degrees of development are needed to advance these
therapies towards clinical use. As an FDA-approved antibiotic with an excellent
safety history, AZM could, in theory, be rapidly deployed into the clinic.
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Realistically, however, we need additional basic research to maximize its modest
effects (Kopper et al., 2019) and gain preliminary clinical before it could be widely
deployed. Conversely, cPLA2 displays robust effectiveness as a therapeutic
target in pre-clinical studies in vitro (Kopper et al., 2021); however, it will require
fairly extensive pre-clinical work before it can be targeted in patients. Similarly,
numerous alternative therapies in development to target macrophages, which,
while promising, also need significant development to advance them toward
clinical use. Given the current pharmacological gap in our ability to treat
individuals with SCI, it is imperative that new SCI therapies, including those
discussed here, are thoroughly investigated.
Collectively, these studies highlight the critical role macrophages play in
pathogenic inflammation and the urgent need to develop an immunomodulatory
macrophage therapy towards FDA approval.
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Figure 4.1. cPLA2 KO macrophages exhibit reduced reactivity to myelin
under pro-inflammatory conditions relative to cPLA2 WT macrophages.
BMDMs were isolated from cPLA2-/- (KO) or cPLA2+/+ (WT) mice and stimulated
as in Fig 2.3. (A) Genetic ablation of cPLA2 reduced myelin mediated ROS
increases in M1 (IFN-γ and LPS) macrophages. (B) Genetic ablation of
cPLA2 reduced myelin mediated nitric oxide production. (C) Genetic ablation of
cPLA2 reduced the neurotoxic potential of M1 macrophages treated with myelin
as determined by an MTT assay measurement of N2a cell viability. (D) Genetic
ablation of cPLA2 did not significantly alter arginase activity. Representative of 3
biological replications of both BMDMs and myelin source. *p < 0.05, **p < 0.01,
***p < 0.001 mean ± SEM.
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Figure 4.2. Altering the antibiotic properties of azithromycin does not
decrease macrophage viability.
Bone marrow-derived macrophages (BMDMs) were isolated from adult mice and
were treated with AZM, AZM1, AZM4, AZM5, and AZM7 at concentrations of 1,
5, 25, and 125 μmol/L for 24 h Cell viability was measured by using MTT assay.
AZM or AZM derivatives exhibited no cytotoxicity at any tested concentration as
compared to unstimulated, nontreated BMDM control (dotted line). Moreover,
AZM and AZM derivatives at 25 and/or 125 μmol/L significantly increased
proliferation of BMDMs as compared to unstimulated controls at *p < 0.05, **p <
0.01, ***p < 0.001. Data are mean ±SD and representative of three independent
biological replicate experiments
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Figure 4.3. Nonantibiotic macrolides polarize proinflammatory
macrophages to an anti-inflammatory phenotype.
BMDMs were polarized to be M1 macrophages by stimulating with LPS +INFgamma. AZM, AZM1, AZM4, AZM5, and AZM7 were coapplied to M1 cells at
concentrations of 1, 5, 25, and 125 μmol/L for 6 h Protein levels of IL-12 (A) and
IL-10 (B) in cell culture medium were analyzed by ELISA and expressed as fold
change over M1 of mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs M1. Data
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are representative of three independent biological replicate experiments. Each
experiment was performed in triplicates per treatment group. (A) AZM and AZM 5
at the concentrations of 25 and 125 μmol/L significantly decreased
proinflammatory cytokine IL-12, while AZM4 and AZM7 significantly reduced IL12 level only at the concentration of 125 μmol/L. AZM 1 showed no effect in
changing IL-12 secretion. (B) The anti-inflammatory cytokine IL-10 level was
significantly increased in M1 macrophages coincubated with AZM and AZM 5 at
the concentrations of 25 and 125 μmol/L; While AZM1, AZM4, and AZM7
significantly increased IL-10 expression only at the highest tested concentration
of 125 μmol/L.
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Table 4.1: Structure, molecular weight, and antibiotic properties of
derivatives.
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Figure 4.4. LIF treatment decreases IL-12 p40 release and increases IL-10
release in pro-inflammatory BMDMs.
A pro-inflammatory (M1) phenotype was induced in BMDMs via stimulation with
IFNγ and LPS. LIF or PBS were co-administered with stimulants. At 24 h after
stimulation, macrophage-conditioned media from M1 cells treated with LIF had
significantly lower IL-12 p40 release compared to media from M1 cells treated
with PBS (**p < 0.01). b IL-10 release in macrophage-conditioned media from M1
cells treated with LIF compared to M1 cells treated with PBS (*p < 0.05). c The
average ratio of IL-12 p40/IL-10 in the macrophage-conditioned media from LIFtreated M1 cells was significantly lower than the IL-12 p40/IL-10 ratio in the PBStreated M1 cells (**p < 0.01). n = 3 wells per treatment group
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Supplemental Figure 4.1: Altering the antibiotic properties of AZM does not
decrease macrophage viability at the time of protein and RNA isolation.
Bone marrow-derived macrophages (BMDMs) were isolated from adult mice and
were treated with AZM, AZM1, AZM4, AZM5, and AZM7 at concentrations of 1,
5, 25, and 125 μM for 6 hrs (timepoint at which samples are collected for protein,
RNA, and neurotoxicity assays). Cell viability was measured by using MTT
assay. AZM or AZM derivatives exhibited no cytotoxicity at any tested
concentration as compared to unstimulated, non-treated BMDM control (dotted
line). Moreover, AZM and AZM derivatives 1, and, 4 at 125 μM significantly
increased proliferation of BMDMs as compared to unstimulated controls at
*p<0.05, **p < 0.01, ***p < 0.001, however this effect was less robust than the
24hr drug toxicity timepoint in Figure 4.2. Data is mean ± SD and representative
of three independent biological replicate experiments.
Methods: Performed as in Figure 4.2, utilizing a 6hr timepoint.
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Supplemental Figure 4.2: AZM and AZM derivatives decrease proinflammatory macrophage activation. The pro- inflammatory cytokine, IL-1beta, was down regulated by AZM, AZM 4, and AZM 7. Similarly, the proinflammatory cytokine, IL-6 was, down regulated by AZM and AZM 7. Shifts in
the anti-inflammatory cytokine TGF-Beta and the pro-inflammatory cytokine TNFalpha were not statistically significant. Results indicative of 2 independent
biological replications. *p<0.05, **p < 0.01, ***p < 0.001

Methods: BMDMs were polarized to be M1 macrophages by stimulating with LPS
+ IFN-gamma. AZM, AZM1, AZM4, AZM5, and AZM7 were co-applied to M1
cells at concentrations of 1, 5, 25, and 125 μM for 6 hr. 300μL TRIzol LS reagent
(Life Technologies) was added to each well (500,000 cells) to isolate RNA. Total
RNA was isolated based on the manufacturer’s protocol, with an additional phase
separation using BCP, precipitation with isopropanol (Sigma-Aldrich, St. Louis,
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MO), and wash of the isolated RNA in 70 % ethanol. Then, 1 μg RNA was
reverse-transcribed using the high- capacity complementary (cDNA) reverse
transcription kit (Life Technologies). Real-time PCR amplification was performed
on the mixture of 100 ng cDNA sample, Taqman Universal PCR Master Mix, and
Taqman Probes (Life Technologies) using the Applied Biosystems Step One Plus
Real-Time PCR System. Expression of genes was normalized to 18S mRNA for
each sample, and reported values were calculated as 2-ΔΔCT.

149

Chapter 5: Conclusions and Future Directions

5- i. Chapter Summary:
Macrophages are influential mediators of the inflammatory environment
thought to propagate secondary injury processes and impair recovery after SCI.
Macrophage phenotype is a critical determinant on whether the macrophage
response supports reparative vs. destructive functions after SCI (Kigerl et al.,
2009). The pro-inflammatory macrophage activation state predominates after
SCI; however, the underlying mechanisms of this prolonged destructive process
are poorly understood. Here we examine the role of myelin debris in propagating
macrophage inflammatory responses under the spectrum of macrophage
activation states. We then seek to target these macrophages and shift their
activation state as a strategy to improve recovery in mouse models of SCI.
Specifically, we identify cPLA2 as a key mediator of myelin’s pathological effect
on macrophage and utilize the immunomodulatory antibiotic AZM as a means to
shift macrophage activation state and improve SCI recovery. Lastly, we aim to
develop cPLA2 inhibitors, AZM, AZM derivatives, and related therapeutics as
macrophage-targeted therapeutics for use in human SCIs for which there is an
urgent clinical need.

5- ii. Review of Major Findings:
As detailed in chapter 2, myelin debris is an important environmental
factor contributing to the pathological macrophage response after SCI. In vitro,
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myelin robustly potentiates pro-inflammatory macrophages. Pro-inflammatory
“M1” treated with myelin increased production of reactive oxygen species, nitric
oxide, IL-12, and had increased neurotoxicity toxicity. Anti-inflammatory “M2”
macrophages and unstimulated macrophages were largely unaffected by myelin,
indicating that the effects of myelin are specific to the “M1” phenotype. In vivo
after SCI, macrophages contain extensive myelin debris and are predominantly
in a pro-inflammatory activation state, implicating myelin as a contributing factor
to the prolonged destructive macrophage response after SCI.
We then found that inhibition of the enzyme cPLA2 significantly reduced
myelin’s ability to potentiate pro-inflammatory macrophage responses. This
reduction implicates cPLA2 as a key mechanism in the macrophage myelin
response and thus as an important therapeutic target. In vivo after SCI, myelinloaded macrophages express active cPLA2 providing the key spatiotemporal
evidence for cPLA2’s role in pathological SCI inflammation.
We previously targeted macrophage-mediated inflammatory responses
with the immunomodulatory antibiotic AZM (Gensel et al., 2017; Zhang et al.,
2015b). Here in chapter 3, we expand on these prior works by administering AZM
beginning 30-minutes, 3-hours, or 24-hours following SCI, and then daily for
seven days. The 30-minute and 3-hour timepoints improved locomotor recovery
(BMS scale) and increased stepping frequency. The 30-minute timepoint also
exhibited histological improvements with a reduced lesion length. The 24-hour
timepoint was therapeutically ineffective in this model. Lastly, in chapter 4 we
continue to develop additional strategies to target macrophages after SCI,
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including transgenic manipulation of cPLA2, AZM derivative pharmaceuticals with
altered immunomodulatory profiles, and the immunomodulatory cytokine
leukemia inhibitory factor (LIF).
There are few treatment options to improve SCI recovery in humans. Here
we review the steps to advance macrophage-targeted therapies towards use in
humans. While cPLA2 is a promising therapeutic target, there are no established
therapies to target it in humans. Because of this, there are substantial stages of
basic research required to prove efficacy and safety in animal models of SCI.
Conversely, AZM is an FDA-approved antibiotic with widespread clinical use;
however, its effects are modest. Because of this, we need to optimize routes of
delivery and develop non-invasive methods to collect data on patients prescribed
AZM near the time of their injury. Lastly, given the urgent clinical need for SCI
therapeutics, all potential therapeutics need to be investigated. These include
macrophage-targeted therapies, including AZM derivatives, LIF, and liposomebased therapies.
Collectively we identify an underlying mechanism for maladaptive
macrophage activation and investigate macrophage-targeted therapies to
improve recovery after SCI.
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5- iii. Continued Development of Macrophage cPLA2 as a Therapeutic
Target for the Treatment of Spinal Cord Injury and Other Neurological
Conditions
Macrophage cPLA2 activity has been identified as a novel therapeutic
target to improve recovery after SCI; however, additional preclinical research is
required to develop these concepts. First, we need definitive In vivo data showing
therapeutic benefits from targeting macrophage cPLA2 activity after SCI. Next,
we need to identify a chemical cPLA2 inhibitor most likely to be safely tolerated in
humans from the numerous compounds used in the literature. Lastly, we need to
continue to develop methods to deliver therapeutics specifically to macrophages.
Arachidonic acid, released by cPLA2 activity, can be processed into a vast
collection of lipid mediators of inflammation with diverse functions. Further, this
process is differentially regulated in numerous cell types. Given this, it is possible
that cPLA2 can possess both protective and detrimental roles depending on cell
type and environmental conditions. The next step in developing macrophage
cPLA2 activity as a therapeutic target is to specifically target only macrophage
cPLA2 activity. Unfortunately, no macrophage-specific transgenic mouse line has
been developed. Instead, to determine the role of cPLA2 specifically in infiltrating
macrophages following SCI, we will use a bone marrow chimera KO approach as
detailed in Figure 5.1. Specifically, wild-type (WT) C57BL/6 will be irradiated to
deplete bone marrow and peripheral macrophages and then injected with bone
marrow cells isolated from WT or cPLA2-/- mice. These mice will then be housed
for approximately two months to allow for complete bone marrow reconstitution
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(Fenn et al., 2014). This approach will create a controlled scenario in which
cPLA2 can be studied exclusively in myeloid-derived cells, notably infiltrating
macrophages following SCI, leaving cPLA2’s other diverse physiological
functions intact. Functional recovery will be regularly monitored throughout using
the Basso mouse scale (BMS); a gridwalk, and an activity box monitoring
generativity and rearing (Basso et al., 2006; Zhang et al., 2015b). Lastly, we will
assess measures of neuropathic pain (Von Frey, mechanical allodynia) prior to
injury and at 27 dpi. Including pain outcomes is important as many eicosanoids
downstream of cPLA2 are known mediators of pain (Dennis and Norris, 2015;
Deuis et al., 2017). The animals should be sacrificed at 3, 7, and 28 days to
capture acute, peak, and chronic cPLA2 activity (Liu et al., 2006; 2014). The
effect of cPLA2 depletion from infiltrating macrophage on white matter tissue
sparing, total and macrophage-specific ROS production, and acute and chronic
macrophage polarization states will be determined using histology as in (Zhang
et al., 2015a; 2016). Collectively, these studies will provide key evidence on the
impact of cPLA2 on SCI pathogenesis. This data is essential to justify the
continued effort to develop macrophage cPLA2 as a therapeutic target for treating
spinal cord injury and other neurological conditions.
cPLA2 (and related phospholipases) has previously been targeted in
rodent and in vitro models of SCI using a variety of chemical inhibitors, including
PACOCF3, AACOCF3, AX059, AX115, and FKGK2 (Kopper et al., 2021; Liu et
al., 2014; Lopez-Vales et al., 2011). Further, there are additional cPLA2 inhibitor
candidates, such as AVX001, which treats psoriasis (Ashcroft et al., 2020). In this
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case, AVX001 even demonstrated efficacy against plaque psoriasis in a phase
I/IIa clinical trial when used topically (Omland et al., 2017); however, to date, no
known cPLA2 inhibitor is available for clinical use in humans. Fingolimod
(FTY720), an FDA-approved immunomodulatory sphingosine-1-phosphate
agonist, which sequesters lymphocytes to treat multiple sclerosis (Chun and
Hartung, 2010), has also been suggested to inhibit cPLA2 (Payne et al., 2007);
however, whether it could be utilized to inhibit macrophage cPLA2 activity
remains unknown. Interestingly, it has been separately investigated as an SCI
therapeutic in mice with observed improvements in locomotor function
(Norimatsu et al., 2012). Lastly, there are numerous other proposed cPLA2
inhibitors that are commercially available that have not been widely tested. In
order to reach the ultimate goal of targeting cPLA2 in human SCI, a drug will need
to be selected/developed that can be safely administered and pass all FDA
requirements. Current drug candidates to inhibit the PLA2 family of enzymes are
summarized in Table 5.1. Continued work is necessary to screen these
pharmaceutical candidates for cPLA2 inhibition efficacy, relative PLA2 specificity,
and cellular toxicity. Additional collaboration with medicinal chemists could help
screen out candidates unfit for further investigation into human use.
Before any macrophage cPLA2 inhibitor could be developed for human
use, we must first optimize existing methods to target drug delivery specifically to
macrophages. This would likely be achieved by methods designed to target
phagocytes through the use of liposomes or related engineered vesicles (AlDarraji et al., 2020; Kelly et al., 2010; Neupane et al., 2021). The ability to
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package drugs into lipid vessels is highly dependent on the drug’s chemical
structure, so this would be an additional consideration when selecting cPLA2
inhibitor candidates (Sercombe et al., 2015). Once these technicalities are
addressed, these inhibitor-vesicles would need to be tested for efficacy in rodent
models of SCI at multiple doses or dosing paradigms. If successful, these
experiments would then need to be replicated in a larger species (rat and/or pig).
Lastly, in preparation for any potential use in human patients, investigations to
screen for possible side effects and general toxicity (LD50s) would need to be
performed (Mosedale, 2018).
Macrophage cPLA2 activity is a potent regulator of inflammatory reactions
and thus is a promising therapeutic target. While the observed data is
encouraging, there are still significant challenges and continued work needed to
turn a cPLA2 inhibitor into a successful macrophage-targeted therapy for the
treatment of SCI (Figure 5.2).

5- iv. Continued Development of Azithromycin as a Neuroprotective
Therapeutic for the Treatment of Spinal Cord Injury and other Neurological
Conditions
This section was adapted from Kopper and Gensel 2021
Spinal cord injury (SCI) induces a robust inflammatory response largely
mediated by resident microglia and infiltrating macrophages across the bloodbrain barrier. While these cell populations are capable of promoting repair and
regenerative responses, in the days and weeks after SCI they predominately
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adopt pro-inflammatory profiles known to inhibit recovery and potentiate
secondary injury pathways. Continued work is needed to develop clinically viable
immunomodulatory therapeutics and promote pro-reparative macrophage
responses. Recently we published on the therapeutic benefits of the macrolide
antibiotic azithromycin (AZM), which improves locomotor and histological
recovery after SCI in 3-month-old female mice (Kopper et al., 2019). Specifically,
we initiated AZM beginning 30 minutes, 3, or 24 hours after injury and then daily
for 7 days. AZM administration initiated at 30 minutes and 3 hours post-injury
improved locomotor function as detected by an open field locomotor scale and
significantly improved stepping frequency. The 24- hour time point, however, was
ineffective suggesting the importance of early administration. Histologically we
observed modest improvements with the 30-minute treatment time point with
significantly reduced lesion length and evidence of slight increases in tissue
sparing at the lesion epicenter. Previously, we observed that the same AZM
dosing strategy after SCI reduces pro-inflammatory microglia and macrophage
activation as determined by a diverse panel of inflammatory markers (Gensel et
al., 2017). These neuroprotective findings are consistent with recent studies
finding AZM to be therapeutically effective in multiple stroke models (Amantea et
al., 2016b, 2019) a rat model of retinal ischemia/reperfusion injury (Zheng et al.,
2007), and in a rat neonatal hypoxic-ischemic brain injury model (Barks et al.,
2019). AZM is the most commonly prescribed antibiotic due in part to its safety
profile and large therapeutic index (Durkin et al., 2018). Collectively, these
studies highlight the potential for AZM to be developed into a safe,
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neuroprotective treatment for SCI and other neurological conditions. Here, we
highlight additional areas of study that will facilitate the translation of AZM as a
neuroprotective agent.
Extending the therapeutic window of AZM treatment would maximize its
therapeutic development. Based upon studies in animal models of stroke and
SCI, AZM remains effective if the initial dose is delayed up to 3 (oral) or 4.5
(intraperitoneal) hours after SCI and stroke, respectively, with earlier
administration time points being most effective (Amantea et al., 2016a; Kopper et
al., 2019). This may present a challenge for implementation in SCI. Indeed, the
average time of acute methylprednisolone administration in a previous SCI
clinical trial was between 8–9 hours after injury (Bracken et al., 1990). An
extended therapeutic window may be achieved by investigating alternative routes
of administration (e.g., intravenous or intrathecal-we used oral administration in
our studies); improving dosing paradigms (initiation time point, concentrations,
frequency, and duration) or developing more targeted delivery approaches (i.e.,
liposomal formations for targeted macrophage delivery). Similarly, continued
work in medicinal chemistry holds the potential to improve AZM’s therapeutic
benefits and/or pharmacokinetics. In our previous work, we were able to
introduce a series of changes to the molecular structure of AZM in which its
antibiotic activity was reduced but the newly generated derivatives retained their
immunomodulatory and neuroprotective effects (Zhang et al., 2019). Continued
work in this area could identify a closely related drug with improved therapeutic
efficacy. Collectively, given AZM’s large therapeutic index and safety profile is it
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likely that optimization of AZM administration in animal models can be achieved
to fully develop AZM as an effective therapeutic in SCI and other neurological
conditions.
Insight into AZM’s therapeutic mechanisms of action will further facilitate
translation. For example, in our recent work we found that AZM did not prevent
the overall development of neuropathic pain over the course of 28 days (Kopper
et al., 2019), however, previously we found that AZM has analgesic properties
when administered 30 minutes prior to pain testing at chronic time points when
neuropathic pain (heat hypersensitivity) is already established (Gensel et al.,
2019). Microglial activation in the lumbar spinal cord is implicated in chronic pain
after SCI yet acute monocyte- derived macrophage infiltration after injury is
postulated to contribute to neurodegeneration. The current body of in vivo
literature has utilized systemic administrations of AZM targeting both microglia,
infiltrating macrophages, and likely other cell types yet to be examined. Currently,
the relative contribution of each of these cell populations to the therapeutic
effects of AZM is unknown, however, it is possible that AZM’s effects are
localized to one population. Further investigations into the cell-specific effects of
AZM may improve therapeutic strategies and the relatively recent introduction of
microglia- specific antibodies provides new tools to probe these questions.
As we continue to optimize immunomodulatory therapies for SCI, it is
important that we prepare for the logistical challenges of clinical implementation.
AZM has a unique benefit among the many promising drug candidates for SCI in
that AZM is already Food and Drug Administration approved and heavily utilized
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by the general population (Durkin et al., 2018). While these properties ease the
barrier for human treatment, discontinuities in outcome measures of efficacy in
animals models and humans may confound our ability to determine the
therapeutic properties of AZM treatment in a clinical setting. In a clinical
application there are uncertainties as to what would be the best marker of
efficacy in humans. Analyses targeting blood or cerebrospinal fluid would
presumably be the first choices given their clinical availability and non-invasive
nature, however, the best analyte or cellular outcome to detect efficacy is
unknown. Similarly, imaging techniques such as MRI are frequently utilized after
SCI, and thus could be a useful tool in quantifying any therapeutic effects. As
such, ongoing animal studies involving AZM should begin to test and incorporate
blood, cerebrospinal fluid, and/or live animal imaging in order to determine the
best approaches to detect AZM’s therapeutic efficacy in humans. Fortunately,
new SCIs are relatively rare in the United States; however, this may produce a
logistical problem in the optimization of biomarkers of efficacy. In this scenario,
the SCI research community could benefit from collaborating with the larger
stroke field when determining the most useful therapeutic indicators. Once
collected, any data indicating therapeutic and anti-inflammatory activities in the
patient population would then serve as the final push likely needed to initiate fullscale clinical trials in humans.
Initial clinical studies utilizing AZM should certainly investigate potential
improvements in the American Spinal Injury Association Impairment Scale
impairment scale, however, this outcome would likely prove to be a difficult

160

threshold to detect efficacy. Given the modest effects of AZM treatment, patient
and injury variability during this early stage of investigation would likely make a
statistically significant shift in American Spinal Injury Association Impairment
Scale grades unlikely. Even in a larger-scale clinical trial, this may still prove to
be too demanding of a therapeutic threshold to detect efficacy. In contrast, rodent
models of SCI research regularly utilize locomotor recovery as a primary
outcome using highly consistent injuries and optimized testing paradigms
capable of detecting treatments with smaller effect sizes. The discontinuities
between animal and clinical research were recently highlighted at “SCI 2020:
Launching a Decade for Disruption in Spinal Cord Injury Research”, a meeting
hosted by the National Institute of Neurological Disorders and Stroke. Clinicians,
individuals with SCI, and researchers at the meeting emphasized the importance
of incorporating clinically relevant outcomes such as bladder, bowel, and sexual
function, as well as, neuropathic pain and autonomic dysreflexia both into basic
research and when determining therapeutic efficacy in the clinic. In our recent
works, we investigated the ability of AZM to either prevent or suppress
neuropathic pain (Gensel et al., 2019; Kopper et al., 2019), however, AZM’s
impacts on these other important clinical outcomes are currently unknown.
Therefore, continued research into AZM’s impact on other key outcomes in
animal models could highlight specific measures to consider when designing
clinical studies.
As a Food and Drug Administration (FDA) approved drug with an excellent
safety history, AZM holds great promise as a therapeutic to treat SCI and other

161

neuroinflammatory conditions. Although the current research in animal models of
neurological conditions is promising, the clinical variability in the human
population and AZM’s relatively modest effect size will likely become a challenge
in detecting efficacy. To address this, as summarized in Figure 5.3, we need to
better understand AZM’s underlying mechanisms, improve its efficacy by
optimizing dosing paradigms, and begin developing approaches to detect
therapeutic effects non-invasively in humans. Once these challenges are
overcome AZM will have greatly improved chances of moving towards successful
clinical implementation as a neuroprotective treatment.

5- v. Limitations and Alternative Approaches:
Macrophage cPLA2 is a promising therapeutic in vitro; however, it has
never been specifically manipulated in vivo. The genetic cPLA2 chimeric
approach described here, while promising, has several limitations. First, all
hematopoietic cells will be affected. While this is significantly more specific than a
systemic drug injection, it could certainly induce unknown effects in other cell
types such as leukocytes. Similarly, microglia, a significant macrophage
population in the SCI lesion environment, would be unaffected. While infiltrating
macrophages are the primary cell type mediating long-term myelin clearance, the
importance of macrophage vs. microglial cPLA2 activity is unknown. Alternative
approaches to improve specificity could include direct injections of a cPLA2
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inhibitor into the CNS or incorporated them into macrophage-targeted liposomes.
While interesting, each of these approached have unique limitations.
cPLA2 is expressed in many cell types, and eicosanoids downstream of
AA release are commonly exchanged between cells (Dennis and Norris, 2015).
Because of this, despite complete genetic ablation of cPLA2, macrophages could
still produce eicosanoids with AA or downstream products released from other
cell types. While this would presumably be a significant reduction, the extent of
this process is unknown. Use of exogenously released AA in macrophages could
be reduced by using combinatorial approaches with multiple inhibitors of both
cPLA2 and the other major LOX/COX enzymes downstream of cPLA2. This
limitation is less of a concern in less specific approaches to target cPLA2.
The genetic cPLA2 chimeric approach described here is not fully specific to
macrophages, but it is the closest approach currently available. While technically
challenging, macrophage-specific conditional KO mice have been developed in
the past for other gene targets using the Cre-LoxP recombination system (Haydar
et al., 2021; Shi et al., 2018). With continued work, a conditional KO could be
developed to target cPLA2 in macrophages; however, a cPLA2-LoxP mouse line
would first need to be created. While more macrophage-specific than myeloid
genetic chimeras, additional myeloid cells, notably neutrophils, are also affected
under the LysM gene. Similarly, conditional KOs often allow for residual gene
expression compared to a global KO. Each approach has its own set of strengths
and caveats to consider in future studies targeting cPLA2.
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A significant limitation in macrophage-targeted therapies is that they are
specific. The immune response is clearly more complicated than solely
macrophage-induced inflammation. Because of this, it is possible that strategies
that solely target macrophages may not be capable of producing robust
improvements in the complex post-SCI inflammatory environment. Because of
this, it is important to design outcomes that are sensitive to modest
improvements. Given the severe gap in therapeutic options for patients, any drug
with any proven benefits would be a significant improvement. With time,
combinatorial therapies could be developed to improve therapeutic efficacy
further.
While cPLA2 is often considered the most important PLA2 isoform, as it is
critical in the initiation and modulation of inflammatory responses and specifically
targets phospholipids containing AA acyl groups, other PLA2 enzymes, notably
iPLA2, can also release AA non-specifically. These isoforms have even been
shown play pathological roles following SCI (Lopez-Vales et al., 2011).
Therefore, it is possible that our cPLA2 deficient macrophages isolated from the
SCI lesion may still release free AA capable of being synthesized into various
eicosanoids. Although unlikely, if AA levels in KO’s were substantial relative to
the WT chimeric control, we could perform preliminary studies utilizing other
commercially available PLA2 deficient mice such as iPLA2-/- mice to define the
novel role of additional PLA2s in myelin macrophages in-vitro. This would then be
followed by a repetition of our chimeric mice approach targeting an alternative
PLA2 isoform.
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We performed these studies predominantly on young female mice. Given
that the human SCI population is predominantly male, with an increasing average
age of injury occurrence (National Spinal Cord InjuryStatistical Center, 2014), the
use of young female mice is a major limitation. Sex and age are important
biological variables where therapeutics frequently have differential effects.
Macrophage and microglial inflammatory gene profiles examining, activation,
redox, and debris metabolism/clearance, differ in response to sex and age
(Stewart et al., 2021). It is possible that cPLA2, AZM, and the other therapeutics
discussed here have differential roles across these variables not captured in the
current data. In Stewart et al. 2021, cPLA2 did not have notable differences
across age and sex; however, there was higher cPLA2 in microglia relative to
monocyte-derived macrophages. Examining sex and age as biological variable is
an important consideration as we continue to develop macrophage-targeted
therapies. Similarly, going forward studies need to incorporate outcome
measures important to the SCI community, including sexual, bowel, and bladder
health (Anderson, 2004). This is important as therapies without notable benefits
to locomotor recovery could induce sensory recovery which could be missed
when only observing the traditional set of outcome measures.

5. vi. Interactions of Azithromycin and cPLA2
Initial evidence suggests that intracellular membranes, the site of cPLA2
activity, may be a target of macrolide antibiotics, including AZM (Banjanac et al.,
2012; Tyteca et al., 2003). Interestingly, AZM can reduce AA release from the
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J774A.1 macrophage cell line, with similar reductions in eicosanoid profiles as a
cPLA2 inhibitor (Banjanac et al., 2012). Similarly, in human leukocytes, AZM was
found to reduce expression of cPLA2 as well as cyclooxygenase (COX)-1 and
COX-2 (enzymes downstream of cPLA2 in AA processing) (Miyazaki et al., 2003).
This resulted in reduced LPS-induced prostaglandin E2 synthesis (Miyazaki et
al., 2003). These data suggest that AZM may reduce the release of AA by cPLA2
either through direct inhibition or indirectly through downregulation of cPLA2.
Given that substrate availability is a major regulator of LOX/COX activity,
reducing AA release would reduce the total level of eicosanoids produced.
Recent work has shown that AZM has significant antihyperalgesic properties in
treating neuropathic pain after SCI in mice (Gensel et al., 2019). Because
eicosanoids have an established role in pain mechanisms (Dennis and Norris,
2015), it is possible that AZM exerts these effects through its iterations with the
cPLA2, COX-1, and COX-2 (Miyazaki et al., 2003)
While the majority of these lipid metabolites of AA have pro-inflammatory
functions largely detrimental after SCI, under certain conditions, AA can be
synthesized into the potent anti-inflammatory eicosanoid Lipoxin A4. The
synthesis of lipoxins requires the concerted transcellular activity of 12/15
Lipoxygenase (LOX) in macrophages and 5-LOX in other cell types. In
macrophages, these enzymes are expressed in response to the M2 macrophage
cytokine IL-13 stimulation (Mabalirajan et al., 2013; Nassar et al., 1994). Given
our published data showing Azithromycin’s (AZM) ability to polarize toward the
M2 phenotype after SCI (Gensel et al., 2017; Zhang et al., 2015b), I hypothesize
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that AZM treatment will allow for increased Lipoxin A4 production from myelin
derived free AA. This would almost certainly be beneficial after SCI as Lipoxin
A4, and its direct precursors have been found to be neuroprotective and
beneficial when added exogenously after SCI (Liu et al., 2015; Martini et al.,
2014; 2016). Further Lipoxin A4 has been implicating in activating the PPAR-γ
pathway which is strongly associated with polarization to the M2 phenotype
(Bouhlel et al., 2007; Sobrado et al., 2009).
Together after SCI, AZM would decrease the total amount of myelin
derived bioactive AA released from the membrane and promote the conversion
of any free AA present into the anti-inflammatory eicosanoid Lipoxin A4 thereby
promoting the resolution of inflammation and reducing secondary damage after
SCI. Importantly, myelin’s prolonged persistence in these lipid-laden
macrophages drives the hypothesis that the chronic pro-inflammatory
macrophage activation observed months after SCI is a product of persistent AA
release. AZM’s mechanisms of action could interrupt this pathway, specifically
within macrophages, likely even at chronic injury timepoints for which there is a
significant lack of treatment options. While intriguing, additional work is needed to
validate these observations and determine if AZM can be used to interfere with
cPLA2 mediated pathophysiology after SCI.

5- vii. Significance
Myelin is an integral part of the CNS, carefully maintained by
oligodendrocytes around many types of neurons. In SCI, however, the
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homeostatic balance in the spinal cord is severely disrupted through physical
damage and the massive infiltration of immune cells, blood, and inflammation.
Myelin sheaths soon constitute the bulk of cellular debris as the neurons they
encapsulate begin to die at the site of injury. Macrophages attempt to clear the
extensive debris during which they become loaded with myelin-derived lipids
nearly indefinitely, adopt pro-inflammatory activities, and begin to cause further
damage (Gensel et al., 2009; Horn et al., 2008; Kigerl et al., 2009; Wang et al.,
2014). This process, while critically important, is poorly understood. Here we
examine in detail how macrophage activation affects myelin uptake, how myelin
uptake affects macrophage polarization, and the mechanisms through which
myelin impacts macrophage physiology. This evidence provides meaningful
improvements in our understanding of how macrophages develop from a wellintended immune cell into a destructive, pro-inflammatory, and long-lasting
presence in the core of the SCI lesion.
An SCI is a life-changing, often permanent, event impacting an individual’s
physical and mental health. Unfortunately, despite great advances in our
understanding of SCI pathophysiology, most individuals who sustain an SCI have
few or no therapeutic options to help their recovery. Here we identify cPLA2 as an
important therapeutic target mediating detrimental macrophage activation. Next,
we provide continued evidence that the immunomodulatory antibiotic AZM has
neuroprotective effects in a mouse model of SCI. Lastly, we examine the steps
needed to continue to develop macrophage-targeted therapies towards clinical
use. Given the clinical lack of a therapeutic standard of care for SCI, continued
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work towards new therapeutics and combinatorial therapies is critical (Emerich et
al., 2012; Hall and Springer, 2004; Hurlbert, 2000). With continued development,
a macrophage-targeted therapy could eventually promote recovery in patients
who currently have very few treatment options available (Emerich et al., 2012;
Hurlbert, 2000).
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Table 5.1. Chemical inhibitors of the PLA2 family
PLA2 Inhibitor Structure

Name
PACOCF3

AACOCF3

cPLA2
iPLA2

AX059

cPLA2

FKGK11

iPLA2
cPLA2 (partial)
sPLA2 (partial)

AK115

cPLA2
iPLA2
sPLA2

FKGK22

cPLA2
iPLA2
sPLA2
iPLA2

Bromoenol
lactone

AVX001
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PLA2
Specificity
cPLA2
iPLA2

cPLA2

Figure 5.1. Targeting macrophage cPLA2 with transgenic mouse chimeras.
Wild-type cPLA2+/+ (WT) C57BL/6 will be irradiated to deplete bone marrow and
peripheral macrophages and then injected with bone marrow cells isolated from
WT or cPLA2-/- (KO) mice. These mice will then be housed for approximately two
months to allow for complete bone marrow reconstitution (Fenn et al., 2014). This
approach will create a controlled scenario in which cPLA2 can be studied
exclusively in myeloid-derived cells, notably infiltrating macrophages following
SCI. Following SCI, the animals will be evaluated for locomotor, sensory, and
histological recovery.
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Figure 5.2. Important steps in developing macrophage cPLA2 as a
therapeutic target for spinal cord Injury.
To advance cPLA2 as a therapeutic target for the treatment of SCI we need to
complete several stages of pre-clinical research. First, we must establish
Macrophage cPLA2’s pathological role in SCI through mechanistic studies using
cPLA2 transgenic studies in mice. Next, a suitable cPLA2 inhibitor candidate
needs to be selected and screened for suitability for human use. Lastly, this final
drug candidate would likely require replicate studies in higher order species
before it could progress towards clinical trials and human use.
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Figure 5.3. Important steps in repurposing of AZM as a neurotherapeutic
agent.
Additional work in animal models is needed to both improve AZM’s efficacy and
develop outcome measures feasible for use in non-invasive human studies.
Application of these outcome measures in the patient population already taking
AZM near time of injury could provide key evidence for the transition of AZM into
clinical trials and use as a therapeutic for SCI. AZM: Azithromycin; SCI: spinal
cord injury.
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Appendix: List of abbreviations
AA: Arachidonic acid
ABCA1: ATP-binding cassette transporter A1
ANOVA: Analysis of variance
Arg-1: Arginase-1
AZM: Azithromycin
BODIPY: Dipyrrometheneboron difluoride (Neutral lipid stain)
BMDM: Bone marrow-derived macrophage
BMS: Basso Mouse Scale
CNS: Central nervous system
COX: Cyclooxygenase
cPLA2: cytosolic phospholipase A2
CR3/CD11b/MAC-1: complement receptor 3
CTL: Control
DAMP: Damage associate molecular pattern
DAPI: 4′,6-diamidino-2-phenylindole (DNA stain)
DCF: 2', 7' –dichlorofluorescein (Fluorescent ROS indicator)
DMEM: Dulbecco's Modified Eagle Medium
Dpi: Days post injury
EC/NF Eriochrome cyanine and neurofilament
ELISA: Enzyme-linked immunosorbent assay
FACS: Fluorescence-activated cell sorting
FBS: Fetal bovine serum
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FDA: Food and drug administration
GFAP: Glial fibrillary acidic protein
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (buffer)
IFN: Interferon
IL: Interleukin
IH: Infinite Horizons impactor device
iPLA2: Calcium-independent phospholipase A2
Kdyn: Kilodyne force
KO: Knock out
LD50: median lethal dose
LIF: Leukemia inhibitory factor
LOX: Lipoxygenase
LPS: Lipopolysaccharide
LXR/RXR: Liver X and retinoid X receptor
MAC-2: Galectin-3 (activated macrophage)
MAPK: Mitogen-activated protein kinase
MARCO: Macrophage receptor with a collagenous structure
MCM: Macrophage conditioned media
MIC: Minimum Inhibitory Concentration
MRI: Magnetic resonance imaging
MS: Multiple sclerosis
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NASCIS: National Acute Spinal Cord Injury Study
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NF-κB: Nuclear factor kappa B
NIH: National Institutes of Health
NINDS: National Institute of Neurological Disorders and Stroke
n.s: Not significant
N2a: Neuro-2a
OCT: Optimal cutting temperature compound
OMgp: oligodendrocyte myelin glycoprotein
Opti-MEM: Reduced-Serum Medium is an improved Minimal Essential Medium
PBS: Phosphate-buffered saline
p-cPLA2: phosphorylated cytosolic phospholipase A2 (activated)
PFA: Paraformaldehyde
PNS: Peripheral nervous system
ROS: Reactive oxygen species
RPM: Rotations per minute
PPAR/RXR: peroxisome proliferator-activated receptors
RPMI: Roswell Park Memorial Institute medium
PRR: Pattern recognition receptor
P/S: penicillin/ streptomycin
SCI: spinal cord injury
SD: Standard deviation
SEM: standard error of the mean
sPLA2: Secretory phospholipase A2
SRAI/II: Scavenger receptor AI/II
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TLR: Toll like receptor
TNF: Tumor Necrosis Factor
TomL: Tomato lectin
TREM2: Triggering receptor expressed on myeloid cells 2
VCP: Valosin-containing protein
WT: Wild type
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